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Il semble que la perfection soit atteinte non quand il n'y a plus rien à ajouter,  
mais quand il n'y a plus rien à retrancher.  
 
 
 
 
 
 
 
Perfection is achieved, not when there is nothing more to add,  
but when there is nothing left to take away.  
Antoine de Saint-Exupéry, Le Petit Prince (The Little Prince) (1943), Ch. III 
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Introduction 
 
ATP Binding Cassette (ABC) transporters form one of the largest families of membrane 
transport proteins expressed in all organisms. This diverse transporter family has been 
extensively studied and its members play a vital role in many cellular processes. ABC 
transporters are responsible for multidrug resistance of cancer cells (1), but may also be 
capable of transporting several substrates like metal ions, peptides, amino acids, sugars and a 
large number of hydrophobic compounds and metabolites across the plasma membrane as 
well as intracellular membranes (2).  
The human ABC transporter family consists of 49 members which are divided in 7 
subfamilies, from A to G, based on similarity in gene structure, order of the domains and 
sequence homology. Until now, 14 ABC genes have been linked to inherited diseases, like 
Tangier disease (ABCA1), Dubin Johnson syndrome (ABCC2), Pseudoxanthoma elasticum 
(ABCC6) and Cystic Fibrosis (ABCC7) (2). Although some ABC transporters have been 
extensively studied, the functions of many others are still unknown. The development of ABC 
transporter knockout animals has provided us with some insights into the function and 
characteristics of ABC transporters (3). 
ABC transporters have an important role in tissue defense through the excretion of 
toxic compounds and their metabolites (4). The expression levels of the transporters are 
tightly regulated, emphasizing their importance in organ protection (5). Moreover, two ABC 
transporters, Multidrug Resistance Gene 1 (MDR1/ABCB1) or P-glycoprotein (P-gp) and 
ABCG2 or Breast Cancer Resistance Protein 1 (BCRP), have been implicated in tissue 
regeneration. Both efflux pumps are highly expressed on side population (SP) cells, a 
population of primitive bone marrow-derived stem cells with long term repopulating 
capacities. Loss of expression leads to differentiation, indicating that P-gp and BCRP might 
determine stem cell-induced tissue remodeling through their differential expression. 
SP cells have been implicated in the regeneration of various organs, like liver (6), 
skeletal muscles (7) and heart (8). Several studies addressed their participation in renal 
regeneration, but controversial results were reported (9-11). This chapter gives an overview of 
the role of ABC transporters in tissue defense and organ regeneration and focuses on the role 
of P-gp and BCRP in these processes.  
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ABC transporters in tissue defense 
 
The localization of ABC transporters in organs with a barrier function and their broad 
substrate specificities suggest an important role in tissue defense. The efflux pumps are 
determinants for the absorption, distribution and excretion of drugs, xenobiotics and their 
metabolites. Entrance in the systemic circulation is prevented by the apical expression of 
ABC transporters in the intestine (12), like P-gp and BCRP, and the action of these 
transporters leads to a decreased drug concentration in the liver. The liver is the major site of 
xenobiotic metabolism in the body, in which enzymes, like the cytochrome P-450 (CYP) 
family members catalyze the oxidative metabolism of many drugs, eventually affecting both 
drug efficacy and drug toxicity (13). P-gp is able to mediate cellular efflux of CYP 
modulators, like rifampicine. Rifampicine induces CYP3A activity in a dose-dependent 
manner, thus a lower intracellular concentration results in a decreased CYP3A activity 
(14,15).  
Drug distribution to the brain is hampered by transporters like P-gp, Multidrug 
resistance protein 1 and 2; MRP1/2 (ABCC1/2), MRP4 (ABCC4) and BCRP in the blood 
brain barrier (16-18). Although these transporters protect the central nervous system (CNS), 
effective drug treatment of brain tumors, epilepsy and several mental disorders is limited (19-
23). The importance of transporters in the blood brain barrier was emphasized in mdr1a(-/-) 
mice, which died from the neurotoxic action of ivermectin after treatment for mite infestation 
(24,25). 
ABC transporters affect, besides drug absorption and drug distribution, also the 
excretion of drugs into the bile or urine. In the liver, ABC transporters are responsible for the 
elimination of xenobiotics and their metabolites into bile (P-gp, Bile Salt Export Protein 
(BSEP), MRP2) or in the systemic circulation (MRP1/3). More water-soluble drugs can be 
excreted into urine by the kidney, where ABC transporters are localized along the apical 
membrane (P-gp, MRP2/4 and BCRP) of proximal tubular cells.  
 The defense mechanism formed by ABC transporters under physiological 
circumstances is directed against accumulation of potentially harmful compounds. 
Interestingly, in a situation of organ damage or disease, changes in the expression levels of 
ABC transporters have been observed, likely to compensate for the increased load of harmful 
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products of oxidative stress formed during an insult or to compensate for the loss of efflux 
pumps in damaged tissues. In severe human liver disease (primary biliary cirrhosis, cell 
necrosis or chronic hepatitis), P-gp, MRP1 and MRP3 (ABCC3) were upregulated, suggesting 
protection against the accumulation of toxic bile constituents and prevention of further liver 
damage (81). A genetic defect in ABCC2 leads to mild hyper-bilirubinemia, called the Dubin 
Johnson syndrome. These patients show upregulation of MRP3 in the liver, likely to 
compensate for the lack of MRP2 (26). In this way, the body uses a compensatory mechanism 
to prevent (further) injury, a phenomenon also seen in other organs. In the intestine, a 
temporary upregulation of P-gp was found after ischemic reperfusion damage, stimulating 
tissue recovery indirectly by reducing accumulation of potentially harmful substances (27). 
After an ischemic insult in the brain, various ABC transporters were upregulated, among 
which the increase in Bcrp was most pronounced. This not only prevents brain penetration of 
harmful compounds, but might also positively affect neurogenesis (28). In the skin, cellular 
cholesterol levels regulate ABCA1 expression, which suggests that this key cholesterol efflux 
carrier controls the maintenance of the keratinocyte barrier (29).  
Information on renal ABC transporters during injury or tissue repair is limited. After partial 
nephrectomy mRNA levels of P-gp were elevated, which was also found for Mrp2 (30). 
Following renal damage induced by cadmium or lipopolysaccharide, increased P-gp levels 
were seen as well (31,32). In addition, after the induction of ischemia-reperfusion injury in 
mice, expression levels of p-gp and bcrp were upregulated in contrast to a decrease in mrp2 
levels (33). This is in contrast to experiments performed in rats, where Mrp2 levels were 
clearly upregulated after renal injury (32).  
In the mammary gland of lactating animals, expression of BCRP was highly upregulated and 
responsible for the active secretion of nutrients into milk, but also responsible for the 
excretion of toxicants and drugs, like topotecan, PhIP (2-amino-1-methyl-6-phenylimidazo 
[4,5-b]pyridine) and cimetidine. (34). 
The transporters P-gp and BCRP also define the specific SP cell phenotype, where it was 
suggested that the efflux pumps protect stem cells from genetic damage because naturally 
occurring toxic compounds are substrates for these transporters (35). Moreover, expression 
levels are downregulated upon SP cell differentiation and hematopoietic maturation (36,37). It 
was suggested that BCRP expression may play a role in early stem cell self-renewal by 
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partially blocking differentiation, and P-gp may promote differentiation and engraftment (36). 
Apparently, both efflux pumps are essential in tissue remodeling by SP cells. 
 
P-glycoprotein/ABCB1 
 
P-glycoprotein was discovered in 1976 as an efflux pump in a colchicin-resistant cell line, and 
ten years later, the gene encoding for P-gp was discovered. Until now, it is the most 
extensively studied ABC transporter. P-gp is expressed in a number of tissues with a barrier 
function (Figure 1), but also in many hematopoietic cell types (38), including CD34+ stem 
cells (39), c-kit+ stem cells (40) CD56+ Natural Killer (NK) cells and CD8+ cytotoxic T cells 
(38,39,41,42).  
P-gp is capable of transporting many drugs and endogenous substrates. P-gp substrates 
are cationic or amphipathic in nature and mainly hydrophobic, indicating that they can diffuse 
passively across the membrane and penetrate tissues. In addition to its ability to induce 
chemotherapy resistance, P-gp confers resistance to a vast array of clinically and 
toxicologically relevant compounds, including immunosuppressive drugs, HIV protease 
inhibitors and antibiotics (43,44). To overcome the problem of multidrug resistance, P-gp 
function is inhibited with substrates usually acting as competitive inhibitors, like verapamil 
and cyclosporin A (first and second generation of P-gp inhibitors), or by blocking P-gp 
function directly, like elacridar (GF120918) (third generation inhibitor) (45-49).  
The development of P-gp-deficient mice, the mdr1a/1b(-/-) mice, contributed to the 
identification of more specific substrates. Rodents have two genes encoding for the efflux 
pump, mdr1a and mdr1b. At first sight, no obvious phenotype was discovered in these mice 
except for a larger susceptibility to drug toxicity due to accumulation in the brain or liver (24), 
however, after careful characterization altered gastrointestinal and renal phenotypes were 
discovered. Under specific pathogen-free conditions, mdr1a-deficient (mdr1a(-/-)) mice 
developed spontaneous colitis and signs of severe chronic inflammation of the gut, probably 
caused by abnormalities in the epithelial lining of the gut (50). The double knockout 
(mdr1a/1b(-/-)) mice shows disturbed renal tubular function caused by decreased intracellular 
ATP levels and impaired mitochondrial morphology (51). The generalized proximal tubular 
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dysfunction shows striking similarities with renal Fanconi syndrome, as tubular reabsorption 
of amino acids and low molecular weight proteins were decreased. These findings emphasize 
the importance of the efflux pump for intestinal and renal tubular function.  
Apart from its protective function, P-gp has also been implicated in resistance to 
apoptosis. Several mechanisms have been described that could explain this event. First, P-gp 
might inhibit Fas-induced caspase-3 activation possibly by inhibiting activation and 
processing of caspase 8. The binding of ATP to P-gp in the plasma membrane is essential for 
this inhibition, as P-gp mutants are not able to protect against Fas killing. Secondly, P-gp may 
affect ceramide-induced apoptosis. Ceramide mediates cell death, but is intracellularly 
converted into the non-toxic glucosylceramide. By mediating the translocation of 
glucosylceramide from the cytosolic to the luminal face of the Golgi, P-gp influences 
ceramide metabolism and, indirectly, causes apoptosis resistance (52-54). After injury, 
apoptosis contributes to tissue remodeling and elimination of redundant or damaged cells and 
by stimulation of this pathway, P-gp may affect the regeneration process in damaged tissue.  
 
Breast Cancer Resistance Protein 1/ABCG2 
 
Breast Cancer Resistance Protein (BCRP) was first cloned by Doyle et al. (55) in the drug 
resistant breast cancer cell line (MCF-7). BCRP is a half-transporter with a size of 72 kDa, 
and, like other ABC half-transporters, BCRP probably functions as a homodimer, but whether 
it may also function as a heterodimer with other ABCG subfamily members is unclear (56). 
BCRP expression overlaps largely with P-gp, as the protein can be found on tissues like the 
placenta, prostate, small intestine, brain, colon, liver and ovary (55). We recently discovered 
BCRP in human kidney as well, where the protein is localized to the apical membrane of the 
proximal tubules (51). In addition, BCRP was identified in the mammary gland of cows, 
humans and mice.  
 BCRP transports a wide range of substrates including large molecules, uncharged or 
with an amphiphilic character. There is considerable overlap in anticancer drug substrate 
specificity between BCRP and P-gp, but there are also several differences in the substrate 
specificity of both transporters (57). Like P-gp, the efflux pump does not require glutathione 
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(58), but in contradiction to P-gp, BCRP is able to transport phase two metabolites, like 
sulfated substrates (59-62). The substrate specificity of BCRP is clearly distinct from other G-
subfamily members, like ABCG1, ABCG5 and ABCG8, which were all identified as 
cholesterol transporters. Several of the substrates transported by BCRP were discovered using 
BCRP-deficient mice (bcrp1(-/-) mice) (63). These mice showed lethal porphyrin-related 
phototoxicity, suggesting that BCRP excretes porphyrins. Moreover, careful characterization 
of BCRP-deficient mice revealed a novel estrogen deficiency phenotype, with elevated levels 
of testosterone, dehydroepiandrosterone (DHEA) and luteinizing hormone (LH), but normal 
levels of follicle-stimulating hormone (FSH). Glucose homeostasis is disturbed in these mice, 
due to insulin resistance. Treatment of male BCRP-deficient mice with 17ß-estradiol 
improved the glucose response and restored testosterone and LH levels, supporting the 
hypothesis that BCRP is important for estrogen and androgen homeostasis (Huls et al., this 
thesis). It has been reported that BCRP transports estradiol, estrone-3-sulfate (E1S) and 
dehydroepiandrosterone sulfate (DHEAS), and recently, also transport of other androgens and 
phytoestrogens were found (64-66). Furthermore, BCRP expression appeared to be sex-
specific (67) and may be highly influenced by sex steroids (68). These findings are consistent 
with a role for BCRP in steroid metabolism.  
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Figure 1. Tissue distribution of P-gp and BCRP. Dotted arrows indicate the direction of efflux of substrates excreted by P-gp 
or BCRP. Both transporters are expressed in the luminal membrane of the endothelial cells comprising the blood brain 
barrier, where they protect the brain from toxic substrates, the choroid plexus within the brain, the canalicular membrane of 
hepatocytes, the brush border membrane of proximal tubules which mediates the excretion into the urine, the apical 
membrane of the intestinal epithelial cells, which prevents the absorption of substrates into the human body, the 
syncitiotrophoblasts and the side population within the bone marrow. Moreover, BCRP is expressed in the apical membrane 
of alveolar epithelial cells of the mammary gland during lactation.  
 
Role of P-gp and BCRP in stem cells 
 
In 1991, Chaudhari and Robinson (39) discovered the expression of P-gp on CD34+ 
hematopoietic cells. Ten years later, expression and functional activity of BCRP on these cells 
are identified (69). These transporters are responsible for the side population (SP) phenotype, 
which is characterized by its low retention of rhodamine 123 (Rho123), transported by P-gp 
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and a BCRP mutant (57,70) and Hoechst 33342, transported by BCRP in the cells. Although 
mRNA of other ABC transporters, like ABCG1, ABCA1, MRP1, ABCD4 and ABCB2, was 
also detected in these cells, they are not responsible for the ‘SP’ phenotype (71). SP cells are 
highly enriched for hematopoietic stem cell (HSC) activity and represent approximately 
0.05% of the adult nucleated bone marrow cells in mice (72). The classic stem cell population 
KSL (ckit+/Sca-1-/ Lin-) which is known for its repopulation capacities, overlaps with the SP 
phenotype for 73% (37).  
 In recent years, it has become clear that the SP population of cells not only resides 
within the bone marrow, but also in other non-hematopoietical organs, like spleen tissue, 
umbilical cord blood, brain, kidney, heart, intestine, skin and lungs (73-75). In these organs, 
they appear to have the ability to differentiate into many cell types following reintroduction in 
vivo, including skeletal and cardiac muscle, neurons and epithelial cells like hepatocytes 
(6,8,76-79) but also in hematopoietic cells in lethally irradiated mice (7,80). This multipotent 
differentiation capacity of HSCs suggests that these cells contribute significantly to tissue 
remodeling. This was, for example, shown in mice suffering from tyrosinemia type I due to 
genetic fumarylacetoacetate hydrolase (FAH) deficiency, where bone marrow transplantation 
resulted in a restoration in FAH activity in the liver (6). P-gp is expressed and upregulated 
after hepatic damage in resident liver progenitor cells, also designated as oval cells (81). 
Apparently, the transporter protects these cells against toxic bile constituents and oxidative 
stress, and in this way, progenitor cells are able to initiate liver repair. Furthermore, after 
partial hepatectomy, the amount of oval cells increased and the subsequent liver tissue 
remodeling correlated with the observed expression of BCRP (82). A similar phenomenon 
was described for SP cells in the heart. During early cardiac development, BCRP expressing 
cells were observed, but the appearance of these cells decreased upon maturation (83). 
However, a small population of cells exhibiting the SP phenotype remains in the heart and 
these cells are capable of proliferation and differentiation, and likely also responsible for 
repair and regeneration of heart tissue after damage. Furthermore, cardiac SP cells were able 
to regenerate the myocardium after cold-induced transplantation injury (84). This 
phenomenon was also seen in the ischemic kidney, where bone marrow-derived cells 
contributed to kidney remodeling after inducing renal ischemia (9).  
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In addition to P-gp and BCRP, other ABC transporters may be involved in 
differentiation and regeneration processes. In human liver disease, expression levels of MRP1 
and MRP3 were markedly increased, which was also seen in a comparable model conducted 
in rats (81,85). Additionally, in human keratinocytes, the differentiation of epidermal cells is 
characterized by the RNA upregulation of several ABC transporters, like MRP1, MRP3, 
MRP4, ABCG1 and especially ABCA7 (86). It was suggested that ABCB1 and ABCG1 
mediate the transport of phospholipids and the translocation of cholesterol. ABCA7 may have 
a dual role by keeping the lamellar body lipid homeostasis and in promoting the expansion of 
the cellular ceramide pool. This might direct the cells to execute essential programs, like cell 
cycle arrest, differentiation and apoptosis (86). Although knowledge of the role of ABC 
transporters in organ repair and tissue regeneration increases, this is limited and more research 
needs to be done to gain more insight in this process. It seems that several ABC transporters 
are involved in tissue repair, although P-gp and BCRP may be dominant in this process. Their 
specific function and mechanism are not yet understood, but their variable and controlled 
expression levels on SP cells, but also on renal epithelial cells, suggests an important function 
in tissue repair. 
 
Role of P-gp and BCRP in renal regeneration 
 
The kidney has the capacity to regenerate almost completely after renal injury and stem cells 
either residing in the kidney and/or derived from bone marrow may take part in this process. 
Besides HSCs and mesenchymal stem cells (MSCs) (9,87,88), also differentiated epithelial 
cells within the kidney have been implicated in renal remodeling. After renal injury, epithelial 
cells may acquire mesenchymal characteristics before proliferation thereby contributing to 
basement membrane repair (10,89). This process, called epithelial to mesenchymal transition 
(EMT) is known to be influenced by different cytokines and growth factors, influencing 
signal transduction pathways (90).  
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Figure 2. Proposed mechanisms of renal regeneration. Differentiated tubular cells are able to regenerate the injured tissue 
after proliferation and spreading. Moreover, differentiated tubular cells could dedifferentiate via the process of EMT towards 
more primitive mesenchymal cells. Subsequently, cells migrate to the sites of injury and repair the damaged tubules. In 
addition, stem cells either localized within the kidney or derived from bone marrow might regenerate the damaged tissue by 
differentiation towards tubular cells.  
 
The importance of P-gp and BCRP as xenobiotic efflux pumps, their apical localization in the 
kidney (51,91) and their increased expression after ischemia-reperfusion injury in mice (33), 
suggest that absence of either transporter might lead to an increased sensitivity to injury. 
However, to our surprise we found the opposite in studies performed with P-gp- and BCRP-
deficient mice. Both mice appeared to be resistant to ischemia-reperfusion with no signs of 
renal injury, suggesting that the absence of both transporters is an advantage for renal repair 
(51 and unpublished). After bone marrow transplantation from P-gp- or BCRP-deficient mice 
into wild type mice, also protection against ischemic injury was observed. This is in line with 
the hypothesis that bone marrow-derived cells differentiate into renal tubular cells and that P-
gp and BCRP are key players in this process (this thesis). The decreased amount of dead cells 
after an apoptotic stimulus (H2O2) to bone marrow cells derived from P-gp-deficient mice 
indicates that these cells are less sensitive to apoptosis. The amount of apoptotic cells is a 
major determinant for the extent of renal damage after acute kidney injury, causing 
obstruction of the tubular lumen leading to a decrease in renal function (92). In addition, the 
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amount of ’helper cells’ (monocytes and granulocytes) in bone marrow from P-gp- and 
BCRP-deficient mice is significantly higher compared to this population in wild type mice. 
These cells are able to release chemokines and pro-inflammatory cytokines regulating local 
tissue recovery processes, like angiogenesis. The hypothesis that angiogenesis is responsible 
for the increased renal regeneration is furthermore strengthened by the observation that the 
amount of endothelial progenitor cells in the bone marrow of P-gp- and BCRP-deficient mice 
is increased. In this way, bone marrow derived from these mice might stimulate the 
regeneration process. 
Altogether P-gp and BCRP appear to play a dual role: they protect cells and tissues by 
reducing the accumulation of harmful compounds, but may also enhance inflammatory 
processes, thereby stimulating tissue damage after an insult.  
 
Aim and outline of this thesis 
 
Acute kidney injury (AKI) is a frequent clinical problem with a high mortality rate often 
caused by insults like inflammation, hypoxia or exposure to nephrotoxic agents. The kidney 
has, however, a high capacity to regenerate after injury. The general aim of the research 
described in this thesis was to study the role of ABC transporters in renal regeneration. 
Furthermore, we investigated the role of bone marrow-derived stem cells and the ABC 
transporters P-gp and BCRP in this process. 
As an experimental model we used mice subjected to ischemia-reperfusion injury, in which 
the role of both efflux pumps was evaluated. Transplantation studies were performed to 
evaluate the role of bone marrow-derived stem cells in kidney regeneration after ischemic 
injury, and to determine the importance of P-gp and BCRP in this process by using donor 
bone marrow from P-gp- and BCRP-deficient mice. 
 The experimental methods of bone marrow transplantation and AKI, established 
through a short period of ischemia followed by reperfusion, are described in detail in chapter 
2. In chapter 3, the expression of 45 mouse ABC transporters in AKI is described and their 
role in renal regeneration is discussed. The renal phenotype of the P-gp-deficient mice was 
thoroughly studied and is described in chapter 4. Here, the relation between P-gp and 
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proximal tubular dysfunction is discussed. In chapter 5, the phenotype of the BCRP-deficient 
mice is described illustrating the important role of BCRP in estradiol action and glucose 
homeostasis. In chapter 6, the functional expression and localization of BCRP in human 
kidneys are shown and compared with its expression in rats and mice. The role of BCRP and 
P-gp in renal regeneration after ischemia-reperfusion injury is studied and the contribution of 
bone marrow-derived cells is described in detail in chapter 7. Moreover, this chapter 
discusses the beneficial effect of bone marrow cells in renal regeneration in absence of P-gp 
and BCRP. In chapter 8, we describe the potential of multipotent adult progenitor cells 
(MAPCs) to differentiate towards a renal progenitor cell type. The differentiation processes 
and the protocols used focus on the diverse stages of renal development. Gene and protein 
expression but also functional tests are used to study the development of MAPCs towards an 
epithelial cell type and the subsequent differentiation towards a renal epithelial cell.  
 The thesis is concluded with a general discussion and a summary in chapters 9 and 10, 
respectively. 
 
 
Reference List 
 
  1.  Hyde SC, Emsley P, Hartshorn MJ et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance 
and bacterial transport. Nature 1990; 346: 362-365. 
  2.  Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42: 1007-1017. 
  3.  Schinkel AH, Mayer U, Wagenaar E et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) 
P-glycoproteins. Proc Natl Acad Sci U S A 1997; 94: 4028-4033. 
  4.  van Aubel RA, Masereeuw R, Russel FG. Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol 
2000; 279: F216-F232. 
  5.  Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue 
defense. Toxicol Appl Pharmacol 2005; 204: 216-237. 
  6.  Lagasse E, Connors H, Al Dhalimy M et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000; 
6: 1229-1234. 
  7.  Jackson KA, Mi T, Goodell MA. Hematopoietic potential of stem cells isolated from murine skeletal muscle. Proc Natl Acad Sci U S A 
1999; 96: 14482-14486. 
  8.  Jackson KA, Majka SM, Wang H et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin 
Invest 2001; 107: 1395-1402. 
  9.  Kale S, Karihaloo A, Clark PR et al. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest 
2003; 112: 42-49. 
10.  Poulsom R, Alison MR, Cook T et al. Bone marrow stem cells contribute to healing of the kidney. J Am Soc Nephrol 2003; 14 Suppl 1: 
S48-S54. 
11.  Duffield JS, Bonventre JV. Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair 
after ischemic injury. Kidney Int 2005; 68: 1956-1961. 
Chapter 1 27
12.  Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005; 7: E118-E133. 
13.  Schuetz EG, Schinkel AH, Relling MV et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome 
P4503A in mice and humans. Proc Natl Acad Sci U S A 1996; 93: 4001-4005. 
14.  Schuetz EG, Umbenhauer DR, Yasuda K et al. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 
genes. Mol Pharmacol 2000; 57: 188-197. 
15.  Yasuda K, Lan LB, Sanglard D et al. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther 2002; 
303: 323-332. 
16.  Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). 
Drug Discov Today 2001; 6: 150-156. 
17.  Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des 2004; 10: 1295-1312. 
18.  Perriere N, Yousif S, Cazaubon S et al. A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux 
transporters. Brain Res 2007; 1150: 1-13. 
19.  Potschka H, Fedrowitz M, Loscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain 
barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002; 327: 173-176. 
20.  Tate SK, Sisodiya SM. Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opin Pharmacother 2007; 8: 1441-1449. 
21.  Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a 
treatment paradigm. J Clin Oncol 2007; 25: 2306-2312. 
22.  Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602. 
23.  Fellner S, Bauer B, Miller DS et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 
2002; 110: 1309-1318. 
24.  Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997; 8: 161-170. 
25.  Schinkel AH, Wagenaar E, van Deemter L et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and 
pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698-1705. 
26.  Corpechot C, Ping C, Wendum D et al. Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient 
with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. Am 
J Gastroenterol 2006; 101: 2427-2432. 
27.  Omae T, Goto M, Shimomura M et al. Transient upregulation of P-glycoprotein reduces tacrolimus absorption after ischemia-
reperfusion injury in rat ileum. Biochem Pharmacol 2005; 69: 561-568. 
28.  Dazert P, Suofu Y, Grube M et al. Differential regulation of transport proteins in the periinfarct region following reversible middle 
cerebral artery occlusion in rats. Neuroscience 2006; 142: 1071-1079. 
29.  Jiang YJ, Lu B, Kim P et al. Regulation of ABCA1 expression in human keratinocytes and murine epidermis. J Lipid Res 2006; 47: 
2248-2258. 
30.  Laouari D, Yang R, Veau C et al. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. 
Am J Physiol Renal Physiol 2001; 280: F636-F645. 
31.  Thevenod F, Friedmann JM, Katsen AD et al. Upregulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation 
protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem 2000; 275: 1887-
1896. 
32.  Heemskerk S, van Koppen A, van den Broek L et al. Nitric oxide differentially regulates renal ATP-binding cassette transporters during 
endotoxemia. Pflugers Arch 2007; 454: 321-334. 
33.  Huls M, van den Heuvel JJ, Dijkman HB et al. ABC transporter expression profiling after ischemic reperfusion injury in mouse kidney. 
Kidney Int 2006; 69: 2186-2193. 
34.  Jonker JW, Merino G, Musters S et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic 
xenotoxins into milk. Nat Med 2005; 11: 127-129. 
35.  Krishnamurthy P, Ross DD, Nakanishi T et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions 
with heme. J Biol Chem 2004; 279: 24218-24225. 
36.  Bunting KD, Zhou S, Lu T et al. Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side 
population stem cells in vitro and repopulating cells in vivo. Blood 2000; 96: 902-909. 
Chapter 1 28
37.  Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002; 20: 11-20. 
38.  Drach D, Zhao S, Drach J et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug 
resistant phenotype. Blood 1992; 80: 2729-2734. 
39.  Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. 
Cell 1991; 66: 85-94. 
40.  Sorrentino BP, McDonagh KT, Woods D et al. Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in 
hematopoietic cells of transplanted mice. Blood 1995; 86: 491-501. 
41.  Neyfakh AA, Serpinskaya AS, Chervonsky AV et al. Multidrug-resistance phenotype of a subpopulation of T-lymphocytes without 
drug selection. Exp Cell Res 1989; 185: 496-505. 
42.  Klimecki WT, Futscher BW, Grogan TM et al. P-glycoprotein expression and function in circulating blood cells from normal 
volunteers. Blood 1994; 83: 2451-2458. 
43.  Bauer B, Hartz AM, Fricker G et al. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med 
(Maywood) 2005; 230: 118-127. 
44.  Sarkadi B, Homolya L, Szakacs G et al. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity 
defense system. Physiol Rev 2006; 86: 1179-1236. 
45.  Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS 
penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27: 17-24. 
46.  Hyafil F, Vergely C, Du VP et al. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide 
derivative. Cancer Res 1993; 53: 4595-4602. 
47.  Dantzig AH, Shepard RL, Cao J et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent 
cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996; 56: 4171-4179. 
48.  Pussard E, Merzouk M, Barennes H. Increased uptake of quinine into the brain by inhibition of P-glycoprotein. Eur J Pharm Sci 2007; 
32: 123-127. 
49.  Ejsing TB, Hasselstrom J, Linnet K. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its 
metabolites. Drug Metabol Drug Interact 2006; 21: 139-162. 
50.  Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed 
mdr1a-/- mice. Am J Physiol Gastrointest Liver Physiol 2005; 289: G153-G162. 
51.  Huls M, Kramers C, Levtchenko EN et al. P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against 
ischemic renal injury. Kidney Int 2007; 72: 1233-1241. 
52.  Ruefli AA, Tainton KM, Darcy PK et al. P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal 
complex (disc) following Fas ligation. Cell Death Differ 2002; 9: 1266-1272. 
53.  Turzanski J, Grundy M, Shang S et al. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute 
myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp Hematol 2005; 33: 62-72. 
54.  Pallis M, Turzanski J, Higashi Y et al. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both 
a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002; 43: 1221-1228. 
55.  Doyle LA, Yang W, Abruzzo LV et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci 
U S A 1998; 95: 15665-15670. 
56.  van Herwaarden AE, Schinkel AH. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion 
of drugs and xenotoxins. Trends Pharmacol Sci 2006; 27: 10-16. 
57.  Litman T, Brangi M, Hudson E et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-
transporter, MXR (ABCG2). J Cell Sci 2000; 113 ( Pt 11): 2011-2021. 
58.  Krishnamurthy P, Schuetz JD. Role of abcg2/bcrp in biology and medicine. Annu Rev Pharmacol Toxicol 2006; 46: 381-410. 
59.  Suzuki M, Suzuki H, Sugimoto Y et al. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 2003; 278: 
22644-22649. 
60.  Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells 
and its induction by Ah-receptor agonists. Carcinogenesis 2005; 26: 1754-1763. 
Chapter 1 29
61.  Ebert B, Seidel A, Lampen A. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of 
benzo[a]pyrene-3-sulfate. Toxicol Sci 2007; 96: 227-236. 
62.  Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE et al. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary 
excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther 2006; 319: 459-467. 
63.  Jonker JW, Buitelaar M, Wagenaar E et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary 
phototoxin and protoporphyria. Proc Natl Acad Sci U S A 2002; 99: 15649-15654. 
64.  Janvilisri T, Venter H, Shahi S et al. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus 
lactis. J Biol Chem 2003; 278: 20645-20651. 
65.  Huss WJ, Gray DR, Greenberg NM et al. Breast cancer resistance protein-mediated efflux of androgen in putative benign and 
malignant prostate stem cells. Cancer Res 2005; 65: 6640-6650. 
66.  Enokizono J, Kusuhara H, Sugiyama Y. Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in the Disposition of Phytoestrogens : 
the Importance of Bcrp in the Efflux Transport in the Blood-Brain and -Testis Barriers. Mol Pharmacol 2007; 72: 967-975. 
67.  Merino G, van Herwaarden AE, Wagenaar E et al. Sex-dependent expression and activity of the ATP-binding cassette transporter breast 
cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol 2005; 67: 1765-1771. 
68.  Wang H, Zhou L, Gupta A et al. Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental 
BeWo cells. Am J Physiol Endocrinol Metab 2006; 290: E798-E807. 
69.  Zhou S, Schuetz JD, Bunting KD et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a 
molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034. 
70.  Honjo Y, Hrycyna CA, Yan QW et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in 
MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001; 61: 6635-6639. 
71.  Jonge-Peeters SD, Kuipers F, de Vries EG et al. ABC transporter expression in hematopoietic stem cells and the role in AML drug 
resistance. Crit Rev Oncol Hematol 2007; 62: 214-226. 
72.  Goodell MA, Brose K, Paradis G et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in 
vivo. J Exp Med 1996; 183: 1797-1806. 
73.  Asakura A, Rudnicki MA. Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp 
Hematol 2002; 30: 1339-1345. 
74.  Larderet G, Fortunel NO, Vaigot P et al. Human side population keratinocytes exhibit long-term proliferative potential and a specific 
gene expression profile and can form a pluristratified epidermis. Stem Cells 2006; 24: 965-974. 
75.  Yano S, Ito Y, Fujimoto M et al. Characterization and localization of side population cells in mouse skin. Stem Cells 2005; 23: 834-
841. 
76.  Mezey E, Chandross KJ, Harta G et al. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. 
Science 2000; 290: 1779-1782. 
77.  Krause DS, Theise ND, Collector MI et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 
2001; 105: 369-377. 
78.  Ferrari G, Cusella-De Angelis G, Coletta M et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 
279: 1528-1530. 
79.  Alison MR, Poulsom R, Jeffery R et al. Hepatocytes from non-hepatic adult stem cells. Nature 2000; 406: 257. 
80.  Taniguchi H, Toyoshima T, Fukao K et al. Presence of hematopoietic stem cells in the adult liver. Nat Med 1996; 2: 198-203. 
81.  Ros JE, Libbrecht L, Geuken M et al. High expression of MDR1, MRP1, and MRP3 in the hepatic progenitor cell compartment and 
hepatocytes in severe human liver disease. J Pathol 2003; 200: 553-560. 
82.  Shimano K, Satake M, Okaya A et al. Hepatic oval cells have the side population phenotype defined by expression of ATP-binding 
cassette transporter ABCG2/BCRP1. Am J Pathol 2003; 163: 3-9. 
83.  Martin CM, Meeson AP, Robertson SM et al. Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac 
SP cells in the developing and adult heart. Dev Biol 2004; 265: 262-275. 
84.  Oyama T, Nagai T, Wada H et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in 
vitro and in vivo. J Cell Biol 2007; 176: 329-341. 
Chapter 1 30
85.  Ros JE, Roskams TA, Geuken M et al. ATP binding cassette transporter gene expression in rat liver progenitor cells. Gut 2003; 52: 
1060-1067. 
86.  Kielar D, Kaminski WE, Liebisch G et al. Adenosine triphosphate binding cassette (ABC) transporters are expressed and regulated 
during terminal keratinocyte differentiation: a potential role for ABCA7 in epidermal lipid reorganization. J Invest Dermatol 2003; 121: 
465-474. 
87.  Lin F, Cordes K, Li L et al. Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion 
injury in mice. J Am Soc Nephrol 2003; 14: 1188-1199. 
88.  Morigi M, Imberti B, Zoja C et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute 
renal failure. J Am Soc Nephrol 2004; 15: 1794-1804. 
89.  Sun DF, Fujigaki Y, Fujimoto T et al. Possible involvement of myofibroblasts in cellular recovery of uranyl acetate-induced acute renal 
failure in rats. Am J Pathol 2000; 157: 1321-1335. 
90.  Li Y, Yang J, Dai C et al. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial 
fibrogenesis. J Clin Invest 2003; 112: 503-516. 
91.  Pavelic ZP, Reising J, Pavelic L et al. Detection of P-glycoprotein with four monoclonal antibodies in normal and tumor tissues. Arch 
Otolaryngol Head Neck Surg 1993; 119: 753-757. 
92.  Kribben A, Edelstein CL, Schrier RW. Pathophysiology of acute renal failure. J Nephrol 1999; 12 Suppl 2: S142-S151. 
 
 
 
   
 
 
 
 
 
 
Insights into the role of bone marrow-
derived stem cells in renal repair 
 
 
Miriam Huls1 
Frans G.M. Russel1 
Rosalinde Masereeuw1 
 
 
 
 
 
 
 
 
 
1Department of Pharmacology and Toxicology, Nijmegen Centre for Molecular Life Sciences, Radboud  
 University Nijmegen Medical Centre, The Netherlands. 
 
 
 
 
 
 
Kidney and Blood Pressure Research (2008) 31, 104-110.  
C
h
apter
 2 
 Chapter 2 32 
Abstract 
 
Acute kidney injury (AKI) is a frequent clinical problem with a high mortality rate, generally 
caused by ischemic insults. Nevertheless, the kidney has a remarkably high capacity to 
regenerate after ischemic injury. Tubular cells can restore renal function by proliferation and 
dedifferentiation into a mesenchymal cell-type, but also stem cells residing in bone marrow 
may contribute. We compiled a protocol from several published methods to study the 
contribution of bone marrow-derived cells to renal regeneration. Bone marrow was isolated 
from donor FVB mice and labeled with enhanced green fluorescent protein (eGFP) through 
adenovirus transduction. After cell sorting, eGFP-labeled cells were transplanted in sub-
lethally irradiated recipient FVB mice. Four weeks after transplantation, we have provoked 
AKI in mice by inducing unilateral ischemic-reperfusion injury for 30 min. Seven days after 
the injury, eGFP positive bone marrow-derived cells were clearly detectable in ischemic 
kidney tissue, and they contribute to the regeneration of approximately 10% of proximal 
tubular mass. In this review the advantages and shortcomings of our procedure are critically 
discussed and compared with other methods described.  
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Introduction 
 
Acute kidney injury (AKI) is defined as a rapid decrease in glomerular filtration rate (GFR) 
caused by both vascular and tubular factors, including increased renal vasoconstriction, loss 
of autoregulation and tubular obstruction (1,2). Although incidence rates are decreasing, AKI 
is still associated with a high mortality rate. Nevertheless, the kidney has a remarkable 
regenerative capacity and is able to recover completely after renal failure. Ischemia 
reperfusion injury is the major cause of AKI, and after an ischemic event different processes 
are involved in the restoration of renal function. First, tubular epithelial cells have the ability 
to proliferate very rapidly and to migrate to the outer medulla where the majority of injury is 
observed (3). Secondary to proliferation, tubular cells can dedifferentiate into a more 
mesenchymal cell-type (4) and spread to the damaged area. In addition, bone marrow derived 
stem cells may contribute to the regeneration of renal damage (5,6).  
Because stem cells have powerful self-renewing and tissue regenerating properties 
they provide promising new therapeutic approaches for many unmet medical needs. 
Traditionally, stem cells were believed to be lineage restricted and organ specific. However, 
recent studies have demonstrated that bone marrow-derived hematopoietic stem cells are 
capable of forming functional components of other organ tissues, like skeletal muscle (7), 
heart (8), liver (9) and kidney (5,6,10). In addition, after tissue injury, differentiation of 
hematopoietic stem cells into parenchymal cells seems to be stimulated, suggesting that these 
adult stem cells may also contribute to tissue repair. This review gives an overview of the 
techniques used in mice to study the role of bone marrow-derived stem cells in renal 
regeneration, which are summarized in Table 1. We critically compare our protocol developed 
for induction of acute ischemic kidney injury and full bone marrow cell transplantation with 
other published methods in order to gain more insight into renal regeneration by stem cells.  
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Isolation of bone marrow cells and transplantation 
 
Freshly isolated bone marrow cells are used in all studies that investigate the regeneration 
potential of the stem cells they contain. We isolated full bone marrow by flushing the femurs 
and tibiae of the donor mice with medium or PBS (see methods for detailed research 
protocol). Bone marrow can also be isolated by mincing the bones in very small pieces 
followed by collagenase treatment (11). This procedure is likely to be equally effective but is 
more time-consuming. The isolated cells can be transplanted directly, or cultured and labeled 
prior to transplantation (3,5,11). In our study, isolated bone marrow cells were cultured and 
labeled with enhanced green fluorescent protein (eGFP). Upon culturing, it is a prerequisite 
that cells remain in the primitive stage, which can be achieved by addition of several specific 
growth factors, including thrombopoeitin (TPO), stem cell factor (SCF) and haematopoiesis 
blockers like transforming growth factor (TGF)-β. To prevent host-versus-graft reaction, 
donor mice should be of the same strain to exclusively study the regenerative capacity of the 
bone marrow. After transplantation, donor bone marrow-derived cells have to be identified 
and discriminated from host cells. For that purpose different labeling procedures have been 
described in literature, of which the most effective are generation of chimeric mice (LacZ, 
eGFP, male/female mismatching) after transplantation.  
Bone marrow transplantation can be performed with different cell populations. We 
used full bone marrow, but transplantations of the purified stem cell fraction, c-kit+ Sca-1- 
Lin- (KSL), have been described as well (5,10). The KSL markers are typical for a primitive 
population of cells in the bone marrow with a high reconstitution capacity (12,13). The KSL 
fraction can be isolated using fluorescence-activated cell-sorting (FACS) analysis, by means 
of specific markers. To minimize the influence of the host bone marrow, recipient mice are 
irradiated either sub-lethally (3.5 Gy/animal) or lethally (11-12 Gy/animal (5)). Lethal 
irradiation of recipient animals increases the risk of (post-operative) infections, but minimizes 
the influence of endogenous bone marrow. As a result, a more reliable prediction of the 
influence of bone marrow cells in the regeneration processes is obtained. However, this may 
also be achieved after sub-lethal irradiation of the mice followed by transplantation of labeled 
bone marrow cells. In addition, high irradiation doses can cause tissue damage and promote 
cell fusion, which leads to false positive results (14). After testing both methods, we preferred 
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sub-lethal irradiation because of the improved health condition and survival rate of the 
animals. After irradiation, we transplanted one million eGFP-labeled bone marrow cells in 
recipient animals via tail vein injection, which is the most commonly used method. The 
quantity of transplanted cells varies between 200,000 and 5,000,000 for full bone marrow and 
for a KSL fraction an amount of 20,000 to 30,000 cells is often used (5,6,10,15,16). An 
advantage of KSL selected cells is the specificity of this traditional bone marrow stem cell 
fraction. However, other stem cell fractions with a high differentiation potential, like 
multipotent adult progenitor cells (MAPCs, Lin-Sca-1lowc-kit-) (17), are excluded during KSL 
selection. A major advantage of using full bone marrow is that supporting cells are 
transplanted as well. This may contribute to a more stable population and, eventually, a more 
successful and reliable transplantation outcome. 
 
Induction of renal ischemic injury to study bone marrow-derived 
stem cell mobilization 
 
After a harmful insult bone marrow-derived stem cells are mobilized to the damaged tissue 
where they differentiate into a specific phenotype for regeneration (5-8,18). Renal ischemia 
followed by reperfusion induces AKI, which triggers off the mobilization of bone marrow-
derived stem cells. Nephrotoxicants like mercuric chloride (HgCl2) (19), gentamicin or 
cisplatin (20-22), are occasionally used to study the role of bone marrow-derived stem cells in 
renal repair. We induced AKI by applying a clamp on the renal artery and vein for 30 min. 
Prior to the induction of renal ischemic injury, mice were anesthetized with isoflurane and 
renal arteries and veins were exposed by an incision at the flank. Alternatively, a midline 
incision through the abdomen can be made. The extent of ischemic damage is comparable for 
both methods; however, an abdominal incision increases the risk of complications. Moreover, 
post-operative pain medication can be minimized after a flank incision. The clamping time is 
variable and depends on the strain of mice used (5,10). Depending on the extent of kidney 
injury, renal tubules regenerate with varying degrees of functional and structural recovery 
(23). Histological examinations are required to confirm the degree of injury after ischemia. 
The ideal time point to induce renal ischemia after bone marrow transplantation is rather 
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difficult to adjust. Ischemia can be induced directly after irradiation and transplantation 
(5,10), but also after a longer period of time (3). Inducing ischemia directly after 
transplantation and, consequently also shortly after irradiation, is often associated with post-
operative infections due to bone marrow deprivation (5). Obviously, this limits the 
transplantation success. Moreover, after a longer time period it is expected that donor bone 
marrow cells move to the recipient bone marrow following spreading in the circulation. From 
that point of view, cells are able to react to ischemic signals and migrate to the site of injury, 
which might be less stressful for the transplanted cells although this has not been described. In 
our study, AKI was induced four weeks after bone marrow transplantation. Animal health 
improvement and survival rate were decisive for the protocol that was chosen eventually. 
 
Contribution of bone marrow-derived stem cells to renal 
regeneration 
 
For quantification of the involvement of bone marrow-derived stem cells in renal tissue 
regeneration, different detection methods have been described. They are based on either cell 
labeling (e.g. with LacZ, eGFP) or gender-mismatching (3). These techniques have all been 
proven reliable, however, false positive results were reported for gender mismatching caused 
by non-specific binding of probe aggregates (3,10). For the cell labeling it should be noticed 
that positively stained cells are all derived from bone marrow but may not necessarily be 
labeled tubular cells. These false positive results are most often caused by labeled leukocytes. 
This can, however, be prevented by performing a counterstaining of leukocytes with anti-
CD45 antibodies or by antibodies directed against cell-specific markers, e.g. megalin for 
tubular cells. In addition, utilization of confocal microscopy in the analysis of bone marrow-
derived cells is recommended. A confounder of eGFP detection may be a high 
autofluorescence of renal cells (24), therefore, the use of a primary antibody directed against 
GFP is recommended to raise the fluorescent signal above background levels.  
After renal ischemic injury we observed that approximately 10% of the integral 
tubular segments originated from transplanted bone marrow cells, which confirmed the results 
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described in other publications (5,10). Figure 1 is a representative image of the infiltration of 
eGFP-labeled bone marrow-derived cells seven days after ischemia-reperfusion injury.  
Figure 1. Infiltration of enhanced green fluorescent 
protein (eGFP) labeled bone marrow-derived cells in 
mouse kidney, before (A), 2 (B) and 7 days (C) after 
ischemia induction. Cryostat sections (2 µm) were fixed in 
acetone for 10 minutes and air-dried. Subsequently, kidney 
slices were incubated with the primary antibodies against 
eGFP (Roche Diagnostics, Basel, Switzerland) diluted 
1:200, or Ter-119/Ly-76 (Becton Dickinson, Breda, The 
Netherlands), a marker for erythrocytes, diluted 1:200. 
Next, slices were washed 3 times and incubated with the 
secondary antibody; goat anti rabbit Alexa Fluo 488 was used for eGFP (green staining) or goat anti rat Alexa Fluo 594 
for Ter-119/Ly-76 (red staining; both secondary antibodies obtained from Invitrogen, Breda, The Netherlands). Stained 
sections were examined using a confocal laser-scanning microscope (CLSM; Leica lasertechnik GmbH, Heidelberg, 
Germany). Magnifications 200x.   
Figure 2. Ischemic kidney injury recruits bone marrow–derived cells to renal tubules in gender-mismatched chimeras. 
After the transplantation of female bone marrow (XX) into male recipient (XY) mice, only XY cells were found and 
engraftment of female donor mice bone marrow cells in the recipient male kidney seems negligible four weeks after 
bone marrow transplantation before ischemic injury (A). However, seven days post-ischemia, infiltration of XX 
A B
C
A B
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positive cells (indicated with arrow) in the male kidney was observed (B). Fluorescence in situ hybridization was 
performed using a mouse whole chromosome X paint (FITC, green) and Y (Cy3, red) (Cambio, Sanbio BV, Uden, The 
Netherlands). To this end, kidneys were perfused prior to isolation and snap freezing in liquid nitrogen. Cryostat 
sections (2 µm) were pre-treated with pepsine (Sigma-Aldrich, Zwijndrecht, The Netherlands), pre-fixed in 70% 
ethanol -20º C, washed with Nonidet P40 (Sigma) and dehydrated. Of each chromosome paint, 3 µl was used in a total 
of 10 µl hybridization mix (Cambio) and administered under a coverslip of 20 x 20 mm and denatured simultaneously 
on a Hybaid Omnislide (Thermo Electron, Breda, The Netherlands). Post-hybridization was performed by a wash step 
of 0.4x SSC/Tween-20 at 68,5ºC (1xSSC is 0.15 M sodium chloride/0.015 M sodium citrate) followed by several steps 
of 2x SSC, 4x SSC and PBS at room temperature. After dehydration the slides were hybridized with fluorescent probes 
to detect Y- and X-chromosomes, and counterstained with DAPI (blue) to show nuclei. A Zeiss Axiophot-2 microscope 
equipped with appropriate fluorescence filters was used for analysis of the fluorescence signals. Images were captured 
by Leica DC 350FX camera using a Leica CW4000 software package. Magnifications 630x.  
 
This was confirmed in gender-mismatched chimeras in which bone marrow–derived 
cells were recruited to renal tubules (Figure 2). In accordance with Li et al. (25), fusion of 
stem cells with somatic cells does not account for the majority of the conversion of bone 
marrow cells to renal cells after ischemic injury. Western blot analysis can be used to quantify 
the amount of eGFP positive bone marrow-derived cells in the kidney. A critical note, 
however, is that Western blot analysis can only differentiate between eGFP/LacZ expression 
in tubular cells or in leukocytes when the kidney is perfused before isolation. Inflammatory 
processes often play a significant role in the pathophysiology of AKI causing, among others, 
outer medullary congestion (2). Consequently, erythrocytes stick to the outer medulla, which 
hampers the perfusion procedure. In addition, attention should be paid to single tubular-like 
cells derived from the transplanted bone marrow, because these cells may also originate from 
donor leukocytes that fuse with residing tubular cells. To overcome these limitations, different 
identification techniques should be employed to confirm the findings. 
Renal function tests are required to determine the outcome of the regeneration process. 
The most common functional parameters used are creatinine clearance and blood urea 
nitrogen (BUN) concentration (5,26). Creatinine clearance is a widely accepted parameter for 
GFR assessment, although, one should be cautious for misinterpretations caused by 
inadequate urine collection and differences in creatinine production. A decreased creatinine 
clearance accompanied by an unchanged serum creatinine concentration can be caused by 
inadequate urine collection. In addition, production of creatinine differs among and within 
individuals over time, depending on dietary intake (vegetarian diet, creatine supplements) or 
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muscle mass. In this case, determinations of the renal clearance of inulin or other exogenous 
compounds, such as iothalamate, iohexol, or DTPA, are more reliable markers of GFR (27-
29). Individual variations in mice are, however, easy to exclude by using control animals 
which are genetically identical and are housed under the same conditions. Using our research 
protocol, a decreased creatinine clearance was observed 2 days after the induction of ischemia 
(P<0.001), which returned to near normal levels on day 7 post-ischemia (data not shown). 
The BUN concentration, on the other hand, is not as reliable as creatinine clearance, 
because it can vary independently of GFR changes due to variations in the rate of urea 
production. For example, a high protein diet results in an increase in BUN, as does enhanced 
tissue breakdown due to haemorrhage, trauma or corticosteroids. Whenever BUN values are 
used to predict renal function, additional tests, like creatinine clearance or fractional sodium 
excretion, should be performed to get a more reliable assessment of renal function.  
 
 
Table 1. Comparison of technologies used to study renal regeneration after bone marrow transplantation. 
a,b Numbers in rows refer to technologies described in the same column. 
Technology Isolation of bone marrow cells and transplantation Induction of renal ischemic injury 
Quantification of bone marrow-
derived stem cells in kidney repair 
Specific 
technologies 
(1) Labeling donor cells 
(2) Irradiation techniques 
 -lethal vs. sub-lethal 
(3) Transplantation:  
 aFull bone marrow vs. 
 specific population 
 bTime of transplantation 
(1) Operation procedure 
 -flank vs. midline incision 
(2) Clamping time  
(3) Time point ischemia induction 
(1) Immunohistochemistry 
(2) Western Blot analysis 
(3) Functional analysis 
Pros (1) Detection bone marrow derived 
cells 
(2) No or limited influence of 
recipient bone marrow cells 
(3) aFull bone marrow contains all 
(supporting) cell populations 
 -specific regenerative 
capacities can be studied 
 bDonor bone marrow cells can 
‘home’ and spread 
(1) Convenient methods of ischemia 
induction; 
     -flank incisions less harmful for 
animal 
(2) Controlled time leads to fixed 
degree of damage 
(3) Directly after transplantation is 
less time consuming 
(1) Direct overview of infiltrated 
cells in the kidney 
(2) Semi-quantitative results of the 
contribution of infiltrated cells 
(3) Creatinine clearance and 
fractional sodium excretion are 
relatively simple and reliable 
tests. 
Cons (1) eGFP sorting procedure causes 
a loss of cells 
(2) -Post-operative infections 
(lethal irradiation) 
      -Influence recipient     bone 
marrow prevents precise 
prediction of the stem cell 
regenerative capacity (sub-
lethal irradiation) 
(3) aSpecific regenerative 
capacities are missed; 
 bTime consuming experiments 
(1) Midline incisions cause more often 
post-operative infections 
(2) Directly after transplantation 
causes higher mortality 
(1) False positivity is seen; 
additional tests are needed  
(2) False positivity, perfusion of 
the kidney is needed 
(3) BUN values are not reliable; 
additional tests need to be done 
References (3,5,6,8,10) (3,5,10) (10,28,30) 
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Conclusions 
 
Considerable progress has been made in the development of different techniques to study the 
role of bone marrow-derived stem cells in ischemia-induced AKI. Using the method 
described in this review, we have shown that at least 10% of the regenerated proximal tubular 
segments originate from donor bone marrow. However, controversial results have been 
reported in the literature, mainly originating from differences in experimental models. We 
have listed the currently available techniques in Table 1 to aid in the selection of the most 
appropriate experimental model. Bone marrow consists of several stem cell populations and 
the specific types responsible for regeneration of damaged kidney tissue are still not known. It 
is likely that more subpopulations are responsible for this process, but their contribution has 
yet to be investigated by transplantation of the purified fractions.  
To study the regeneration process in vivo, mice should be in a good health condition to 
prevent the influence of other confounding factors. To achieve this, AKI should not be 
induced sooner than a few weeks after transplantation. In addition to a better physical 
condition of the recipient mice, a longer period between transplantation and injury induction 
is also beneficial for the regeneration process. Moreover, a longer time period allows cells to 
spread and migrate in the circulation, and to reconstitute the bone marrow.  
Finally, to assess the overall contribution of bone marrow-derived stem cells in kidney 
regeneration several methods can be applied, of which immunohistochemistry is the most 
reliable technique. An important issue is the exclusion of false positive cells. The use of 
confocal microscopy and (double-) staining of the kidney samples in quantitative analysis and 
the gender mismatching procedure in donor and recipient mice reduces the chance of false 
positive results. The outcome of kidney renewal after acute injury can be investigated by 
several functional tests. Although these tests do not cover the contribution of bone marrow 
cells, they give detailed information about the progression of the regeneration process and 
help in the comparison of different protocols.  
The use of appropriate in vivo models accompanied with more in vitro data about the 
differentiation process from stem cell into renal cell, will provide research tools to obtain 
more mechanistic insight in the regeneration process. Yet, the development of an in vitro 
assay, in which cultured renal cells differentiate from primitive stem cells, is still a major 
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challenge. Within the bone marrow, several stem cell populations have pluripotent 
characteristics. Transplantations with the hematopoietic stem cell population or mesenchymal 
stem cell population did not improve the renal repair process, but a third cell population, the 
multipotent adult progenitor cells (MAPC), may still be promising (17). This cell type might 
have the capacity to differentiate in vitro towards renal cells, and eventually could provide a 
valuable source of cells for transplantation and therapy. However, the kidney consists of a 
very heterogeneous cell population. At this moment an in vitro assay cannot imitate the 
complexity of kidney development in vivo, which limits the use of cultured renal cells for our 
research questions. The transplantation of bone marrow-derived stem cells in vivo is, 
however, promising and opens new possibilities for cellular therapies of renal disease. 
Autologous transplantation of stem cells may evidently minimize the use of donor organs and 
immunosuppressants, and possibly maximizes the success of tissue remodeling. Obviously, 
this is a next challenge to regeneration science. 
 
Methods 
 
Bone marrow culture medium 
Bone marrow cells are cultured using two different media: Iscove’s Modified Dulbecco’s 
Medium (Sigma Aldrich, Zwijndrecht, The Netherlands) supplemented with 
penicillin/streptomycin (1x) and β-mercaptoethanol (1x) (IMDM/PenStrep/ β-
mercaptoethanol) (Invitrogen, Breda, The Netherlands), and double concentrated 
prestimulation medium containing 65% IMDM/PenStrep/ β-mercaptoethanol, 10% Bovine 
Serum Albumin (Roche Diagnostics, Almere, The Netherlands), 2 µg/ml cytidine, adenosine, 
uridine 2’deoxycytidine, 2’deoxyadenosine, thymidine and 2’deoxyguanosine, 4 mg/ml 
Bovine Insulin, 7.5 mM cholesterol, 7.5 mM Linolic Acid, 2.5 µM FeCl3.6H2O, 77 mg/ml 
human transferrine (Sigma-Aldrich, Zwijndrecht, The Netherlands) 50 ng/ml murine Stem 
Cell Factor, 10 ng/ml Murine Interleukine-12, 10 ng/ml Murine Interleukine-3, 50 ng/ml 
human Flt-3, 10 ng/ml human thrombopoeitin (TPO) (Tebu-Bio, Heerhugowaard, The 
Netherlands), 1 µg/ml TGF-β (Sanquin Regentia, Amsterdam, The Netherlands) and 10% 
Fetal Calf Serum (Greiner Bio One, Alphen a/d Rijn, The Netherlands).  
 Chapter 2 42 
 
Isolation and maintenance of bone marrow cells 
Male FVB (Friend leukaemia virus B strain) mice (8 weeks old; obtained from Charles River, 
Germany), are euthanized by cervical dislocation and femur bones are removed. After 
removing the detached muscles, bones are flushed very vigorously into a 15 ml tube until they 
appear transparent, using a 23-gauge needle and IMDM/PenStrep/β-mercaptoethanol. 
Approximately 10-20 ml of medium is used for flushing the cells. After isolation, cells are 
filtered through a 40-µm filter, plated in a concentration of 1.106 cells/well in 6-wells plates 
(Greiner Bio One, Alphen a/d Rijn, The Netherlands) in IMDM/PenStrep/β-mercaptoethanol 
(1x) and prestimulation medium (1x) and cultured for 48 hours at 37˚C.  
 
Transduction and sorting procedure 
Humane Embryo Kidney (HEK) 293 cells are infected with an adenovirus expressing eGFP to 
convert them to packaging cells. These cells are cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) with glutamax (glutamine) (Sigma-Aldrich, Zwijndrecht, The Netherlands) 
supplemented with 10% Fetal Calf Serum (Greiner Bio One, Alphen a/d Rijn, The 
Netherlands), penicillin/streptomycin (1x) (Invitrogen, Breda, The Netherlands) and 1µg/mL 
puromycin (Becton Dickinson, Breda, The Netherlands). To produce the virus, cells are 
cultured in medium without puromycin for 36 hours and harvested by spinning down the 
suspension. The viral particles are stored at -80˚C until usage. Transduction takes place on 
plates coated with 0,12 mg/ml retronectine (Takara, Lucron Bioproducts B.V, Gennep, The 
Netherlands) and PBS for 2 hours at room temperature. Before plating the cells, coated plates 
are washed 3 times with Hanks’ Balanced Salt Solution/10 mM Hepes (HBSS/Hepes; 
Invitrogen, Breda, The Netherlands). Pre-stimulated cells are collected and washed two times 
with HBSS/Hepes. Cells are plated in a concentration of 1.106 cells/well in pre-stimulation 
medium containing the virus (dilution 1:1) and transduction procedure takes place for 24 h at 
37˚C. After the transduction period of 24 h, cells are collected and wells are washed three 
times with HBSS/Hepes. Subsequently, cells are sorted on GFP using Epics Altra flow 
cytometer (Beckman Coulter, Miami, FL).  
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Irradiation and transplantation procedure 
Mice are irradiated with a single dose of 3.5 Gy using a 137Cs irradiator and, subsequently, 
1.106 eGFP positive bone marrow cells, diluted in 100 µl 0.9% NaCl (B. Braun Melsungen 
AG, Melsungen, Germany), are injected via the tail vein. After transplantation, mice are 
housed under semi sterile conditions to avoid infections. 
 
Induction of Acute Renal Failure 
Four weeks after transplantation of the bone marrow cells, mice undergo unilateral ischemic 
injury. Mice are anesthetized using isoflurane, a flank incision is made and clamping the left 
renal artery and vein for 30 minutes induces ischemia. The flank incision is covered with 
gauze moistened in 0.9% NaCl, and mice are maintained at 37ºC using a warming path. After 
30 minutes, the clamp is removed and reperfusion is visually confirmed. In order to supervise 
the condition of the mice, animals are weighed before and after entering the metabolic cages 
and checked for abnormalities every day. After sacrificing the mice, kidneys are perfused with 
HBSS, divided in four pieces and snap frozen in liquid nitrogen for immunohistochemistry 
and light microscopy.  
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Abstract 
 
Renal ABC transporters have an important role in the elimination of metabolic waste products 
and compounds foreign to the body. The kidney has the ability to tightly control the 
expression of these efflux transporters to maintain homeostasis, and as a major mechanism of 
adaptation to environmental stress. 
In the present study, we investigated the expression of 45 ABC transporter genes in the mouse 
kidney under basal conditions, after induction of ischemia and after regeneration. 
Two days after clamping, mice showed a 76% decrease in renal creatinine clearance, which 
improved clearly within 7 days. This was confirmed by histological examinations. Seven days 
after ischemia, RQ-RT PCR data showed that transcript abundance of abcb1, abcb11 and 
abcc4 was increased, and that of abca3, abcc2 and abcg2 decreased. Expression of all 
transporters returned to baseline after 14 days, except for abcb11, which was reduced. 
Abcb11 is the major liver canalicular bile salt export pump. Here we show for the first time 
expression in the kidney and localization of the transporter to the apical membrane of 
proximal tubules. The presence of another novel renal transporter, abca3, was confirmed by 
Western blotting. Immunohistochemistry showed that abca3 is localized to the peritubular 
capillaries and apical membrane of proximal tubules. 
In conclusion, after inducing ischemic reperfusion injury in the kidney ABC transporters 
appear to be differentially regulated, which might be associated with the renal regeneration 
process. Furthermore, we showed for the first time expression and subcellular localization of 
abcb11 and abca3 in mouse kidney.  
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Introduction 
 
Members of the ATP Binding Cassette (ABC) superfamily of transporters are expressed in 
almost all tissues and cells where many of them are involved in the cellular defense against 
endogenous and exogenous xenobiotics, and their metabolites (1,2). Their overexpression in 
tumor cells is associated with multidrug resistance, which is a major complication for 
successful cancer chemotherapy. The transport proteins couple ATP hydrolysis to the 
transport of specific substrates. In excretory organs, like the kidney, ABC transporters have an 
important role in the elimination of metabolic waste products and compounds foreign to the 
body. The kidney has the ability to optimize the effectiveness of the excretory systems 
through a dynamic functional regulation at transcriptional and post-transcriptional levels in 
order to maintain homeostasis (3). Under pathological conditions waste products and 
xenobiotics may accumulate in the kidney due to tubular dysfunction (4), and there is 
increasing evidence from animal models that the expression level of efflux transporters is 
tightly controlled as a major mechanism of adaptation to environmental stress (5).  
 In addition to their efflux function, ABC transporters have been implicated in cellular 
protection against apoptosis and hypoxic damage (6,7) Furthermore, they have been 
associated with cell proliferation and differentiation in regeneration of, among others, liver, 
heart and skeletal muscle (8-11), but it is unknown whether they play a role in kidney repair 
after renal injury. For a few ABC transport proteins differential expression was found 
following renal injury. After induction of acute renal failure in rats, a decrease in Abcb1 
protein levels was observed in the kidney, whereas the expression in liver and brain was 
unchanged (12). In contrast, using nephrectomy as a model of chronic renal failure in rats in 
vivo, Laouari et al. (13) showed that renal Abcb1 mRNA expression levels were unchanged 3 
weeks and significantly increased 6 weeks after nephrectomy. However, protein levels 
remained unchanged during both periods. On the other hand, Abcc2 protein and mRNA levels 
were clearly elevated in kidney and liver, possibly as an adaptive response to elevated levels 
of circulating toxins (13).  
 The present study was designed to evaluate the renal expression of 45 different ABC 
transporters after damage of the mouse kidney. One of the most frequently occurring clinical 
problems concerning the kidney is acute kidney injury, which is associated with a high 
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morbidity and mortality. Because of the necrosis of renal tubules observed, the clinical 
phenomenon is termed acute tubular necrosis (ATN). Renal tubular cells are very sensitive to 
oxygen deprivation, therefore, ischemic insults, especially in combination with potentially 
toxic drugs, are the most important causes of ATN. Ischemia may be a result of operative 
cross-clamping of the aorta and/or renal arteries leading to necrosis in certain segments of the 
proximal tubule and to a lesser extent the thick ascending limb (4). Despite the high 
vulnerability of the kidney to ischemia and toxicity, the organ has a natural ability to recover 
and regenerate after acute damage. Dedifferentiation of glomerular and tubular cells to a more 
embryonic/mesenchymal phenotype represent key processes for recovery in response to 
damage (14). Whether ABC transporters play a role in the renal recovery process is yet 
undefined. After applying ischemia-reperfusion injury to mouse kidneys we found that a 
number of ABC transporters are differentially regulated, which might be associated with renal 
regeneration. Furthermore, we show for the first time expression and localization of abcb11 
and abca3 in mouse kidney.  
 
Results 
 
Ischemic-reperfusion injury in the kidney 
Histological examination two days after inducing renal ischemia revealed serious damage to 
the proximal tubules, compared to the control (Figure 1A). Loss of proximal tubule cells and 
loss of brush border membranes caused tubular obstruction (arrows in Figure 1B). After seven 
days, recovery of the proximal tubules was observed. New brush border membranes were 
formed but also cast formation is seen (arrows in Figure 1C). Finally, after fourteen days, the 
proximal tubules were almost fully recovered (arrows in Figure 1D).  
Blood and urine samples were collected 24h before, and two and seven days after surgery, 
and creatinine concentrations were determined. After two days, creatinine clearance decreased 
significantly by 75% (one-way ANOVA), and recovered partially to a level of 60% seven 
days after ischemia as compared to the normal baseline creatinine clearance in sham operated 
mice (Figure 2).  
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Figure 1. Histopathology of the mouse kidney. Characteristic histological signs of renal injury and regeneration after an 
ischemic insult. (A) Control kidney slice showing a glomerulus (G) surrounded by proximal tubules (P). (B) Two days after 
bilateral clamping of the renal artery and vein for 30 minutes, serious damage to the proximal tubules (P) is observed with 
debris in tubular lumen (indicated by arrows). (C) Seven days after the insult the tubules are partially recovered as can be 
concluded from repaired brush border membranes (indicated by arrows). (D) Almost completely restored tubular segments 
(indicated by arrows) were found after fourteen days. All magnifications 400x. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Effect of kidney ischemia reperfusion on renal creatinine handling. Creatinine clearances from sham operated mice 
and mice that underwent bilateral ischemia for 30 minutes followed by 7 days of recovery. Data are presented as mean ± 
SEM of 8 independent experiments. *** Significantly different from basal value (P<0.001). 
 
Gene expression in the mouse kidney before and after ischemia 
In mice, 51 members of the abc family have been identified, which show high concordance 
with their corresponding human gene orthologs. The ABC family is divided into seven classes 
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(A-G) of which the A and C classes contain the largest number of members (12 each). The 
expression patterns of 48 different transporter genes were assessed by RQ-RT PCR. Their 
expression was normalized for the average cycle threshold (CT) value for the housekeeping 
gene, Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (CT= 19.2 ± 0.48, n=16), and 
expressed as delta CT values. GAPDH expression remained stable after inducing ischemia 
(CT= 19.8 ± 0.32, n=16) and during the recovery period (CT= 19.1 ± 0.19, n=16). Other 
housekeeping genes Glucuronidase (GUS) and Hypoxanthine guanine phosphoribosyl 
transferase 1 (HPRT) gave comparable values to GAPDH (data not shown). Table 1 presents 
the expression values of the transporter genes before (control) and seven days and fourteen 
days after the induction of ischemia. Measuring the expression values 2 days after ischemia 
was not possible because of the poor quality of the mRNA. Transporters that showed a high 
gene expression in controls are abca3, abcc2, abcd3, abcd4 and abcg2 with delta CT values 
varying between 2.1 and 4.1. After ischemic injury, several transporter genes were 
upregulated (i.e. at least a 2 times higher expression), or downregulated (at least a 2 times 
lower expression), compared to control values from sham operated animals (15). Fourteen 
days after ischemia, the expression levels of all genes returned to baseline except for abcb11, 
which was downregulated. Based on their variable expression pattern or remarkably high 
expression in the kidney, the transporter gene products of abca3, abcb1a/b, abcc2, abcc4 and 
abcb11 were investigated further.  
Furthermore, the expression of the transcription factor, NF-κB, was investigated. The gene 
expression was induced seven days after ischemia (Delta CT values: 1.96 ± 0.52 vs. 4.26 ± 
0.98). Fourteen days after the ischemic insult still an increased gene expression of NF-κB was 
observed (Delta CT values: 1.66 ± 0.36). 
Table 1. ABC transporter gene expression along the kidney after inducing ischemia. 
ABC transportera Delta CT valuesb ABC transportera Delta CT valuesb 
Gene symbol        Assay Id’s FVB controls FVB 
7 days after ischemia 
FVB 
14 days after 
ischemia 
Gene Symbol        Assay Id’s FVB controls FVB 
7 days after ischemia 
FVB 
14 days after 
ischemia 
Abca1 Mm00442646_m1   6.4 ± 0.11   4.1 ± 0.42   6.9 ± 0.10 Abcc2 Mm00496899_m1   4.1 ± 0.08   6.1 ± 0.98   4.5 ± 0.37 
Abca2 Mm00431553_m1   6.2 ± 0.02   7.4 ± 0.95   7.0 ± 0.66 Abcc3 Mm00551550_m1 10.1 ± 0.18   7.1 ± 0.11 11.1 ± 0.07 
Abca3 Mm00550501_m1   2.1 ± 0.56   3.9 ± 0.82   2.2 ± 0.25 Abcc4 c   7.1 ± 0.25   6.0 ± 0.21   6.8 ± 0.67 
Abca4 Mm00492004_m1   9.3 ± 0.12 12.5 ± 0.38   8.8 ± 0.46 Abcc5 Mm00443360_m1   7.3 ± 0.23   7.4 ± 0.04   8.3 ± 0.09 
Abca5 Mm00461656_m1   6.9 ± 0.18   7.5 ± 0.34   7.5 ± 0.44 Abcc8 Mm00803450_m1 11.0 ± 0.19 12.3 ± 0.39 14.5 ± 0.83 
Abca6 Mm00461636_m1 11.0 ± 0.07   8.7 ± 0.54 11.6 ± 0.11 Abcc9 Mm00441638_m1   6.7 ± 0.21   6.7 ± 0.09   7.0 ± 0.10 
Abca7 Mm00497010_m1   5.6 ± 0.06   5.4 ± 0.94   6.6 ± 0.77 Abcc10 Mm00467403_m1   6.5 ± 0.32   7.5 ± 0.08   8.0 ± 0.28 
Abca8a Mm00462440_m1   9.5 ± 0.26   8.2 ± 0.32   7.9 ± 0.13 Abcd1 Mm00431749_m1   6.3 ± 0.51   6.3 ± 0.05   7.5 ± 0.24 
Abca8b Mm00457361_m1 10.1 ± 0.04   9.4 ± 0.68 10.9 ± 0.06 Abcd2 Mm00496455_m1   8.5 ± 0.21   8.6 ± 0.21 10.1 ± 0.18 
Abca9 Mm00461704_m1   8.0 ± 0.22   7.2 ± 0.31   8.2 ± 0.65 Abcd3 Mm00436150_m1   3.5 ± 0.31   4.8 ± 0.18   3.2 ± 0.21 
Abcb1a Mm00440761_m1   9.2 ± 0.03   9.4 ± 0.07   9.4 ± 0.25 Abcd4 Mm00436180_m1   4.1 ± 0.47   5.7 ± 0.32   4.4 ± 0.19 
Abcb1b Mm00440736_m1 11.0 ± 0.35   8.7 ± 0.13   8.7 ± 0.41 Abce1 Mm00649858_m1   3.5 ± 0.05   5.5 ± 0.59   6.7 ± 0.14 
Abcb4 Mm00435630_m1 14.3 ± 0.02   9.0 ± 0.03 12.6 ± 0.62 Abcf2 Mm00457400_g1   6.3 ± 0.21   6.4 ± 0.36   6.1 ± 0.13 
Abcb6 Mm00470049_m1   6.1 ± 0.28   7.3 ± 0.19   6.9 ± 0.97 Abcf3 Mm00658695_m1   6.3 ± 0.17   7.0 ± 0.21   7.9 ± 0.44 
Abcb9 Mm00498197_m1   8.1 ± 0.44   9.5 ± 0.15   8.5 ± 0.58 Abcg1 Mm00437390_m1   6.7 ± 0.28   5.3 ± 0.09   7.4 ± 0.27 
Abcb10 Mm00497927_m1   7.5 ± 0.26   8.4 ± 0.23   8.4 ± 0.60 Abcg2 Mm00496364_m1   2.2 ± 0.18   4.8 ± 0.31   3.3 ± 0.28 
Abcb11 Mm00445168_m1 11.4 ± 0.23   5.4 ± 0.56 21.2 ± 0.09 Abcg3 Mm00446072_m1 12.9 ± 0.63   9.9 ± 0.57 13.1 ± 0.13 
Tap1 Mm00443188_m1   6.8 ± 0.03   4.3 ± 0.06   8.0 ± 0.17 Abcg4 Mm00507250_m1 14.5 ± 0.18 12.3 ± 0.27 15.5 ± 0.33 
Tap2 Mm00441668_m1   6.5 ± 0.26   5.7 ± 0.35   7.0 ± 0.58 Abcg5 Mm00446249_m1 15.2 ± 0.09 11.7 ± 0.48 15.0 ± 0.31 
Abcc1 Mm00456156_m1   6.7 ± 0.29   5.6 ± 0.28   7.4 ± 0.12 dAbcg8 Mm00445970_m1 20.6 ± 0.41 15.9 ± 0.26 21.2 ± 0.78 
aGene expression values of different ABC transportersa (http://nutrigene.4t.com/humanabc.htm) in the mouse kidney before inducing ischemia, 7 and 14 days after inducing 
ischemia. bData of 16 pooled samples, measured in duplicates, are given. cPrimers and probe designed by PrimerExpress Software, version 1.5 (Applied Biosystems; see methods 
section). dLow expressed transport protein: CT value is not considered as valid.  
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Protein expression 
Seven days after inducing ischemia, we performed Western blotting to determine the protein 
expression of abca3, abcb1a/b, abcb11, abcc2, abcc4 and abcg2. The presence and 
localization of abca3 (150 kDa) in the kidney has, as yet, not been described. Figure 3A 
shows that after inducing ischemia, abca3 was downregulated. On the other hand, abcb1, with 
a size of approximately 140 kDa, was clearly upregulated (Figure 3B). Abcb11 is the major 
liver canalicular bile salt export pump (bsep), however, its expression in the kidney was not 
detected until now. Our Western blot results confirmed the RQ-RT PCR data and showed that 
the transport protein is present in the mouse kidney, but, in contrast with its gene expression, 
the protein disappeared within seven days after renal injury (Figure 3C). Both abcc2 and 
abcc4 showed a slight downregulation (Figure 3D-E), whereas, the expression of abcg2 was 
upregulated after inducing renal injury (Figure 3F).  
 
Immunohistochemistry 
Because RQ-RT PCR data and Western blotting revealed two ABC transporters that have not 
been described before in the kidney, viz. abca3 and abcb11, we investigated their renal 
distribution in more detail. Immunohistochemical analysis indicated that abca3 is localized in 
the peritubular capillaries of the kidney (Figure 4A-B). After counterstaining against heparan 
sulfate (Figure 4A-B) a specific staining of the abca3 transporter was observed in the apical 
membrane of several segments of the proximal tubule. Furthermore, Bowman’s capsule 
appeared to express abca3.  
Figure 4C and D show expression of abcb11 in the kidney. The transporter was found 
to be localized to the apical membranes of the proximal tubules (Figure 4C-D), which 
indicates that abcb11 may function as a urinary efflux pump. The localization of Abcc4/abcc4 
to the apical membranes of renal proximal tubules has been described previously (16,17), 
however, its segmental distribution is unknown. A representative immunohistochemical 
image (Figure 4E) indicates that the protein is expressed in all segments of the proximal 
tubule. Finally, the expression of abcg2 was investigated. After counterstaining with Na+,K+-
ATPase (18) a clear apical staining of abcg2 in the proximal tubules is observed (Figure 4F). 
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Figure 3. Immunoblot analysis of ABC proteins in FVB mice before and 7 days after inducing ischemia. Total membrane 
fractions of mice kidneys were isolated and analyzed for expression of abca3 (A), abcb1 (B), abcb11 (C), abcc2 (D), abcc4 
(E) and abcg2 (F). Data are expressed as mean ± SEM n = 4, where pixel intensity (arbitrary units) was set at 1.0 in the 
control. Significantly different from control (*: P<0.05, **: P<0.01, ***: P<0.001). 
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Figure 4. Renal distribution of mouse abca3, abcb11, and abcg2. (A) Representative immunohistochemical images show that 
abca3 is expressed in the peritubular capillaries (indicated by arrows) and the apical membranes of the proximal tubules (*). 
(B) In addition, abca3 is expressed in Bowman’s capsule. (C and D) Abcb11 is expressed in the apical membrane of the 
proximal tubules, as observed using two different antibodies (C): antibody from Kamiya Biomedical Company, Seattle, 
USA; (D): antibody from Prof. Dr. B. Stieger, University Hospital Zürich, Switzerland). (E) Abcc4 expression seen in the 
apical membrane of the proximal tubules. (F) After double staining with Na+K+-ATPase, which is localized to the basolateral 
membrane, it is clear that abcg2 is expressed in the apical membrane of the proximal tubules. G, glomerulus; B, Bowman’s 
capsule, P, proximal tubule, D, distal tubule [(A and B) x 500; (C) x 200; (D, E and F) x 400].  
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Discussion 
 
In the present study, we investigated the gene expression profile of ABC transporters after 
ischemia reperfusion injury in the mouse kidney. Histological and functional data indicate 
that the post-ischemic kidney has the ability to restore its damaged nephron segmental 
structure and its function, which is in good agreement with previously published studies 
(19,20). Two days after ischemia, brush border membranes are lost and cell debris is 
deposited in the lumen of the proximal tubules. Seven days after ischemia cast formation is 
seen but brush border membranes are nearly intact, and after fourteen days the kidney is 
almost completely recovered from injury.  
Our RQ-RT PCR experiments demonstrated increased mRNA levels of the transporter 
genes abcb1, abcb11 and abcc4, 7 days after inducing ischemia. The upregulation of abcb1 is 
likely to be an adaptive response in the regeneration process of the kidney after injury, and 
facilitates in this way the efflux of waste products. Reoxygenation of the kidney following 
ischemia is accompanied by the production of free radicals, potentially leading to oxidative 
damage. In the brain, Abcb1 expression was also found to be upregulated after oxidative 
stress (21). Abcb1 is upregulated in other stress situations as well, like cadmium toxicity and 
after insulin stimulation (22,23), however, a downregulation was observed after chronic renal 
failure (13). Under these conditions, the induction of the abcb1a/1b transporter was suggested 
to be mediated through signaling of the NF-κB pathway. It is known that reactive oxygen 
species (ROS) are formed in proximal tubules after ischemia (24,25) that activate NF-κB 
(23,26). NF-κB gene expression was 4.0-fold increased seven and fourteen days after 
ischemia, which suggests an activation of this pathway. This issue will be addressed further in 
the near future.  
In contrast to their mRNA levels, Western blot analysis, however, showed that protein 
levels of abcb11 and abcc4 were decreased after the ischemic insult, which indicated that 
these transporters are regulated by a posttranscriptional mechanism. This is in good 
agreement with previous observations for abcb11 in the liver and abcc4 in the kidney 
(17,27,28). ABC transporters expression is clearly regulated at the transcriptional level (29), 
but several mechanisms of post-transcriptional regulation have been described as well, 
including phosphorylation and protein routing (30,31). Using two different antibodies, we 
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showed by immunohistochemistry that abcb11 localizes to the apical membrane of the 
proximal tubular cells of the kidney. Abcb11 has been studied intensively in the liver where it 
is localized to the canalicular microvilli and to subcanalicular vesicles of the hepatocyte (32). 
The efflux pump mediates the ATP-dependent transport of conjugated monovalent bile salts, 
like glycocholate, taurochenodeoxycholate and tauroursodeoxycholate (33). In addition to 
these bile salts, compounds like vinblastine, pravastatine, taxol and calcein have been 
reported to be Abcb11 substrates (34-36). Expression in human and rat liver is variable under 
cholestatic conditions and in advanced cirrhosis, in which the protein and the gene were 
upregulated (37). In addition, Abcc4 was upregulated in rat liver in obstructive cholestasis 
whereas the protein was downregulated in the kidney (17). As suggested for Abcc4, the 
downregulation of abcb11 and abcc4 in the kidney in the present study may be an adaptive 
response to increased urinary substrates in renal failure (17). 
A downregulation after ischemia at the mRNA level was established for abca3, abcc2 
and abcg2. Abca3 and abcc2 protein levels were also decreased, in contrast to abcg2 which 
was upregulated. Abca3 is expressed in the lung in the alveolar type II cells, where it is 
supposed to play an important role in the formation of pulmonary surfactant (38). Mutations 
in the human ABCA3 transporter have been identified as a cause of acute respiratory distress 
syndrome (RDS) and can cause fatal surfactant deficiency in newborns (39). Our data 
demonstrate that abca3 is highly expressed in the kidney and that it is localized in the 
peritubular membranes, the apical membranes of the proximal tubule and in Bowman’s 
capsule of the kidney. We can only speculate about the function of the transporter in the 
kidney. ABCA3 likely plays a role in lipid homeostasis, since it closely resembles other 
ABCA family members that are known to transport phospholipids. Reorganization of 
membrane lipids may be an important function in the regeneration process of damaged tissue 
(40).  
Abcc2 was downregulated after ischemia at both the mRNA level and protein levels. 
This is different from study by Laouari et al. where they found an increase in Abcc2 after 
chronic renal failure (13), however, a downregulation is in agreement with our findings in 
killifish renal tubules after short-term exposure to nephrotoxic compounds (41,42). 
Remarkably, in liver failure the transport protein is downregulated in the hepatocyte but 
upregulated in the kidney, probably to facilitate the renal excretion of accumulating bile salts 
Chapter 3 59
(43,44). The expression of Abcc2 in the liver is under the control of nuclear receptor 
activation which is impaired during cholestasis (29,37), but post-transcriptional mechanisms 
of downregulation have been reported as well (31). Similar to abcc4, the expression of abcc2 
in liver opposes from those in the kidney in liver failure, indicating that regulation of transport 
proteins in the kidney is clearly distinct from the mechanisms observed in the liver.  
Abcg2 or Breast Cancer Resistance Protein 1 is highly expressed in the mouse kidney 
and is known to transport several anti-cancer drugs, like methotrexate, topotecan and 
doxorubicin (45). After inducing an ischemic insult, mRNA levels were downregulated in 
contrast to the protein levels that were upregulated. Its localization in the apical membrane of 
renal proximal tubules and substrate specificity, suggest that upregulation of abcg2 after 
injury is an adaptive response to accumulating harmful compounds that have to be excreted 
into urine. In addition to its role in detoxification through efflux, ABCG2 has been shown to 
be a determinant in the side population phenotype of progenitor cells (46,47), has been 
associated with regeneration and repair of skeletal muscle and heart tissue  and it was 
suggested that the protein protects cells from hypoxic damage by controlling porphyrins 
and/or heme levels (6). Because of its high expression in the mouse kidney and upregulation 
after ischemic-reperfusion damage, we speculate that abcg2 may have a role in tissue defense 
and regeneration by cell differentiation in the kidney as well. 
In conclusion, our results show for the first time expression and subcellular 
localization of abcb11 and abca3 in the kidney. Several transporter genes and proteins appear 
to be differentially regulated after renal injury, which might be associated with the renal 
regeneration process. Further research is needed to elucidate the functional role of the 
transporters in renal tissue repair and regeneration. 
 
Methods 
 
Materials 
Primer and probe sets for quantitative real-time PCR (RQ-RT PCR) were purchased at 
Applied Biosystems, (Zwijndrecht, The Netherlands). Primers for PCR experiment were 
obtained from Biolegio (Malden, the Netherlands). Paraplast was obtained from Amsterstad 
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(Amsterdam, the Netherlands). Nitrocellulose membranes were acquired from Amersham 
(Buckinghamshire, UK). Vectashield, mounting medium, normal goat serum, avidine and 
biotine and the vectastain ABC kit were obtained from Vector Laboratories Inc. (Burlingame, 
CA). Antibody directed against ABCB1 (C219), and peroxidase labeled and biotinylated 
secondary antibodies were purchased from DakoCytomation (the Netherlands). Secondary 
fluorescent antibodies were obtained from Molecular Probes. DAB chromogene was acquired 
from Sigma-Aldrich (Zwijndrecht, The Netherlands). The antibody directed against abcg2 
was obtained from Kamiya Biomedical Company (Seattle, USA). The abca3 antibody was a 
kind gift from Dr. Nobohiro Ban (Akita, University School of Medicine, Akita, Japan). 
Antibodies directed against abcb11 were obtained from Kamiya Biomedical Company 
(Seattle, USA) and from Prof. Dr. Bruno Stieger. Antibody used for heparan sulfate staining 
was obtained from Dr. T.H. van Kuppevelt (48) and the antibody against Na-K-ATPase was 
from Dr. J.B. Koenderink (18). All other chemicals used were of the highest purity available 
and obtained from Sigma-Aldrich (St Louis, Mo). 
 
Animals and ischemia induction 
All procedures involving animals were approved by the Animal Experimental Committee of 
the Radboud University Nijmegen. Male FVB (Friend leukaemia virus B strain) mice (6-8 
weeks) were obtained from Charles River (Germany), and were housed under routine 
laboratory conditions at the Central Animal Facility Nijmegen. Mice were anesthesized using 
isoflurane and ischemia was induced by bilateral clamping of the renal artery and vein for 30 
minutes; control mice were sham operated. Mice were placed in metabolic cages 2, 7 and 14 
days after inducing ischemia to collect urine and blood. Mice were sacrificed by 
exsanguination. Kidneys were removed and divided in two parts: one part was used for 
histological examination and was fixed in Bouin’s solution. The other part was used for 
immunohistochemistry, RNA and membrane isolation and was stored at -80ºC until further 
use. Serum creatinine levels were determined using the Jaffé method (49). 
 
RNA isolation and cDNA reaction 
RNA isolation was performed using the micro-dismembrator (Sartorius BBI Systems GmbH, 
Melsungen, Germany). Total RNA was isolated with Trizol reagent (Invitrogen, Breda, The 
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Netherlands). RNA material from 16 mice was pooled in two groups and used for reverse 
transcription in duplicate. Reverse transcription was performed in a total mixture of 20 µl 
containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, 12.5 mM 
dNTP mix, 200 U of Mo-MLV reverse transcriptase (Invitrogen, Breda, The Netherlands), 20 
U RNAsin (Promega, Madison, WI, USA) and 5 µg of random hexamers (Pharmacia, 
Uppsala, Sweden). This reaction mixture was incubated at 20ºC for 10 minutes, at 42ºC for 45 
minutes and at 95ºC for 10 minutes.  
 
Quantitative PCR 
For RQ-RT PCR, 2 pooled samples obtained from 16 different mice were used. RQ-RT PCR 
was performed in duplo using the ABI/PRISM 7900HT Gene Expression Micro Fluidic Card 
(Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. 
Primer and probe set ID numbers are given in Table 1. Abcc4 was performed separately 
because it was not available at the Micro Fluidic Card, and the utilized primers and probe 
were designed by PrimerExpress Software (version 1.5, Applied Biosystems, Foster City, CA, 
USA). The primers used were 5’-CTGCAGGACGCCAACCTCTG-3’, mMRP4_RT_Fw; 5’-
CTTCTTCCAGTCTCCGCTTATGA-3’, mMRP4_RT_Rev. Probe sequence was TET-5’-
CGCGCGTGTTCTTCTGGTGGC-3’-TAMRA (Applied Biosystems, Zwijndrecht, The 
Netherlands). cDNA amplification was performed with TaqMan® Universal PCR Master Mix 
(Applied Biosystems, Zwijndrecht, The Netherlands), 5 pmol of TET-labeled probe, 15 pmol 
forward and reverse primer in a total reaction volume of 25 µl. The thermal cycling conditions 
were 2 minutes at 50ºC and 10 minutes at 95ºC, followed by 40 cycles of 9 seconds at 95ºC 
and 1 minute at 60ºC. PCR reactions were analyzed either using ABI PRISM 7900HT 
Sequence Detection System or the 7700 Sequence Detection System (Applied Biosystems, 
Foster City, CA, USA). For normalization, the housekeeping genes GAPDH, GUS and HPRT 
were used.  
 
Membrane Preparation and Western Blotting 
Total membrane fractions were obtained using the micro-dismembrator (Sartorius BBI 
Systems GmbH, Melsungen, Germany). To this end, frozen kidneys were pulverized (2000 
rpm, 30 seconds) and transferred to ice cold TS buffer (10 mM Tris-HCl, 250 mM Sucrose) 
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including protease inhibitors (1 mM PMSF, 1µg/ml aprotinin, 5 µg/ml leupeptin, 1 µg/ml 
pepstatin and 10 µM E64). From these suspensions, a supernatant was prepared (12000×g, 30 
minutes, 4ºC) which was centrifuged for 75 minutes at 105000×g at 4ºC. The resulting pellet 
containing crude membrane fractions (30 µg) was solubilized in Laemmli sample buffer, 
heated at 65ºC for 10 min, separated on a 6% or 10% polyacrylamide gel and transferred to 
Hybond-C pure nitrocellulose membrane. Transfer of proteins was confirmed by the 
reversible staining of the membrane with Ponceau Red. Subsequently, the blot was blocked 
for 60 min with 5% nonfat dry milk powder in Tris-buffered saline supplemented with 0.1% 
Tween-20 (TBS-T), after which the blot was washed twice in TBS-T. The membrane was 
incubated at 4ºC overnight with the primary antibody: Abca3 diluted 1:1000 (50), Abcb1a/b 
diluted 1:200, Abcb11 diluted 1:500, Abcc2 diluted 1:1000 (51), Abcc4 diluted 1:1000 (16) 
and Abcg2 diluted 1:50. After two times of washing for 5 min with TBS-T, the blot was 
blocked for 30 min as described above. The blot was then washed twice with TBS-T and 
incubated at room temperature for 60 min with the secondary antibody goat anti-mouse, goat 
anti-rabbit and goat anti-rat diluted 1:5000. Finally, the blot was washed twice for 5 min with 
TBS-T and TBS, respectively. Proteins were visualized using enhanced chemiluminescence 
(Pierce, Rockford, IL). For semi-quantification we measured the pixel intensity of the bands 
using Scion image version beta 4.02 for Windows (Scion Corp. Frederick, Maryland). 
 
Histological examination 
For light microscopy, kidney fragments taken 2, 7 and 14 days after inducing ischemia were 
fixed in Bouin’s solution, dehydrated and embedded in paraplast. Sections of 3 µm were 
stained with periodic acid-schiff (PAS). 
 
Immunohistochemistry 
Serial tissue sections of 1,5 µm were obtained using a cryostat, air dried and fixed in acetone 
for 10 minutes. Again, slices were air dried and incubated for 60 minutes with the first 
antibody in PBS supplemented with 1% BSA. Slides were rinsed with PBS for 10 minutes 
and incubated with the secondary antibody Alexa Fluor 488 or Alexa Fluor 594 for 45 
minutes, diluted 1:200. After rinsing, slices were mounted in Vectashield mounting medium. 
For the antibodies abcb11 and abcc4 (16), slices of 4 µm were obtained using a cryostat and 
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fixed in acetone for 5 minutes. Endogenous peroxidase was quenched by incubation with 5% 
H2O2 for 5 minutes. Sections were air dried, incubated with normal goat serum for 10 minutes 
and incubated with the primary antibody in PBS 1% BSA overnight. Slices were rinsed with 
PBS and incubated with successive avidine for 10 minutes and biotine for 10 minutes. Slices 
were rinsed and incubated with the biotinylated goat anti-rabbit secondary antibody (dilution 
1:200) for 30 minutes followed by incubation with vectastain ABC kit for 45 minutes. 
Subsequently, color reaction was developed using DAB chromogene. Slices were 
counterstained with haematoxylin, dehydrated, and mounted in mounting medium. Sections 
were examined with a confocal laser-scanning microscope (CLSM; Leica lasertechnik GmbH, 
Heidelberg, Germany). 
 
Data analysis 
Data are presented as mean ± SEM. Mean values were considered to be significantly 
different, when P<0.05 by use of a student’s t-test. Software used for statistical analysis was 
GraphPad Prism® (version 4.03 for Windows; Graph Pad Software, San Diego CA). 
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Abstract  
 
The multidrug resistance gene 1 product, P-glycoprotein (P-gp), is expressed in several 
excretory organs including the apical membrane of proximal tubules. After inducing acute 
renal failure P-gp expression is upregulated and this might be a protective function by 
pumping out toxicants and harmful products of oxidative stress. We characterized renal 
function of P-gp knockout mice and studied its consequences in renal ischemic damage. 
Compared to wild type mice, knockout mice have a lower glomerular filtration rate and renal 
plasma flow. An augmented urinary excretion of sodium, numerous amino acids, calcium, 
glucose and low molecular weight proteins was observed along with an increased diuresis. A 
higher lithium plasma clearance in the knockout mice suggested proximal tubular 
dysfunction. Electron microscopy showed mitochondrial abnormalities in proximal tubular 
cells that could account for decreased ATP levels in the cortex. After inducing ischemia, wild 
type mice showed a decrease in creatinine clearance and severe proximal tubular necrosis. In 
contrast, knockout mice had no signs of tubular damage. Our data indicate that P-gp knockout 
mice have impaired renal function but are protected against ischemic renal injury. 
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Introduction 
 
The multidrug resistant gene 1 (MDR1) product, P-glycoprotein (P-gp), is a well characterized 
ATP-dependent efflux transporter. The transport protein was originally identified because of 
its overexpression in tumor cells associated with an acquired cross-resistance to various 
cytotoxic anticancer agents. However, further research indicated that P-gp is also expressed in 
normal tissues, like the intestine, liver, kidney, pancreas, blood-brain barrier and testis (1). 
The presence of P-gp in these excretory organs and tissue barriers indicates that this 
transporter has an important role in the protection of the organism against toxic compounds. 
Indeed, studies in mice genetically deficient in one of the P-gp genes, mdr1a, showed severe 
toxicity upon exposure to ivermectine as a result of elevated drug levels in many tissues, 
especially in brain, and decreased drug elimination. Remarkably, these knockout mice have 
no apparent phenotype under normal conditions (2). 
In the kidney, P-gp is localized to the apical membrane of the proximal tubules where 
its exact function is at present unknown, but given the demonstrated functions elsewhere in 
the body and its substrate specificity, a role in the extrusion of xenobiotics and metabolic 
wastes from blood into urine is expected (3). The transporter is regulated through the activity 
of hormones, protein kinases and nuclear receptor signaling pathways (4), however, the 
physiological regulation may be influenced by exogenous factors, like exposure to 
(nephro)toxicants and cellular oxidative stress. We and others showed an upregulation of the 
transport protein after ischemic-reperfusion damage (5-7) or exposure to cadmium (8), in 
which signaling of an NF-κB-dependent pathway might be involved. The observed 4.7 times 
upregulation in P-gp in the kidney after acute injury suggests that this transporter possibly 
plays a role in the renal regeneration process.  
The kidney has a high capacity to regenerate after injury. In contrast to many other 
organs, the postischemic kidney has the ability to restore its function and structure completely 
(9). Regeneration of the tubular epithelial cells may result from dedifferentiation, cell division 
and cell spreading of neighboring viable tubular epithelial cells (9-11). Alternatively, stem 
cells may be involved either residing within the kidney or derived from circulating bone 
marrow (12-16). Studies by Bunting et al. indicated that P-gp may function as a regulator for 
stem cell differentiation (17,18). P-gp is highly expressed on primitive hematopoietic stem 
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cells and a downregulation of this transporter triggers differentiation of these progenitor cells. 
Whether P-gp is essential in regeneration of the kidney after injury is unknown.  
The present study was designed to investigate the role of P-gp in the kidney in more 
detail. We hypothesized that P-gp plays an important role in proximal tubular physiology and 
in the renal regeneration after ischemia reperfusion injury. To test this hypothesis we 
extensively studied renal functional parameters in mice lacking the expression of the two 
murine homologs, mdr1a and mdr1b, the mdr1a/1b(-/-) mice. Furthermore, we studied the role 
of P-gp in renal regeneration after ischemia reperfusion injury. Our data indicate that 
mdr1a/1b(-/-) mice have an impaired renal function caused by generalized proximal tubular 
dysfunction. In addition, mdr1a/1b(-/-) mice are protected against ischemic renal damage.  
 
Results 
 
Mdr1a/1b(-/-) mice show altered renal function parameters 
After careful observation of the mdr1a/1b(-/-) mice several remarkable differences were seen 
(Table 1). Diuresis was more than 2-fold increased in the knockout mice, after collecting 
urine for 24 hours (P<0.001). Mean arterial pressure (MAP) was increased compared to wild 
type animals (P<0.05). Furthermore, mdr1a/1b(-/-) mice showed elevated levels of ureum in 
serum as compared to FVB wild type mice (Table 2). In contrast, serum glucose and ionized 
calcium levels were significantly lower in the knockout mice (P<0.01). All other parameters 
determined remained unchanged.  
 
Table 1. General characteristics of mdr1a/1b(-/-) mice and wild type FVB mice. 
Genotype Sex Age 
(weeks) 
Body weight 24 h urine volume 
(ml) 
Kidney weight 
(mg) 
Mean arterial 
pressure (mmHG) 
FVB M 8 24 ± 2 0.75 ± 0.03 152 ± 3 79. ± 2 
mdr1a/1b(-/-) M 9 23 ± 2  1.90 ± 0.11a 156 ± 7    94 ± 7b 
Phenotypic characterization of mdr1a/1b(-/-) mice revealed no changes in body weight and kidney weight. Diuresis was 
significantly increased in mdr1a/1b(-/-) mice, after collecting 24-hour urine obtained from mice maintained in metabolic cages 
(n=24), (three mice per cage). In addition, mean arterial blood pressure was significantly decreased (n=9). Data are presented 
as mean ± SEM. a: P<0.001, b: P<0.05 versus FVB wild type mice. 
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Food and water intake was measured after housing mice individually in metabolic cages. 
Food intake was increased in both mice after switching to a low sodium diet. Water intake, 
weight loss, creatinine clearance and urinary sodium excretion were significantly different in 
mdr1a/1b(-/-) mice after changing diet contents. Additionally, aldosterone levels increased in 
mdr1a/1b(-/-) mice 7 days after changing diet contents. Data were obtained from 5 FVB and 5 
mdr1a/1b(-/-) mice, aldosterone values were determined in blood from 5 pooled mice. a: P<0.05 
versus FVB wild type on day 0, b: P<0.01, c: P<0.001 versus wild type levels at the same time 
point after changing diet contents. 
 
Table 2. Serum and blood gas analysis of FVB wild type and mdr1a/1b(-/-) mice. 
 FVB wild type                        mdr1a/1b(-/-) 
Creatinine (µmol/l) 3.4 ± 0.3                         3.8 ± 0.2 
Ureum (mmol/l) 6.0 ± 0.1                         7.6 ± 0.5a 
Sodium (mmol/l)         157.2 ± 0.2                     156.4 ± 0.6 
Albumin (g/l)           11.5 ± 0.2                       11.6 ± 0.3 
Lactate (mmol/l)             9.0 ± 1.2                         8.3 ± 1.0 
Glucose (mmol/l)           13.2 ± 0.1                         9.4 ± 0.4b 
Ionized Calcium (mmol/l)           1.23 ± 0.01                       1.20 ± 0.01b 
Potassium (mmol/l)             4.6 ± 0.1                         4.2 ± 0.1 
Base Excess (mmol/l)            -8.9 ± 2.0                        -6.3 ± 1.1 
HCO3 (mmol/l)           21.8 ± 1.6                       23.0 ± 0.5 
PCO2 (kPa)             9.3 ± 0.4                         8.7 ± 0.6 
pH              7.1 ± 0.03                         7.2 ± 0.03 
Serum concentration of ureum was significantly increased in mdr1a/1b(-/-) mice compared to FVB wild type mice, in contrast 
to glucose and ionized calcium values which were decreased in mdr1a/1b(-/-) mice compared to FVB wild type mice. Data are 
presented as mean ± SEM, n= 24 mice. a: P<0.05 versus wild type mice, b: P<0.01 versus FVB wild type mice.  
 
 For the determination of urinary parameters, 24-hour urine was collected from mice 
maintained in metabolic cages (n=24, three mice per cage). Urinary sodium (P<0.05), calcium 
(P<0.001), protein (P<0.001) and glucose (P<0.01) excretion was significantly increased in 
the knockout mice as compared to wild type mice (Table 3). Correcting the urinary values for 
creatinine excretion revealed comparable results.  
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Table 3. Analysis of different compounds in urines from FVB wild type compared to mdr1a/1b(-/-) mice. 
 FVB wild type mdr1a/1b(-/-) 
Creatinine (mmol/24h) 2.3 ± 0.5 2.3 ± 0.3 
Ureum (mmol/24 h) 0.5 ± 0.1 1.0 ± 0.2 
Sodium (mmol/24h) 0.2 ± 0.1  0.3 ± 0.1a 
Calcium (µmol/24h) 0.8 ± 0.1  3.8 ± 0.4c 
Protein (mg/24h) 1.7 ± 0.2 11.6 ± 1.7c 
Glucose (mg/24h) 2.2 ± 0.6   5.1 ± 0.4b 
Urine was collected after housing 24 mice in groups of 3 in metabolic cages. Excretion of sodium, calcium, proteins and 
glucose were significantly increased in mdr1a/1b(-/-) mice compared to FVB wild type mice. Urinary values were corrected 
for diuresis and collecting time. Correction for creatinine excretion revealed similar results. Data are presented as mean ± 
SEM. a: P<0.05 versus control, b: P<0.01 versus control, c: P<0.001 versus control.  
 
After placing mice on a low-sodium diet, we observed comparable increasing sodium intake 
in both mice (Table 4), but water intake was significantly higher in the mdr1a/1b(-/-) mice. 
This increased water intake was accompanied by an augmented urinary sodium excretion and 
loss of weight in the mdr1a/1b(-/-) mice compared to FVB wild type mice. Plasma aldosterone 
levels were measured in pooled samples of 5 mice, before and 7 days after placing the mice 
on a low-sodium diet. In mdr1a/1b(-/-) mice, aldosterone levels showed a two-fold increase 
compared to basal levels in contrast to FVB wild type mice, in which levels remained 
unchanged (Table 4). This points to extracellular volume contraction in mdr1a/1b(-/-) mice. 
 
Table 4. Analysis of food- and water intake, weight loss and diuresis in FVB wild type mice and mdr1a/1b(-/-) 
mice receiving a diet with a low-sodium content. 
FVB wild type mdr1a/1b(-/-) Days after low sodium diet 
0 2 7 0 2 7 
Sodium intake (mg/day)   1.7 ± 1.5  1.2 ± 0.2  1.1 ± 0.3  6.1 ± 4.1    1.0 ± 0.4
 
    1.0 ± 0.7 
Water intake (g/day)   1.4 ± 0.2  1.9 ± 0.6  1.7 ± 0.4  2.7 ± 0.9a    4.2 ± 0.8b     3.0 ± 0.6b 
Weight loss (% of day 0)  -  8.1 ± 3.1  4.2 ± 2.2 -  10.5 ± 3.9b   15.9 ± 1.9c 
Creatinine clearance (µ l/min) 474 ± 17    463 ± 18 479 ± 12 424 ± 19   358 ± 15b    296 ± 20c 
Urinary sodium excretion 
(mmol/day) 
  0.2 ± 0.1  0.2 ± 0.2  0.2 ± 0.1  0.3 ± 0.1    0.8 ± 0.2b     0.4 ± 0.1b 
Plasma aldosterone (nmol/l) 0.42      0.53     0.38         0.80 
Food and water intake was measured after housing mice individually in metabolic cages. Food intake was increased in both 
mice after switching to a low sodium diet. Water intake, weight loss, creatinine clearance, and urinary sodium excretion were 
significantly different in mdr1a/1b(-/-) mice after changing diet contents. Additionally, aldosterone levels increased in 
mdr1a/1b(-/-) mice 7 days after changing diet contents. Data were obtained from five FVB and five mdr1a/1b(-/-) mice, 
aldosterone values were determined in blood from five pooled mice. Data are presented as mean ± SEM. a: P<0.05 versus 
FVB wild type on day 0. b: P<0.01, c : P<0.001 versus wild-type levels at the same time point after changing diet contents. 
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To investigate the renal function in mdr1a/1b(-/-) mice in more detail, we determined 
the GFR and RPF by the clearances of [3H]-inuline and [14C]-para-aminohippuric acid (PAH), 
respectively. In mdr1a/1b(-/-) mice, GFR was significantly decreased (P<0.01) compared to 
wild type mice. RPF was decreased in mdr1a/1b(-/-) mice (P<0.05; Figure 1) as well.  
 
Figure 1. Renal hemodynamics in FVB wild type mice and mdr1a/1b(-/-) mice. Mdr1a/1b(-/-) mice show a decreased 
glomerular filtration rate (GFR) (A) and renal plasma flow (RPF) (B) compared to FVB wild type mice. GFR and RPF were 
measured using [3H]-inulin and [14C]-para-aminohippuric acid clearances, respectively. Data are presented as mean ± SEM of 
6 mice. Significantly different from FVB wild type mice (*: P<0.05; **: P<0.01). 
 
Proximal tubular function is disturbed in mdr1a/1b(-/-) mice 
The proximal tubular cells are responsible for the reabsorption of the majority of the filtered 
water and electrolytes in the kidney and excretion of metabolic wastes. Moreover, tubular 
cells are involved in the reabsorption of a large amount of essential compounds, for instance 
glucose, phosphate, calcium, uric acid and amino acids. The increased urinary excretion of 
sodium, calcium, proteins and glucose may reflect a disturbed proximal tubular function. To 
investigate the reabsorptive function of the proximal tubule, we studied lithium plasma 
clearance after a single subcutaneous injection of lithium chloride (10 mmol/kg bodyweight). 
One hour after the injection, plasma concentrations of lithium were at maximum and did not 
differ between both mice (Figure 2). However, 3, 6 and 8 hours after injection the decline in 
the lithium concentration curve was faster in the knockout mice as compared to the wild type 
mice, indicating that lithium plasma clearance was significantly higher in mdr1a/1b(-/-) as 
compared to FVB wild type mice (13.3 ± 0.2 vs. 8.5 ± 0.1 ml/h, P<0.001). Under normal 
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conditions, lithium is highly reabsorbed by the proximal tubules and a reduction in lithium 
reabsorption points at a disturbed proximal tubular function. 
  
Figure 2. Time course of lithium plasma 
concentrations after injecting 10 mmol/kg bodyweight 
lithium chloride in FVB WT mice and mdr1a/1b(-/-) 
mice. Lithium plasma concentrations are significantly 
decreased in mdr1a/1b(-/-) mice (□), in time compared to 
FVB wild type mice (■; 8.5 ± 0.1 vs. 13.3 ± 0.2 
mmol/l, P<0.001). Data are measured in 16 mice, 
divided in 4 groups and presented as mean ± SEM. 
Significantly different from FVB wild type mice (***:  
P<0.001). 
 
Furthermore, we investigated the amount and pattern of proteins excreted in urine by gel 
electrophoresis. Bovine serum albumin was used as an internal control at two concentrations 
(Figure 3). Gels were loaded with 25 µl of urine collected from FVB wild type and the 
mdr1a/1b(-/-) mice. Both mice showed an equivalent urinary albumin excretion, but low 
molecular weight protein levels were abundantly present in urines from mdr1a/1b(-/-) mice but 
not from FVB wild type mice. This confirms the proximal tubular reabsorption dysfunction in 
the knockout mice.  
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Figure 3. Representative gel showing the amount and pattern of urinary proteins. Representative images of urine samples 
separated on a 10% polyacrylamide gel. Urines from mdr1a/1b(-/-) mice show an increased excretion of low molecular weight 
proteins compared to FVB wild type mice, corrected for albumin excretion. (A) 25 µl of urine from FVB (lane 3) and 
mdr1a/1b(-/-) (lane 4) was used to determine protein patterns by gel electrophoresis. Bovine serum albumin (lane 1 and 2) was 
used as a control, in two different concentrations, 1.3 en 0.65 µg respectively. (B) Semi-quantification of gels by 
measurement of pixel intensities (arbitrary units). Values are means ± SEM, n = 5. Significantly different from wild type 
FVB mice (***: P<0.001). 
 
Most proteins filtered by the glomerular apparatus are reabsorbed by endocytosis in 
the proximal tubules, a process in which the transmembrane receptor protein megalin is 
involved. Megalin is a cell surface receptor localized in the brush border membrane of the 
proximal tubules. Here, it mediates the tubular reabsorption of various filtered proteins, like 
β2-microglobulin and immunoglobulin light chains (19-21). Figure 4 shows a clear positive 
immunostaining of megalin and normal brush border composition, indicating that the 
differences in protein handling between both mice are not explained by alterations in megalin 
expression. 
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Figure 4. Megalin expression in FVB wild type mice and in mdr1a/1b(-/-) mice. Representative immunohistochemical images 
show that megalin is expressed in the apical membrane of the proximal tubules in FVB wild type mice (A) and mdr1a/1b(-/-) 
mice (B). Green counterstaining indicates Na+/K+-ATPase expression. Arrows point to megalin staining in the apical 
membrane of the proximal tubules. DT= distal tubule. 
 
 
 
 
 
 
 
 
 
 
Figure 5. Fractional tubular reabsorption of free amino acids in mdr1a/1b(-/-) mice compared to FVB wild type mice. 
Percentage of the amino acids that are reabsorbed in the proximal tubule. A decreased tubular reabsorption of several free 
amino acids is seen in mdr1a/1b(-/-) mice (□), compared to wild type mice (■). Data are measured in 4 pooled samples from 8 
mice each, given as a mean ± SEM.  
 
In addition, the urinary excretion of free amino acids in mdr1a/1b(-/-) mice was 
compared to the excretion in wild type mice. Figure 5 presents an overview of the calculated 
tubular reabsorption of 23 different compounds. The tubular reabsorption of glutamine, 
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proline, phenylalanine, ornithine and arginine was severely decreased in mdr1a/1b(-/-) mice 
compared to FVB wild type mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Mitochondrial morphology of mdr1a/1b(-/-) mice compared to FVB wild type controls. (B, C) The mdr1a/1b(-/-) mice 
show mitochondrial adaptations as compared to FVB wild type mice (A). These abnormalities are accompanied by decreased 
ATP levels in kidney cortex (D). N=Nucleus, BB= Brush Border membrane, L= tubulary lumen, M= mitochondria, BL= 
basolateral membrane. Data are measured in 3 pooled samples from 12 mice each, given as a mean ± SEM (**: P<0.01). [(A 
and B) x 2000 (C) x 10000]. 
 
Finally, the proximal tubules were examined morphologically with electron 
microscopy. Representative images show mitochondrial adaptations in the mdr1a/1b(-/-) mice 
compared to the FVB wild type mice: mitochondria were swollen, and cristae morphology 
was altered (Figure 6B-C). Other abnormalities were not observed: the brush border 
membrane appears to be intact as is the glomerular apparatus. Mitochondrial adaptations in 
mdr1a/1b(-/-) mice were accompanied by a 50% reduction in ATP compared to FVB wild 
content type mice (Figure 6D).  
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Mdr1a/1b(-/-) mice are less sensitive to ischemic reperfusion damage 
To study the role of P-gp in renal regeneration we induced acute tubular necrosis in FVB wild 
type and mdr1a/1b(-/-) mice. In agreement with our previous study (5), a significantly 
decreased creatinine clearance was observed in wild type FVB mice two days after ischemia 
induction (P<0.001). Renal function recovered partially seven days after ischemia as 
compared to the normal baseline creatinine clearance in sham operated mice. In contrast, 
mdr1a/1b(-/-) mice only showed a slight decrease in creatinine clearance (not significant) two 
days after inducing ischemia, which remained unchanged until seven days after ischemia 
(Figure 7). A significant difference in creatinine clearance between wild type and the 
knockout mice was observed two days after inducing ischemia (P<0.01). Histological 
examination two days after inducing renal ischemia confirmed unaltered renal function in 
mdr1a/1b(-/-) mice, whereas serious damage is observed in the FVB wild type mice (Figure 8). 
  
Figure 7. Effects of renal ischemia reperfusion on renal 
function in mdr1a/1b(-/-) mice compared to FVB wild 
type. FVB wild type (■) mice show a normal reaction to 
an ischemic insult: creatinine clearance decreased after 2 
days and increased to baseline values after 7 days. In 
contrast, mdr1a/1b(-/-) mice (□) showed no changes in 
creatinine clearance 2 and 7 days after inducing 
ischemia. Data are expressed as mean ± SEM of 6 mice. 
Significantly different from sham operated FVB wild 
type mice (***: P<0.001).  
 
 
To investigate the mechanism of protection in more detail, we isolated bone marrow cells 
from FVB wild type and mdr1a/1b(-/-) mice and studied the level of apoptosis. After exposure 
of cells for 12 hours to 1 mM H2O2, we found that 16% of cells from wild type mice were 
early apoptotic and 34% late apoptotic (Figure 9A). Cells from mdr1a/1b(-/-) mice show 
significantly less sensitivity to the apoptosis trigger (13% of the cells is early and 9% late 
apoptotic, Figure 9B).  
 
 
cr
e
a
tin
in
e
 
cl
e
a
ra
n
ce
 
(m
l/m
in
) 
Time (days) 
Chapter 4 79
Figure 8. Histopathology of the mouse kidney after inducing ischemia. Characteristic histological signs of renal injury and 
regeneration after an ischemic insult in FVB wild type mice (A-C) and mdr1a/1b(-/-) mice (D-F). (A) Control kidney slices 
from FVB wild type mice showing a proximal tubule (P). Intact brush border membranes are indicated by arrows. (B) Two 
days after bilateral clamping of the renal artery and vein from 30 minutes, serious damage to the proximal tubules (P) is 
observed with debris in tubular lumen (indicated by arrows) and destroyed brush border membranes. (C) Seven days after the 
insult the tubules are partially recovered as can be concluded from repaired brush border membranes (indicated by arrows). 
(D) Control kidney slice from mdr1a/1b(-/-) mice. (E) Two days after the ischemic insult, no histological changes are seen in 
the knockouts. Brush border membranes are still intact (indicated with arrows) and there is no debris observed in the tubular 
lumen. (F) Seven days after ischemia still no abnormalities were observed. G. Glomerulus. (x400).  
 
Figure 9. Representative picture (N=6) of early (lower 
right) and late apoptotic (upper right) bone marrow 
cells from FVB wild type (A,C) and mdr1a/1b(-/-) mice 
(B, D). In untreated bone marrow-derived cells from 
FVB wild type mice, 7% of the cells are early 
apoptotic and 0% of the cells were late apoptotic (A). 
In healthy mdr1a/1b(-/-) mice, 4% is early apoptotic 
compared to 0% in the late apoptotic phase (B). After 
inducing apoptosis using 1mM H2O2, 34% of the cells 
gated were late apoptotic in and 16% was early 
apoptotic in FVB wild type mice (C). In mdr1a/1b(-/-) 
mice, 9% of the cells gated were late apoptotic and 
13% of the cells were early apoptotic (D).  
A B C
D E F 
P P 
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Discussion 
 
P-glycoprotein plays a key role in excretory organs, like intestine, liver and possibly also 
kidney, where it exports xenobiotics and waste products out of the cell lowering their 
intracellular concentration (3). Variable P-gp expression levels due to genetic diversity 
influences the absorption and excretion of P-gp substrates resulting in an altered drug 
response (22). The absence of mdr1a and mdr1b in knockout mice appears to lead to 
increased sensitivity to toxicants (23). In addition, mdr1a(-/-) mice maintained under specific 
pathogen-free conditions developed spontaneous colitis (24). In the present study we showed 
that in addition to these characteristics, mdr1a/1b(-/-) mice suffer from generalized proximal 
tubular dysfunction. Furthermore, we showed that mdr1a/1b(-/-) mice were resistant to 
ischemic damage.  
In comparison with wild type mice, the knockout mice showed a two-fold increased 
diuresis and a loss of sodium, low molecular weight proteins, glucose and calcium in the 
urine. This increased urinary sodium excretion was not caused by an increased ingestion, 
which can be concluded after performing an experiment with a low-sodium diet for one week. 
The increased water intake, weight loss and decreased creatinine clearance point at a renal 
problem in the mdr1a/1b(-/-) mice. No significant reduction in basal creatinine clearance was 
observed as compared to wild type mice, although glomerular filtration rate, measured by 
inulin clearance, was found to be reduced. This discrepancy might be attributed to the 
differences in proximal tubular secretion of creatinine. Another possible explanation is that 
the inulin clearance measurement was performed under isoflurane anesthesia, which gives a 
fall in blood pressure leading to a temporarily decreased filtration rate as a consequence of 
lower glomerular pressure. The effect might be more pronounced in mdr1a/1b(-/-) mice as 
compared to the wild type mice. This view is in line with the reduced renal plasma flow as 
found by the PAH clearance, which may, however, also be explained by the proximal tubular 
dysfunction in these mice. Slightly elevated blood pressure observed in the conscious 
mdr1a/1b(-/-) mice compared to FVB wild type mice is surprising in view of increased sodium 
and water excretion, but might be a consequence of the loss of kidney function in the 
knockout mice. Hence, this deserves further investigation. The increased plasma lithium 
clearance pinpoints at a proximal tubular defect. In addition, tubular reabsorption of amino 
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acids and low molecular weight proteins was decreased and confirms generalized proximal 
tubular dysfunction or, so called, renal Fanconi syndrome. Most apical proximal tubular 
transport is coupled to sodium and requires a transmembrane electrochemical gradient, 
established by the basolaterally expressed Na+/K+-ATPase. Less fuel for Na+/K+-ATP-ase due 
to intracellular ATP depletion is postulated to cause renal Fanconi syndrome in humans with 
mitochondrial disorders (25) and cystinosis (26,27). Strikingly, decreased intracellular ATP 
levels and impaired mitochondrial morphology were observed in the mdr1a/1b(-/-) mice, 
suggesting that disturbed energy metabolism is responsible for the development of 
generalized proximal tubular dysfunction observed in our model.  
The role of mdr1/MDR1 in this process is speculative, but the localization of the gene 
product, P-gp, in excretory organs indicates that an absence of this transporter may lead to 
barrier dysfunction, which is also observed in mdr1a(-/-) mice developing colitis (24,28). 
Under normal circumstances, waste products and xenobiotics are excreted in the urine, 
however, the absence of P-gp may lead to accumulation of these potentially toxic products. 
Subsequently, mitochondrial function may be impaired and, as a consequence, generalized 
proximal tubular dysfunction will be developed. Future research will be directed to solve this 
issue.  
Mdr1a/1b(-/-) mice are frequently used in pharmacological studies to investigate the in 
vivo role of P-glycoprotein in drug excretion. For drugs excreted primarily via the kidney, like 
digoxin, however, the reduced renal function of the knockout mice, as observed in the present 
study, might have a great influence on their pharmacokinetics. Despite an upregulation of 
mdr1b P-gp in the kidney in mdr1a(-/-) mice (2), the in vivo pharmacokinetics and tissue 
distribution of digoxin were strongly affected (29). These effects may not have been 
influenced solely by the absence of mdr1a, but a decrease in GFR might have contributed to 
the outspoken pharmacological effects, although renal function in the single knockout, 
mdr1a(-/-) mice, has not been determined. Clearly a reduction in renal function in combination 
with an absence of P-gp results in elevated plasma levels of drugs that are substrates for P-gp 
and/or excreted by the kidney, which might lead to toxicity.  
In addition to the proximal tubular dysfunction, the knockout mice show resistance 
against ischemia/reperfusion injury, as determined by histological staining and the clearance 
of creatinine. This was unexpected, because we previously observed an upregulation in P-gp 
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expression after inducing ischemia-reperfusion injury (5), suggesting a protective role of the 
drug efflux pump in renal damage. P-gp has the ability to inhibit Fas-induced apoptosis 
(30,31), and the high expression of P-gp on primitive stem cells indirectly suggests that 
absence of P-gp would exacerbate renal regeneration after an ischemic insult (18). Therefore, 
we expected more severe tissue damage after ischemia-reperfusion and less ability to restore 
the tissue. To rule out a protective effect of volume expansion (32,33), serum aldosterone 
levels were measured and were found to be comparable in both mice in basal situations. After 
a low-sodium diet for one week, however, increased plasma aldosterone concentrations were 
observed in the mdr1a/1b(-/-) mice. This indicates that the RAAS system is activated to 
compensate for the loss of sodium in urine and to protect against the accompanying volume 
depletion. Alternatively, cells derived from mdr1a/1b(-/-) mice and FVB wild type mice were 
exposed to the apoptotic trigger H2O2. We found decreased levels of apoptosis in the cells 
deficient in P-gp. This observation suggests that the smaller degree of renal damage in 
mdr1a/1b(-/-) mice kidneys after ischemia might be caused by a decreased number of apoptotic 
cells causing tubular obstruction. Evidently, the role of P-gp in this process needs to be 
investigated further.  
In conclusion, the results of the present study indicate that decreased intracellular ATP 
levels and impaired mitochondrial morphology may be responsible for the generalized 
proximal tubular dysfunction observed in mdr1a/1b(-/-) mice. The protection against ischemic 
damage might be the consequence of ischemic preconditioning, but more research is needed 
to investigate the exact role of P-gp in this model. 
 
Methods 
 
Materials 
Hank’s Balanced Salt Solution (HBSS) was purchased from GibcoBRL (Breda, The 
Netherlands). methoxy-[3H]-Inulin (inulin) was obtained from Amersham Pharmacia Biotech 
UK Ltd. (Buckinghamshire, UK) and [14C]-para-aminohippurate (PAH) was from NEN Life 
Science. α-chloralose-HBC complex (1,2-O-(2,2,2-Trichloroethylidene)-a-D-glucofuranose: 
2-hydroxypropyl-b-cyclodextrin complex was obtained from Sigma (St.Louis, Mo, USA) and 
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dissolved in a physiological salt solution at a concentration of 0.16 g/ml. All other chemicals 
were of analytical grade and purchased from Sigma (St. Louis, Mo, USA). 
 
Animals 
The animal ethics board of the Radboud University Nijmegen Medical Centre approved all 
experimental procedures. Male FVB (Friend leukaemia virus B strain) mice (6-8 weeks) were 
obtained from Charles River (Germany), and were housed under routine laboratory conditions 
at the Central Animal Facility Nijmegen. Mdr1a/1b(-/-) mice (6-8 weeks, with an FVB 
background) were kindly provided by the group of Dr. Alfred Schinkel (34), but were bred 
and housed in Nijmegen. Embryo transfer was performed with mdr1a/1b(-/-) mice to create 
identical microbiological conditions. To test the genetic background, we performed 
Quantitative Real Time PCR (RQ-RT PCR) on three different housekeeping genes, as 
described in Huls et al. (5). No differences in raw CT values were observed between FVB and 
mdr1a/1b(-/-) mice (Glyseraldehyde-3-phosphate dehydrogenase: FVB 19.7 ± 0.1, mdr1a/1b(-/-) 
19.7 ± 0.2; 18-S rRNA internal control: FVB 13.7 ± 0.2, mdr1a/1b(-/-) 13.6 ± 0.3, 
Glucoronidase: FVB 25.6 ± 0.4, mdr1a/1b(-/-) 26.4 ± 0.6). For collection of urine, 8 groups of 
3 mice were housed in metabolic cages (Techniplast, Exton, USA). Mice were allowed to 
adapt to these cages for one day, where after 24-hour urine samples were collected. Mice were 
injected intraperitoneally 0.5 ml of 0.9% NaCl (B. Braun Melsungen AG, Melsungen, 
Germany) in order to maintain a normal fluid balance. Food and water were available ad 
libitum. Urine was partly frozen at –20 °C or freshly analyzed for basic urinary parameters 
and amino acids, performed by routine laboratory tests. Blood was collected via retro-orbital 
punction and basic blood parameters were determined.  
For the measurement of food intake, water intake, weight loss and aldosterone we 
placed wild type and mdr1a/1b(-/-) mice on a diet with low-sodium content (Ssniff EF R/M, 
Na, Soest, The Netherlands). Mice were housed individually in metabolic cages for 7 days, 
where they received sodium low diet and water ad libitum. Food intake, water intake, diuresis 
and weight were measured every day. Aldosterone levels were measured after extraction and 
paper chromatography as described (35), before and 7 days after diet modification in pooled 
blood samples.  
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Renal function assessment 
FVB wild type and mdr1a/1b(-/-) knockout mice were anaesthetized with isoflurane (3% v/v) 
and placed on a servo-controlled surgical table that maintained body temperature at 37 ºC, 
measured rectally. Animals were allowed to breath air by placing a plastic chamber over the 
nose into which either isoflurane (2% v/v), O2 (250 ml/min) and N2O (50-100 ml/min) were 
continuously passed or O2 (250 ml/min) and N2O (50-100 ml/min) together with intra-arterial 
infused α-chloralose (0.26 ml divided over 3 dosages during experimental time) for 
anaesthesia. The right carotid artery was canulated with PE-10 tubing connected to PE-50 
tubing for administration of α-chloralose and blood sampling. The bladder was catheterized 
with a PE-50 tube to the urethra after which the bladder was ligatured. Urine samples were 
collected continuously. The right jugular vein was catheterized with PE-10 tubing for fluid 
infusion. During surgery and the stabilization period, an HBSS solution supplemented with 10 
mM HEPES at pH 7.4 was infused at a rate of 4.2 µl/min. After the stabilization period (45 
min), intravenous infusion was changed to HBSS-HEPES containing inulin (5 µCi/ml) and 
PAH (1 µCi/ml) and infused at a rate of 25 µl/min during the first 5 min to achieve steady-
state, where after infusion rate was set back to 4.2 µl/min. Three consecutive 30-min urine 
collections were obtained and blood samples (50 µl) were drawn at 30, 60 and 90 min in 
heparinized glass capillaries. After 90 min, mice were sacrificed. Radioactive methoxy-[3H]-
inulin and [14C]-PAH in blood and urine was measured in a liquid scintillation counter to 
determine inulin and PAH. Inulin clearance, a marker for glomerular filtration rate (GFR), 
was calculated as Uv*Uc/Pc. Where Uv is the urine volume, Uc is the urine concentration of 
inulin and Pc is the plasma concentration of inulin. PAH clearance is a marker renal plasma 
flow (RPF), and was calculated similarly to the inulin clearance. 
 
Blood pressure measurements 
After 7 days of acclimation in our animal facilities, MAP was measured in conscious mice 
(n=6 per group) using the ‘Non Invasive Blood Pressure Monitor’ (Columbus Instruments, 
OH, U.S.A), as described (36).  
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Lithium plasma clearance 
To characterize proximal tubular function we injected 16 mice subcutaneously with 10 
mmol/kg of lithium chloride (Merck, Darmstadt, Germany). After collecting blood from all 
mice before injection, mice were divided in groups of 4 and blood was collected 1 hour, 3 
hours, 6 hours and 8 hours after injection. Lithium concentrations were determined in serum 
according to the method described by Tabata et al (37).  
 
Ischemia induction 
FVB wild type and mdr1a/1b(-/-) mice were anesthesized with isoflurane and ischemia was 
induced by bilateral clamping of renal arteries and veins for 30 minutes; control mice were 
sham operated. Mice were placed in metabolic cages 2, 7 and 14 days after inducing ischemia 
to collect urine and blood. Mice were sacrificed by exsanguination. Kidneys were removed 
and fixed in Bouin’s solution. Serum and urinary creatinine levels were measured by HPLC 
(38). 
 
Detection and specification of proteins by electrophoresis 
The amount and pattern of proteins in the urine samples were determined by gel 
electrophoresis. Samples were corrected for differences in diuresis, fractionated, and loaded 
on a 10% SDS polyacrylamide gel. Two different concentrations of bovine serum albumin 
(Sigma Aldrich, Zwijndrecht, The Netherlands) were used to determine the amount of protein 
semi-quantitatively. After electrophoresis, the gels were rinsed 3 times for 5 minutes with 
ultrapure water and subsequently stained for 1 hour with Gelcode blue stain reagent (Pierce, 
Rockford, U.S.A.). Finally, to enhance stain sensitivity, the gels were destained for at least 1 
hour with ultrapure water. 
 
Electron microscopy, imunofluorescence and light microscopy 
For electron microscopy, small pieces of cortex were fixed in 2.5% glutaraldehyde dissolved 
in 0.1 mol/l sodium cacodylate buffer (pH 7.4, for 24h at 4°C), and washed in the same buffer 
(39). Tissue fragments were post-fixed in cacodylate buffered 1% OsO4 for one hour, 
dehydrated and embedded in Epon 812 (Merck, Darmstadt, Germany). Ultrathin sections 
were cut using an ultratome (LKB instruments, Bromma, Sweden) and stained with 4% 
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uranyl acetate for 45 minutes and with lead citrate for 2 minutes at room temperature. 
Sections were examined using an electron microscope (JEOL 1200 EX2, Tokyo, Japan).  
For immunohistochemistry, kidney fragments were snap frozen in liquid nitrogen, and 
2 µm cryostat sections were used. Sections were fixed in acetone for 10 minutes and air-dried. 
Subsequently, slices were incubated with the primary monoclonal antibody against megalin, 
dilution 1:100 (antibody 1H2 was a kind gift from W.S. Argraves; (40)) in PBS, 0.5% BSA 
for 1 hour at room temperature. Counterstaining was done with an antibody directed against 
Na+/K+-ATP-ase (41) diluted 1:1000. Next, slices were washed 3 times with PBS and 
incubated with the secondary antibody; goat anti rabbit Alexa Fluo 488 was used for Na+/K+-
ATP-ase and goat anti mouse Alexa Fluor 594 for megalin (Invitrogen, Breda, The 
Netherlands), diluted 1:200. Sections were examined using a fluorescence microscope (Leica 
lasertechnik GmbH, Heidelberg, Germany). 
For light microscopy, kidney fragments taken 2, 7 and 14 days after inducing ischemia 
were fixed in Bouin’s solution, dehydrated and embedded in paraplast (Amsterstad, 
Amsterdam, the Netherlands). Sections of 3 µm were stained with periodic acid-schiff (PAS). 
 
Measurement of total intracellular ATP 
Mouse kidney cortex was homogenized in ice-cold isolation buffer (300 mM Mannitol, 10 
mM HEPES, 1 mM EGTA, 0.1% BSA, pH 7.4) by hand in a Potter-Elvehjem homogenizer 
with Teflon Pestle (Braun, Melsungen, Germany). After washing in PBS, the homogenate was 
shock frozen in liquid nitrogen and stored at −80ºC until determination. Prior to ATP 
determination, the homogenate was resuspended on ice in 0.5 ml cold PBS. A 25-fold diluted 
fraction (25 µl) of the suspension was transferred to a white microtiter plate and ATP was 
measured using ATP Bioluminescence Assay Kit HSII (Roche, Basel, Switzerland) as 
described by Levtchenko et al. (27) according to the instructions of the manufacturer. The 
residue of the undiluted cell suspension was used for protein determination using the method 
of Lowry.  
 
Bone marrow cell isolation and apoptosis measurements 
Bone marrow cells were harvested by flushing tibiae with Iscove’s Modified Dulbecco’s 
Medium (Invitrogen, Breda, The Netherlands) medium containing 1% Penicilline 
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Streptavidine and 0.1 µM beta mercaptoethanol. Cells were seeded in 6 wells plates and 
exposed to 1 mM of H2O2 for 12 hours. Subsequently, cells were harvested and apoptosis was 
stained using an Annexin V-FITC Apoptosis Detection Kit (BioVision Research Products, 
CA USA), where after cells were analyzed using a cell sorter (FACScan analyzer (Becton 
Dickinson, Oxnard, CA). 
 
Data analysis 
Data are given as mean ± SEM. Mean values were considered to be significant when P<0.05 
by use of a Student’s t-test. Software used for statistical analysis was Graphpad Prism® 
(version 4.03 for Windows; Graphpad Software, San Diego, CA, USA). 
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Abstract 
 
Peripheral estradiol appears to be an important determinant of plasma testosterone levels by 
controlling the feedback on the gonadotropins LH and FSH. The testis, in response to LH 
action, produce testosterone, which, in turn, can be converted into estradiol by aromatase 
cytochrome P450, encoded by the CYP19 gene. Here, we report impaired steroid metabolism 
in male mice deficient in the Breast Cancer Resistance Protein (BCRP). Compared to wild 
type mice, the knockout mice show a 20-fold increase in plasma testosterone levels and also 
dehydroepiandrosterone and LH were elevated. After administration of the GnRH agonist, 
leuprolide, to bcrp(-/-) mice, we observed an adequate response of the hypothalamus to the 
pituitary gland. This indicates that the elevated testosterone and LH levels were caused by a 
defect in the negative feedback mechanism by estradiol, which is synthesized from 
testosterone in peripheral tissues. Elevated serum testosterone levels are often accompanied 
by metabolic disorders due to reduced insulin action. We found 3-fold increased levels of 
fasting insulin in bcrp(-/-) mice, and investigated the glucose homeostasis by performing 
glucose and insulin tolerance tests. Blood glucose levels were significantly higher in the 
knockout mice under basal conditions and impaired glucose and insulin tolerance were 
observed. Treatment of bcrp(-/-) mice with 17β-estradiol improved the glucose response and 
normalized blood testosterone and LH concentrations completely. In conclusion, the absence 
of BCRP leads to an impaired estrogen action and metabolic syndrome. 
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Introduction 
 
Breast Cancer Resistance Protein (BCRP; ABCG2) is a member of the ATP Binding Cassette 
(ABC) transporter superfamily, a family of transmembrane proteins involved in the efflux of 
endo- and xenobiotics. BCRP was originally discovered in a breast cancer cell line resistant 
against chemotherapeutics (1). Unlike multidrug resistance P-glycoprotein (MDR1, ABCB1), 
BCRP is a half transporter that forms homo- or heterodimers with other ABCG family 
members to become a fully active efflux pump (2). BCRP is responsible for the transport of a 
wide range of substances, among which several classes of chemotherapeutic agents like 
mitoxantrones, camptothecin and anthracyclins, but also riboflavin (Vitamin B12), folates 
(folic acid), porphyrins (heme), estrogens, sulfated estrogens and dehydroepiandrosterone 
sulfate (DHEAS) (3-6). The transport protein is expressed in various tissues with a barrier 
function, like the placenta, prostate, small intestine, brain, colon, liver, mammary gland, 
kidney and testes (7-10). BCRP is also highly expressed on the side population (SP) of 
primitive stem cells (11). Although its exact function in these cells is still not clear, BCRP 
likely fulfills a protective function by pumping out toxicants and harmful products of 
oxidative stress. A high expression on SP cells may also control the primitive stem cell status 
(12). 
The generation of mice deficient in BCRP expression has provided more information 
on the physiological and pharmacological function of the efflux pump. Mice lacking BCRP 
showed extreme sensitivity to the dietary chlorophyll breakdown product, pheophorbide A 
(13). As a result, light-exposed skin shows phototoxic lesions that are sometimes lethal.  
Bcrp(-/-) mice also displayed increased levels of protoporphyrins. Furthermore, the oral 
availability and distribution of the phytoestrogens, daidzein, genistein and coumestrol, into 
the brain, testis, epididymus and fetus was influenced by BCRP: the knockout mice showed 
9.2 fold (brain) and 5.8-fold (testis) increased concentrations (14). 
Expression of BCRP is shown to be sex-specific (15) and may be highly influenced by 
steroids (16). Moreover, a role for BCRP in transport of androgens was suggested in prostate 
stem cells and demonstrated for estradiol in membrane vesicles from Lactococcus lactis 
functionally expressing human BCRP (17,18), indicating that the efflux pump may play a role 
in steroid action. In the present study, we showed that BCRP-deficient mice had severe 
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hormonal abnormalities, which was investigated in more detail. We hypothesized that BCRP 
regulates the maintenance of steroid hormone balance by its transport capacities of estrogens 
and androgens. We discovered an impaired estrogen action in bcrp(-/-) mice, leading to steroid 
hormone disturbances and, eventually, metabolic syndrome. 
 
Results 
 
The influence of BCRP on general health parameters 
Male bcrp(-/-) mice were used at the age of 8 weeks and their general health condition was 
carefully investigated by blood and urine analyses and the determination of body weights. No 
difference in body weight was observed for the knockout mice, although food intake was 
increased as compared to FVB wild type animals (P<0.01; Table 1). Moreover, bcrp(-/-) mice 
displayed increased renal and testicular weights (both P<0.001). Examination of serum 
revealed increased levels of creatinine, ureum and ionized calcium. Sodium, phosphate and 
albumin levels were decreased in serum of bcrp(-/-) mice (Table 2). Urinary assessment 
revealed an increased diuresis with concomitant elevated urinary excretion of creatinine, 
ureum, sodium, calcium, protein and glucose (Table 2).  
 
Table 1. General characteristics of wild type FVB mice and bcrp(-/-) mice. 
 food intake 
(g/day) 
body weight (g) kidney weight 
(mg) 
testicular weight 
(mg) 
diuresis (ml/24h) 
FVB wild type      4.6 ± 0.1 23.7 ± 1.9       152 ± 3        68 ± 4      0.8 ± 0.03 
bcrp(-/-)   5.7 ± 0.1** 23.3 ± 2.4 203 ± 6*** 90 ± 6*** 3.4 ± 1.1*** 
Data were collected in 10 mice, and are presented as mean ± SEM. Significantly different from FVB wild type mice (**: 
P<0.01, ***: P<0.001). 
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Table 2.
 
Characteristics in serum and urinary values in bcrp(-/-) and FVB wild type mice. 
Serum concentrations FVB wild type bcrp(-/-) 
creatinine (µmol/l) 3.4 ± 0.3  3.9 ± 0.04** 
ureum (mmol/l) 6.9 ± 0.1                                7.0 ± 0.4** 
sodium (mmol/l)                157.2 ± 0.2                            156.3 ± 0.6* 
Albumin (g/l)                  11.5 ± 0.2                              11.2 ± 0.3*** 
Ionized calcium (mmol/l) 1.22 ± 0.03                              1.32 ± 0.02* 
HCO3 (mmol/l)                  19.3 ± 0.8                              20.9 ± 0.9 
Phosphates (mmol/l) 2.02 ± 0.01                              1.82 ± 0.01*** 
Urinary concentrations FVB wild type bcrp(-/-) 
creatinine (mmol/24 h.) 2.3 ± 0.5 3.6 ± 0.2*** 
ureum (mmol/24 h) 0.5 ± 0.1                               1.6 ± 0.2** 
sodium (mmol/24 h)   0.2 ± 0.03                               0.9 ± 0.2** 
calcium (µmol/24 h) 0.81 ± 0.04                               6.0 ± 0.6*** 
protein (mg/24h) 1.7 ± 0.2                             14.9 ± 2.0*** 
glucose (mg/24 h) 3.6 ± 0.9                                17 ± 4** 
Data were collected in blood and urine obtained from 10 mice and are presented as mean ± SEM. Significantly different from 
FVB wild type mice (*: P<0.05, **: P<0.01, ***: P<0.001). 
 
Bcrp(-/-) mice show highly elevated testosterone and LH levels  
The increased testicular weights in bcrp(-/-) mice suggest altered testicular function. We 
measured the testicular hormone testosterone, but also the pituitary gonadotrophines, LH and 
FSH, and the adrenal steroids, DHEA and corticosterone, in serum from 8 week old FVB wild 
type and bcrp(-/-) animals. We observed up to 20 times elevated levels of testosterone in the 
knockout animals as compared to FVB wild type mice (Figure 1A). Also LH levels were 
highly increased (Figure 1B), but FSH levels were comparable in both groups of mice (Figure 
1C). On the other hand, DHEA concentration was significantly elevated in bcrp(-/-) mice 
(Figure 1D), whereas corticosterone levels were significantly decreased (Figure 1E).  
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Figure 1. Basal hormone levels measured in blood of male bcrp(-/-) mice and FVB wild type mice. Testosterone (A), 
Luteinizing hormone (LH) (B) and dehydroepiandrosterone (DHEA) (D) levels are highly increased in bcrp(-/-) mice 
compared to FVB wild type mice. Follicle Stimulating Hormone (FSH) levels (C) were similar and corticosterone levels (E) 
were decreased in bcrp(-/-) mice compared to FVB wild type mice. Significantly different from FVB wild type mice (*: 
P<0.05, **: P<0.01). Data are presented as mean ± SEM, n=8 mice per group.  
 
BCRP is localized in the hypothalamus, pituitary gland, testis and adipose tissue 
Since we found highly increased steroid and gonadotropin levels in the bcrp(-/-) mice, we 
investigated the localization of BCRP in the hypothalamus, pituitary gland and testis. A high 
testicular expression of BCRP was reported in humans, where the efflux pump is located on 
the luminal side of the endothelial cells (8,14). We investigated the localization of BCRP in 
mouse testicular tissue, pituitary gland, hypothalamus and abdominal and gonadal adipose 
tissue. We confirmed luminal endothelial localization in the testis (Figure 2A). Furthermore, 
we also observed expression in the hypothalamus (Figure 2B) and pituitary (Figure 2C). In 
abdominal and gonadal adipose tissue, BCRP was localized to the plasma membrane (Figure 
2D and E). 
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Figure 2. Breast Cancer Resistance Protein (BCRP) 
expression in testes, hypothalamus, pituitary and 
abdominal and gonadal fat. (A) In the testes, BCRP is 
localized to the luminal side of the endothelial cells. 
Hypothalamus (B) and pituitary (C) show expression of 
BCRP, however, the exact localization remains to be 
determined. In abdominal (D) and gonadal (E) adipose 
tissue, BCRP is localized in the plasma membrane. 
Counterstaining in green is performed with β-actin. 
Magnifications: (A, D-E) x 400, (B-C) x 200. 
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Normal activity of the hypothalamic-pituitary-gonadal axis in bcrp(-/-) mice  
In order to test the activity of the Hypothalamic-Pituitary-Gonadal (HPG) axis, we 
administered the Gonadotropin Releasing Hormone agonist (GnRH), leuprolide, to stimulate 
the pituitary gland. We observed increases in blood testosterone concentrations 2 days after 
start of the leuprolide infusion in male FVB wild type and bcrp(-/-) mice (Figure 3), to levels 
comparably high. After 7 days of infusion, testosterone concentrations were decreased in both 
mice, presumably due to diminished LH levels indicating a normal function of the pituitary 
gland.  
 
Figure 3. Testosterone levels in blood after 
administration of the gonadotropin releasing 
hormone (GnRH) agonist leuprolide in male bcrp(-/-) 
mice and FVB wild type mice. Testosterone 
concentrations were comparable in FVB wild type 
mice and bcrp(-/-) mice at days 2 and 7 of leuprolide 
treatment. This indicates that the pituitary, and 
subsequently, the gonadal response is normal 
towards the stimulus provided by leuprolide. Data 
are represented as mean ± SEM, n=6. Significantly 
different from FVB wild type mice (**: P<0.01). 
 
Bcrp(-/-) mice have abnormal glucose and insulin tolerance 
The elevated insulin levels in blood and increased glucose excretion in urine show that the 
bcrp(-/-) mice have an altered glucose metabolism. At 8 weeks of age, bcrp(-/-) mice had 
increased fasting glucose and 3-fold elevated insulin levels, compared to FVB wild type mice 
(Table 3). These features are characteristic for type 2 diabetes mellitus, and led us to 
investigate the glucose homeostasis in more detail. To determine the glucose-tolerance, the 
bcrp(-/-) and FVB wild type mice were deprived of food for 6 h and were orally loaded with 
glucose. Data presented in Figure 4A indicate that the bcrp(-/-) mice show severely impaired 
glucose tolerance with increased levels at 45 min after glucose injection, which remained 
elevated up to 90 min after injection. FVB wild type mice display a normal glucose tolerance, 
i.e. an increase in glucose shortly after the injection, which returned to baseline levels within 
90 min.  
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The insulin-tolerance test was also significantly different between the two strains 
(Figure 4B). After insulin injection, glucose levels decreased in bcrp(-/-) as well as in FVB 
wild type mice although glucose levels decreased far more in FVB wild type mice compared 
to the BCRP-deficient mice (P<0.001).  
 
Figure 4. Glucose concentrations during the rebound phase of a glucose tolerance test (GTT) and an insulin tolerance test 
(ITT) in male FVB and bcrp(-/-) mice. (A) Blood glucose levels were significantly higher in bcrp(-/-) mice compared to FVB 
wild type mice after oral glucose injection (2g/kg). After insulin (0.85 U/kg) injection (B), significantly lower blood glucose 
levels were seen in bcrp(-/-) mice compared with FVB wild type littermates. Data are presented as mean ± SEM, n=8 mice. 
Significantly different from FVB wild type mice (***: P<0.001). 
 
Insulin resistance is the common link for a set of clinical risk factors defined as metabolic 
syndrome, which includes glucose intolerance, dyslipidemia and an increased risk of 
cardiovascular disease (19). We determined the lipid profile, and observed increased fasting 
triglycerides and cholesterol values in serum of bcrp(-/-) mice (Table 3, P<0.001).  
 
Table 3. Laboratory characteristics in bcrp(-/-) and FVB mice showing disturbed glucose metabolism, 
hyperinsulinemia, hypercholesterolemia and altered lipid profile. 
Data were collected in 10 mice and are presented as mean ± SEM. Significantly different from FVB wild type mice (***: 
P<0.001). 
 FVB wild type bcrp(-/-) 
Fasting glucose (mmol/l)   5.0 ± 0.6   7.6 ± 0.7*** 
Fasting insulin (ng/ml)   0.4 ± 0.1   1.2 ± 0.1*** 
Cholesterol (mmol/l)   4.0 ± 0.1   4.8 ± 0.1*** 
Fasting triglycerides (mmol/l)   1.5 ± 0.1   3.2 ± 0.1*** 
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Table 4. Delta cycle threshold values (∆CT) of cyp19 and estrogen receptor-α (ER- α) in the hypothalamus, 
pituitary gland and testis of the FVB and bcrp(-/-) mice. 
Tissue samples from 18 FVB wild type and 18 bcrp(-/-) mice were pooled and data were measured in 9 samples per strain. 
Data are presented as mean ± SEM.  
 
BCRP: a new player in estrogen action  
The response of the HPG-axis after administration of the GnRH agonist, leuprolide, suggested 
that this axis as well as the hormonal regulation on the gonads is working properly. This 
implicates that the elevated testosterone and LH levels could be caused by a defect in the 
negative feedback mechanism, controlled by circulating estradiol. Moreover, the alterations in 
metabolic parameters are in agreement with a deficiency in estrogen action. This led us to 
investigate the effect of 17β-estradiol substitutions on glucose, LH and testosterone levels. 
After treatment of bcrp(-/-) mice with 17β-estradiol the glucose response and restored 
testosterone and LH levels improved completely (Figure 5). To confirm the impaired estradiol 
action in the bcrp(-/-) mice, we performed RQ-RT PCR and investigated the gene expression of 
cyp19 (Cytochrome P19) and ER-α (estrogen receptor-α) in the hypothalamus, pituitary gland 
and testis of the bcrp(-/-) mice and in the FVB wild type mice. No significant differences in 
gene expression of cyp19 and ER-α between the two mice strains were observed (Table 4), 
indicating that neither the formation of estradiol nor the expression of the estradiol receptor is 
impaired in the bcrp(-/-) mice. 
 Hypothalamus Pituitary gland Testis 
 FVB bcrp(-/-) FVB bcrp(-/-) FVB bcrp(-/-) 
Cyp19 11.7 ± 0.4 13.0 ± 0.7 18.1 ± 0.1 17.8 ± 0.2 12.3 ± 0.3 11.5 ± 0.2 
ER-α   8.4 ± 3.7 11.4 ± 1.4 11.3 ± 2.9   7.9 ± 2.7 13.2 ± 1.9 11.0 ± 2.5 
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Figure 5. Glucose, testosterone and LH levels return to normal levels in bcrp(-/-) mice during the administration of 17-β 
estradiol-acetate . In bcrp(-/-) mice daily estradiol injections were given for 14 days. After 7 and 14 days, blood was collected 
and glucose, LH and testosterone levels were measured and significantly different levels of glucose were measured compared 
to serum glucose levels before administration (A). 14 days after estradiol injection, glucose levels were comparable to the 
glucose levels measured 7 days after estradiol injection. Testosterone and LH levels measured also showed significant lower 
serum values compared to control levels (B/C). Dashed line represents the basal blood values of either glucose, LH or 
testosterone in the FVB wild type mice. Data were given as mean ± SEM, n=4. Significantly different from FVB wild type 
mice (**: P<0.01, ***: P<0.001). 
 
Estrone-Sulfate is transported by BCRP transfected vesicles 
In order to test the ability of BCRP to transport estradiol, membrane vesicles were either 
mock or BCRP transfected. Preliminary results clearly show [3H]-E1S uptake by BCRP 
transfected vesicles (Figure 6A-B). BCRP expression in the vesicles was confirmed by 
Western blot analysis (Figure 6C). In addition, BCRP-mediated [3H]-E1S uptake was sensitive 
to inhibition by different concentrations of estradiol (E2) or the specific BCRP substrate 
mitoxantrone (MXT) (Figure 6D).  
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Figure 6. ATP dependent [3H]-E1S uptake in 
BCRP transfected vesicles isolated from HEK293 
cells. (A) Vesicles from transduced HEK293 cells 
show specific BCRP-mediated uptake of [3H]-E1S 
(B) which was time-dependent. (C) For 
confirmation, vesicular expression of BCRP was 
established by Western blot analysis. (D) 
Inhibition of [3H]-E1S by estradiol (E2) was 
concentration-dependent. Furthermore, inhibition 
was strongest by mitoxantrone (MXT), a BCRP 
specific substrate. 
 
 
 
 
 
 
Discussion 
 
In this study, we showed that absence of BCRP leads to disturbed estrogen action, 
characterized by markedly increased testosterone and LH levels and features of the metabolic 
syndrome, i.e. glucose intolerance (with concomitant increased diuresis and glucosuria), 
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albuminuria, insulin resistance and lipid abnormalities. A reversal in glucose tolerance and 
suppression of testosterone and LH levels were found after estradiol administration in BCRP-
deficient male mice, suggesting a defect in circulating estradiol. A scheme of the proposed 
pathway is depicted in Figure 7. This is a new phenotype for bcrp(-/-) suggesting an important 
role for this transporter in the efflux of estradiol and indirectly in glucose homeostasis and 
steroid metabolism.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Schematic model of the hormonal regulation possibly modulated by BCRP. In adipocytes, BCRP might be 
responsible for the excretion of estradiol, synthesized from testosterone in these cells. Estradiol signals the Hypothalamus-
Pituitary axis to produce less LH, eventually leading to decreased testosterone levels and lower estradiol concentrations. 
However, a disturbed function of BCRP might cause decreased estradiol levels which subsequently leads to LH and 
testosterone levels (dotted line). The elevated testosterone levels are responsible for other secondary abnormalities, like 
insulin resistance.   
 
The phenotype of the bcrp(-/-) mouse shows striking similarities with knockout mice that lack 
a functional aromatase enzyme (ArKO) or the estrogen receptor (ER) (ERKO mice) (20,21). 
Aromatase (CYP19) is the enzyme responsible for the rate-limiting step in the conversion of 
androgens to estrogens. This enzyme is expressed in several tissues, like the ovaries, but also 
the testis, adipose tissue, mesenchymal cells, bone chondrocytes and the brain (20). Like the 
bcrp(-/-) mice, male ArKO mice have elevated levels of testosterone and LH, but normal levels 
of FSH. In contrast, the ERKO mice have no differences in LH levels as compared to FVB 
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wild type mice, but their testosterone levels are moderately higher. The estrogen resistance in 
the ERKO mice is associated with increased fasting glucose levels and reduced insulin action. 
Moreover, these mice suffer from obesity. Both the ArKO and ERKO mouse models have 
contributed to mechanistic insights in human estrogen deficiency. In patients suffering from 
aromatase deficiency, estrogen biosynthesis is absent. In males, this absence results in, among 
others, adiposity, metabolic syndrome, insulin resistance and hepatic steatosis. These clinical 
symptoms resemble the phenotype of the bcrp(-/-) mice and, as the majority of human estrogen 
deficiencies is still not understood, BCRP may be a newly identified player in steroid 
metabolism. 
The observed reversal in glucose tolerance and the restoration of testosterone and LH 
levels after estradiol administration suggest a defect in estradiol action. To exclude possible 
defects in estrogen formation or binding in male bcrp(-/-), we measured cyp19 and ER-α gene 
expressions in hypothalamus, pituitary gland and testis, however, we did not find any obvious 
differences in the gene expressions in these organs between the knockouts and FVB wild type 
mice (Table 4).  
  In recent years, ample information has become available about the function of BCRP 
and its substrates (2). BCRP can transport a functionally and structurally highly diverse range 
of substrates, like chemotherapeutics, antibiotics, nucleoside drugs, lipid lowering drugs, 
nutrients and sulfated androgens and estrogens (including estrone-3-sulfate and DHEAS), but 
controversial findings were reported on the efflux of free estrogens and sterols. BCRP-
mediated transport of estradiol and stimulation of BCRP-associated ATPase activity by 
progesterone and testosterone was reported by Janvilisri et al. (17). In contrast, others implied 
a role for BCRP only in the efflux of sulfated estrogens but not free estrogens, although 
estrogens were found to inhibit BCRP activity (22). In agreement, we clearly found BCRP 
mediated vesicular uptake of estrone sulfate, which was sensitive to inhibition by estradiol. 
Our findings in bcrp knockout mice argue for estradiol being a substrate for the efflux pump, 
in agreement with Janvilisri et al. (17), although direct uptake studies need to confirm this. 
Peripheral estradiol is involved in the negative feedback regulation of gonadotropin secretion 
in men (23,24). Adipose tissue is an important source for peripheral estradiol and the clear 
expression of BCRP in gonadal and abdominal fat tissue implies that BCRP is responsible for 
the efflux of estradiol into the peripheral circulation.  
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Elevated serum testosterone levels are often accompanied by metabolic disorders due to 
reduced insulin action (25,26). Several lines of evidence suggest that estradiol plays a role in 
the regulation of insulin sensitivity by mediating testosterone effects on insulin action, which 
is confirmed by the observed phenotypes in the ArKO and ERKO mice (20,27). We found 3-
fold increased levels of fasting insulin in bcrp(-/-) mice, and we investigated the glucose 
homeostasis in more detail by performing glucose and insulin tolerance tests. Both glucose- 
and insulin-tolerance tests were abnormal in the knockout animals, consistent with an 
important role of BCRP in glucose homeostasis. The alterations in metabolic parameters are 
in agreement with a deficiency in estrogen action, leading to elevated testosterone levels. 
Indeed, treatment of bcrp(-/-) mice with 17β-estradiol improved the glucose response as 
measured by the glucose tolerance test. Moreover, the extremely elevated testosterone and LH 
levels in the bcrp(-/-) mice decreased to almost normal levels. This direct action of estradiol 
administration indicates that the bcrp(-/-) mouse phenotype is caused by an impairment in 
peripheral estradiol. Subsequently, negative feedback on the pituitary is restrained and LH is 
produced continuously, despite the high testosterone levels. Peripheral estradiol is produced 
by the ovaries, but also in the testes, adipose tissue, mesenchymal cells, bone chondrocytes 
and the brain. In several of those tissues, BCRP is expressed, like the testes, mesenchymal 
cells, the brain and adipose tissue (present study) and (7,28). As adipose tissue is one of the 
most important sources of peripheral estradiol, the expression and localization of BCRP in 
adipose tissue suggests that BCRP transports estradiol from the adipose cells into the 
peripheral circulation.  
In conclusion, this study shows that BCRP expression is a prerequisite for 
maintenance of the physiological estrogen and androgen balance. Absence of BCRP leads to a 
disturbance in estrogen action, elevated testosterone and LH levels and to metabolic 
syndrome, characterized by diabetes mellitus and cardiovascular disease risk. 
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Methods 
 
Animals 
The animal ethics board of the Radboud University Nijmegen Medical Centre approved all 
experimental procedures. Male wild type mice of the Friend Leukaemia Virus B (FVB) strain 
were obtained from Charles River (Germany), and were housed under routine laboratory 
conditions. Bcrp(-/-) mice (6-8 weeks, with an FVB background) were kindly provided by the 
group of Dr. Alfred Schinkel (Netherlands Cancer Institute, Amsterdam, The Netherlands) 
(13), and were bred and housed pathogen free through embryo transfer at the Nijmegen 
Central Animal Laboratory, under the same conditions as the FVB wild type mice. Urine 
samples were collected as described (29). Blood was collected via retro-orbital punction.  
 
Determination of steroid hormones  
Serum testosterone was assessed in 0.5 ml of serum by a radioimmunoassay (RIA) after 
prepurification by means of paper chromatography of ether extracts of the samples, including 
correction for procedural losses. Before extraction, [3H]-testosterone was added to correct for 
procedural losses. After chromatography, radio chromatogram scanning identified the 
location of the testosterone zone, which was cut out and soaked in buffer. The recovered 
radioactivity was measured by liquid scintillation counting of an aliquot from the eluate. 
Subsequently, [3H]-testosterone tracer and antiserum were added and after incubation, free 
and bound tracer were separated by means of dextrane-coated charcoal. The antibody-bound 
radioactivity was assessed by liquid scintillation counting of the supernatant. The calculations 
were performed by special software designed for correction of the mass and radioactive 
contribution of the recovery tracer in the RIA. The detection limit was 16 pmol/l when using a 
sample volume of 1 ml. Between-run coefficient of variation (CV) was 5.8% at a level of 6.5 
nmol/l. Accuracy was assessed by measurement of QC samples in which the testosterone 
levels had been established by GC/MS. A bias of –1.3 ± 1.7% (SEM) compared to the target 
value was observed (30). 
 
Corticosterone was measured by a RIA following dichloromethane extraction using an 
antiserum (S-05 230676) raised in sheep against a corticosterone-21-hemisuccinate-bovine 
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serum albumin conjugate (31). Twenty-five µl plasma was diluted to 1 ml and [3H]-
corticosterone was added as a recovery tracer. Diluted plasma was extracted with 
dichloromethane. The between-assay CV was 7.4% at a level of 160 nmol/l, with a limit of 
detection of 2 nmol/l. 
  
DHEA measurements  
Serum dehydroepiandrosterone (DHEA) was assessed by [3H]-Radioimmunoassay after 
prepurification by means of paper chromatography of ether extracts of the samples, including 
correction for procedural losses, as described previously (32). To summarize briefly, before 
extraction [3H]-DHEA was added to correct for procedural losses. After chromatography, the 
location of the DHEA zone was identified by radio chromatogram scanning, the zone was cut 
out and soaked in buffer. The recovered radioactivity was measured by liquid scintillation 
counting of an aliquot from the eluate. Subsequently, DHEA tracer and antiserum were added 
and after incubation, free and bound tracer was separated by means of dextrane-coated 
charcoal. The antibody- bound radioactivity was assessed by liquid scintillation counting of 
the supernatant. The calculations were performed by special software designed for correction 
of the mass and radioactive contribution of the recovery tracer in the RIA. The detection limit 
was 0.2 nmol/l when using a sample volume of 1 ml. Within- and between-run CV’s were 6.4 
and 11.8% respectively at a level of 13.6 nmol/l.  
Estradiol was evaluated after ether extraction of 0.5 ml serum to which recovery tracer 
was added, followed by chromatography on Sephadex LH20 columns by a RIA. The fraction 
containing estradiol was eluted using toluene-methanol (9:1). After evaporation to dryness, 
the residue was dissolved in assay buffer. The between-assay CV was 5.6% at a level of 480 
pmol/l. The limit of detection was 10 pmol/l (33) 
 
LH and FSH measurements 
Luteinizing hormone (LH) and Follicle Stimulating Hormone (FSH) levels were measured 
using the assay for rat LH and FSH as described (34). Results have been expressed in terms of 
rat LH-RP-3 and FSH-RP-2. Within- and between- assay CV’s were below 7 and 8% for LH 
and 5 and 11% for FSH; the detection limits were 7.5 and 20 pg/tube, respectively.  
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Insulin measurements 
Plasma insulin levels were assayed using a rat/mouse insulin ELISA kit (Cat. # EZRMI-13K, 
Linco Research Inc., St Charles, USA). The kit included quality control samples representing 
low and high concentrations. The sensitivity of the assay was 0.2 ng/ml.  
 
Studies on glucose homeostasis 
For the glucose tolerance test, 8 mice were deprived of food for 6 h and were loaded orally 
with glucose (2 g/kg). Glucose concentrations were measured before glucose administration, 
and 45 and 90 min after administration. For the insulin tolerance test, 8 mice were deprived of 
food for 6 h and injected intraperitoneally with human insulin (0.85 U/kg) (Novo Nordisk, 
Bagsværd, Denmark). Glucose concentrations were measured before insulin injection and 30, 
60 and 90 minutes after injection using the Glucocard Memory II (Menorini, Florence, Italy).  
 
Administration of the Gonadotropin Releasing Hormone agonist Leuprolide 
To determine the functionality of the pituitary-testicular axis, the Gonadotropin Releasing 
Hormone (GnRH) agonist leuprolide was chronically administered for 7 days by a micro-
osmotic pump (Alzet model 1007D, Cupertino, CA, USA) releasing 0.5 µl/h, 1.5 mg/kg body 
weight, slow release depot formulation (35). Mice were anesthesized using isoflurane (3% 
v/v) and the micro-osmotic pump was placed subcutaneously. Two and 7 days after placing 
the micro-osmotic pump, blood was collected and testosterone levels were measured as 
described.  
 
Estradiol administration in bcrp(-/-) mice  
To determine the effect of exogenous administered estradiol in bcrp(-/-) mice on testosterone, 
LH and glucose levels, we administered 17β-estradiol acetate (Sigma Aldrich, Zwijndrecht, 
The Netherlands) subcutaneously in a concentration of 200 µg/kg per day for 14 days in 10 
bcrp(-/-) mice. Before estradiol injection, blood was collected from 5 mice and after 7 and 14 
days, 5 mice were exsanguinated for testosterone, LH and glucose measurements.  
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Quantitative Real-time PCR (RQ-RT PCR) 
For RQ-RT PCR, mRNA was isolated from the hypothalamus, pituitary gland and testis 
obtained from 18 mice per strain (pooled to 9 samples per strain) as described before (29). 
Primer probe sets were designed by Applied Biosystems (Forster City, CA, USA). RQ-OCR 
was performed in duplicates using the ABI PRISM 7700 Sequence Detection System 
(Applied Biosystems, Forster City, CA, USA). The housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an internal standard. Data are expressed as 
delta cycle threshold (∆CT) values, indicating the relative expression of ER-α and cyp-19 after 
correcting for the household gene.  
 
Immunohistochemistry 
Serial tissue sections of 1.5 µm were obtained using a cryostat, air dried, and fixed in acetone 
for 10 min. Slices were air dried and incubated for 60 min with the primary antibody in 
phosphate buffered saline supplemented with 1% bovine serum albumin. Primary antibodies 
directed against BCRP, BXP-9 (Kamiya Biomedical Companies, Seattle, USA) diluted 1:100, 
and β-actin (Sigma, Zwijndrecht, The Netherlands) diluted 1:1000, were used. After 
incubation, slices were rinsed with phosphate-buffered saline for 10 min and incubated for 45 
min with the secondary antibodies (diluted 1:200), Alexa Fluor 488 and Alexa Fluor 594. 
After rinsing, slices were mounted in Vectashield mounting medium. Sections were examined 
with a confocal laser-scanning microscope (CLSM; Leica lasertechnik GmbH, Heidelberg, 
Germany). 
 
Vesicular transport assays 
Uptake of [3H]-E1S into BCRP transfected membrane vesicles was performed as described 
previously (36). Transfected HEK 293 membrane vesicles were incubated with either 50 nM 
or 25 nM [3H]-E1S and transport was measured after 1 or during 5 minutes of [3H]-E1S 
incubation. To check BCRP specific transport, [3H]-E1S transport was inhibited by divers 
concentrations of estradiol or the specific BCRP substrate mitoxantrone (MXT). 
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Data analysis 
Data are given as mean ± SEM. Mean values were considered to be significantly different, if 
P<0.05 Student’s t-test). Software used for statistical analysis was GraphPad Prism® (version 
4.03 for Windows; Graph Pad Software, San Diego CA).  
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Abstract 
 
Breast Cancer Resistance Protein (BCRP/ABCG2) is a transporter that restricts absorption 
and enhances excretion of a wide range of compounds, including anticancer drugs. 
BCRP/ABCG2 is highly expressed in placenta, brain, liver, prostate, small intestine, colon 
and mammary gland. However, in human kidney only expression at mRNA level has been 
described in contrast to mouse kidney where the transporter is abundantly expressed. In 
bcrp/abcg2(-/-) mice renal expression of the sterol transporter genes abcg5 and abcg8 was 
strongly increased. Apparently the lack of bcrp/abcg2 needs to be compensated by the 
upregulation of other efflux transporters. Here, we show for the first time expression, 
localization and transport activity of BCRP/ABCG2 in human kidney. Immunohistochemistry 
clearly showed localization of BCRP/ABCG2 to the proximal tubule brush border membrane, 
a staining pattern comparable to other ABC transporters like P-glycoprotein/ABCB1, 
MRP2/ABCC2 and MRP4/ABCC4. Functionally, we show that Hoechst 33342 dye efflux 
from human proximal tubule cells in primary culture can be significantly reduced by the 
BCRP/ABCG2 inhibitors fumitremorgin C and nelfinavir.  
In conclusion, the efflux pump BCRP/ABCG2 is expressed in the brush border membrane of 
human renal proximal tubular cells. In addition to P-glycoprotein/ABCB1, MRP2/ABCC4 
and MRP4/ABCC4, BCRP/ABCG2 may be another important apical ABC transporter in renal 
drug excretion. 
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Introduction 
 
Breast Cancer Resistance protein (BCRP/ABCG2) is a member of the ATP binding Cassette 
(ABC) drug transporter family, which was first discovered in a multidrug-resistant breast 
cancer cell line. BCRP/ABCG2 is a half-transporter and functions most likely as a homodimer 
that actively effluxes its substrates across the cell membrane. In recent years, much more 
information has become available about the function of BCRP/ABCG2 and its substrates. 
BCRP/ABCG2 can transport a functionally and structurally highly diverse range of substrates, 
like chemotherapeutics (mitoxantrone, topotecan), nucleoside analogs (lamivudine), 
fluorophores (Rhodamine 123, Hoechst 33342), conjugated anions (estrone-3-sulfate, 
DHEAS), flavanoids (genistein), folates (folic acid), riboflavin (vitamin B12) and porphyrins 
(heme) (1-4).  
BCRP/ABCG2 is expressed in plasma membranes of different tissues with an 
important barrier function, like the apical membrane of the small and large intestine, the 
canalicular membrane of hepatocytes, the luminal membrane of the capillary endothelium of 
the brain and in the brush border membrane of placental syncytiotrophoblasts (5). In addition, 
BCRP/ABCG2 is expressed in the mammary gland of humans, mice and cows (6), where the 
efflux pump is highly upregulated during lactation. This augmented expression is responsible 
for the active secretion of vitamins into milk, but is also accompanied by the secretion of 
potentially harmful compounds, like carcinogens, dietary toxins and drugs, into milk.  
There is an extensive overlap in substrate specificity and localization on barrier 
epithelia between BCRP/ABCG2 and other multidrug transporters, like multidrug resistance 
protein 2 (MRP2/ABCC2) and P-glycoprotein (P-gp/ABCB1), suggesting a complementary 
role for the efflux pumps. Surprisingly, however, not much is known about the expression 
levels of BCRP/ABCG2 in human kidney. In healthy human tissue low mRNA expression 
levels were found and the transporter protein itself was undetectable (7,8). Renal carcinoma 
samples showed a moderate BCRP/ABCG2 expression (9), although with the use of a 
different antibody no expression in carcinoma tissue has been reported as well (10). In 
contrast, mouse kidney tissue showed a high mRNA expression (11) and 
immunohistochemistry demonstrated a clear staining of bcrp/abcg2 in the apical membrane of 
the cortical proximal tubules (12), which was strongly induced after ischemia reperfusion 
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injury (11). This increased expression supports the hypothesis that BCRP/ABCG2 plays a role 
in renal regeneration after injury.  
In the present study, we investigated the gene and protein expression of 
BCRP/ABCG2 in human kidney, using the antibody BXP-9. We performed Western blot 
analysis and immunohistochemistry, and compared the expression levels in human kidney 
tissue with that in rat and mouse kidney samples. Furthermore, we determined functional 
activity of BCRP/ABCG2 in human kidney cells. 
 
Results  
 
In mouse kidney, high gene and protein expression levels of bcrp were found (11). In this 
study, we compared gene expression levels of 36 ABC transporters in bcrp(-/-) mouse kidney 
with the levels in FVB mouse (wild type) kidney (Figure 1). Several transporters, like abca5, 
abcb4, abcc2 and abcc4 were significantly up- or downregulated in the knockout mice. But 
the most pronounced differential expression was found for the subfamily members, abcg5 and 
abcg8, which showed a 20- to 100-fold upregulation in bcrp(-/-) mice. 
 
In contrast to mouse kidney, not much is known about BCRP expression and localization in 
the human kidney. We compared expression levels of ABCG2 in human kidney with 
expression levels in rat and mouse kidney (Table 1). After performing RQ-RT PCR using 
healthy human kidney samples, we found a moderate expression of BCRP/ABCG2 mRNA. In 
rodent kidney, mRNA levels were clearly higher as compared to human kidney, with highest 
expression in the mouse. Furthermore, BCRP/ABCG2 gene expression levels appeared 
somewhat lower than the mRNA expression levels of other apically expressed ABC 
transporters, viz. ABCB1/P-glycoprotein (P<0.01), ABCC2/MRP2 and ABCC4/MRP4 in 
human kidney (not significant) (Table 1).  
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Figure 1. Quantitative Real-Time PCR analysis of ABC transporters in bcrp/abcg2(-/-) mouse kidney. Gene expression of 
ABC transporters from the abca (A), abcb (B), abcc (C), abcd (D) and abcg (E) subfamilies was determined in bcrp/abcg2(-/-) 
mice and FVB wild type mice. The induction fold indicates the up- or downregulation of the various transporters in 
bcrp/abcg2(-/-) mice compared to FVB mice. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal 
standard for normalization of gene expression levels (CT values GAPDH: FVB wild type mouse= 19.8 ± 0.3, bcrp/abcg2(-/-) 
mouse: 19.7 ± 0.1). *: P<0.05, **: P<0.01, ***: P<0.001, compared to FVB wild type mice.  
 
Table 1. ABC transporter gene expression in the kidney of three different species. 
Gene expression values of four different ABC transporters in the human kidney, mouse kidney and rat kidney. ABCB1 is 
present in two different forms in rat and mouse Abcb1a and Abcb1b, respectively. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an internal standard for normalization of gene expression levels (CT values GAPDH: 
human= 22.3 ± 0.9, mouse= 19.8 ± 0.3, rat= 16.06 ± 0.04). *: P<0.05 vs. human kidney, **: P<0.01 vs. human kidney, ***: 
P<0.001 vs. human kidney. 
 
Recently, we reported that primary cultures of human proximal tubule cells grown as 
monolayers on permeable filter supports, retained a full palette of proximal tubule transport 
ABC transporter Delta CT values 
Gene symbols Human kidney Mouse kidney Rat kidney 
ABCG2 6.9 ± 0.7  2.20 ± 0.08*** 4.1 ± 0.2* 
ABCB1/Abcb1a 4.1 ± 0.4  9.21 ± 0.03***    8.41 ± 0.01*** 
Abcb1b  11.0 ± 0.4***  10.83 ± 0.08*** 
ABCC2 5.1 ± 0.4            4.09 ± 0.03*  6.7 ± 0.3** 
ABCC4 4.9 ± 0.4 7.1 ± 0.3**  6.61 ± 0.07** 
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proteins and provide a powerful model to study the mechanisms and regulation of xenobiotic 
transport, particularly apical efflux transporters (13).  
Figure 2. Breast Cancer Resistance Protein (BCRP/ABCG2) expression in kidney and isolated human proximal tubular 
cells. A representative PCR analysis (A) shows that a 206 bp fragment of BCRP/ABCG2 was detected in human kidney 
cortex (lanes 4 and 5), in human proximal tubule cell monolayers (lane 2) and mixed cell monolayers (~80 proximal tubule 
cells/ ~20% cortical distal/collecting duct cells) (lane 3) but not in purified distal/collecting duct cell monolayers (lane 6). 
Lanes 1 and 7 represent negative controls. Western blot analysis (B) shows that BCRP/ABCG2 was detected in human 
kidney total membranes (lanes 1 and 2) and in isolated human proximal tubular cells (lane 9). In rodents, BCRP/ABCG2 was 
observed in total membranes isolated from rat kidney (lanes 3 and 4) and mouse kidney (lanes 7 and 8). Membranes isolated 
from bcrp/abcg2(-/-) kidney showed no BCRP/ABCG2 signal (lanes 5 and 6). β-actin expression was used to determine semi-
quantitative BCRP/ABCG2 expression in four independent analyzes (C). *: P<0.05, **: P<0.01, compared to BCRP/ABCG2 
expression in human kidney. 
 
In agreement with the RQ-RT PCR results, Figure 2A shows the expression of a PCR product 
encoding a 206bp fragment of BCRP in freshly isolated human kidney cortex (lanes 4 and 5) 
and in the primary cultures of tubule cells derived from this material. At 8 days in culture, we 
found expression of mRNA encoding BCRP/ABCG2 in both the proximal tubule cell 
monolayers (lane 2) and the mixed cell monolayers (~80% proximal, ~20% distal/collecting 
duct cells) (lane 3) but no expression of BCRP/ABCG2 mRNA was detected in pure cultures 
of distal/collecting duct cells (lane 6).  
 We investigated protein expression of BCRP/ABCG2 using the BXP-9 antibody 
(Kamiya Biomedical Company, Seattle, USA). This antibody was specifically raised against 
mice bcrp, but Figure 2B shows that it cross-reacts with rat and human BCRP/ABCG2 as 
well. The efflux pump was detected in isolated human total membranes (lanes 1 and 2), 
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isolated human proximal tubular cells (lane 9), rat kidney brush border membranes (lanes 3 
and 4) and mouse kidney total membranes (lanes 7 and 8) were used. As a negative control, 
isolated total membranes from bcrp/abcg2(-/-) mice were used (lanes 5 and 6). As expected, 
the negative control showed no signal. After semi-quantifying the protein expression levels by 
measurement of pixel intensities of both BCRP/ABCG2 and β-actin bands, we observed that 
the expression of BCRP/ABCG2 was highest in mouse kidney followed by rat kidney 
samples (Figure 2C). Human kidney samples showed a moderate expression level, which is in 
accordance with the expression levels measured by RQ-RT PCR. We could also detect 
BCRP/ABCG2 in proximal tubule cells isolated from healthy human urine samples (14), with 
a relative expression comparable to the human kidney cortex sample.  
Immunohistochemistry was applied to study the localization of BCRP/ABCG2 in kidney 
tissue. Unlike Maliepaard et al., who used BXP-21 and BXP-34 (8), we found a clear staining 
of BCRP/ABCG2 in the human proximal tubule brush border membranes with the BXP-9 
antibody (Figure 3A). Also in rat tissue the efflux pump is present at the apical side of the 
proximal tubules (Figure 3B), identical to the localization in mouse and human kidney (Figure 
3D). Tissue from bcrp/abcg2(-/-) mouse showed no staining (Figure 3C), which emphasizes the 
specificity of the antibody used.  
 
Moreover, in polarized human primary proximal tubule cell monolayers grown on permeable 
filter supports we found extensive staining of the cell membrane with both the BXP-9 (Figure 
4A) and BXP-21 antibody (data not shown). BXP-9 antibody staining was localized primarily 
to the apical membrane of the monolayer with some degree of staining in the cytoplasm just 
below the membrane surface (Figure 4B).  
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Figure 3. Immunofluorescent analysis of BCRP/ABCG2 in human, rat and mouse kidney. Representative 
immunohistochemical images of BCRP/ABCG2 staining (in red) at the brush border membranes of the proximal tubules in 
human kidney (A), rat kidney (B) and mouse kidney (D). No staining was observed in bcrp/abcg2(-/-) mice, serving as a 
negative control (C). Counterstaining (in green) was performed with Na+K+-ATPase, which is localized to the basolateral 
membrane. G, glomerulus, P, proximal tubule. Magnification, x200. 
 
 
Figure 4. Expression of BCRP/ABCG2 in human 
primary renal tubule cell cultures. (A) 
Immunohistochemical staining of a representative 
proximal tubule cell monolayer with BXP-9 antibody 
shows extensive staining of the cell membrane. The 
XY section was taken at the level of the apical 
membrane. (B) An XZ confocal image of the 
monolayer (taken from the location indicated by the 
dotted line in Figure 4A) confirmed the localization of 
ABCG2 to the apical membrane but also suggests some 
degree of subapical membrane localization. Nuclei are 
counterstained with propidium iodide. The scale bar 
represents 10 µm.  
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Finally, we tested the functional expression of BCRP/ABCG2 in monolayers of primary 
proximal tubule cells using a Hoechst 33342 efflux assay (15). As summarized in Figure 5, 
dye retention by the cells in the presence of the specific ABCG2 inhibitor fumitremorgin C 
(10 µM) was 2.36 ± 0.03 fold higher than in control monolayers. Further, in the presence of 
nelfinavir (10 µM) an inhibitor of both P-gp/ABCB1 and BCRP/ABCG2 the cellular retention 
of Hoechst 33342 (1 µM) was 4.92 ± 0.17 fold higher than control values. These data are 
consistent with the inhibition of BCRP/ABCG2-mediated Hoechst 33342 dye efflux across 
the apical membrane of the proximal tubule cell monolayer. Consistent with this, the amount 
of Hoechst 33342 appearing in the apical media during the efflux period was substantially less 
in the presence of inhibitors, e.g. in the presence of FTC (10 µM) the efflux of dye into the 
apical compartment was 53 ± 9% of the efflux rate in the absence of inhibitor. In the presence 
of nelfinavir (10 µM) the appearance of dye in the apical compartment was reduced to 33 ± 
8% of control values reflecting both inhibition of BCRP/ABCG2 and P-gp/ABCB1 mediated 
efflux. 
 
Figure 5. Functional expression of BCRP/ABCG2 in 
human proximal tubule cell monolayers. The cellular 
retention of 1 µM Hoechst 33342 was measured in the 
presence and absence of either 10 µM FTC or 10 µM 
nelfinavir. Both efflux pump inhibitors resulted in a 
significant (P<0.01 ANOVA, Dunnet’s post-test) 
increase in cellular retention of Hoechst 3342. The data 
are expressed as the mean ± SEM from 4 cell 
monolayers. **: P<0.01, compared to control values. 
 
 
 
Discussion 
 
In this study, we demonstrate for the first time expression, localization and transport activity 
of BCRP/ABCG2 in the apical (brush border) membrane of human proximal tubules using 
RQ-RT PCR, immunoblotting, immunohistochemical analysis and a functional Hoechst 
33342 efflux assay. This localization is in agreement with results obtained in mouse kidney 
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tissue (8,11) and in rat kidney (present study). Previous reports investigating the expression of 
BCRP/ABCG2 in healthy human kidney used the antibody BXP-34 (8), but staining of the 
efflux pump was not obtained. In renal carcinoma samples the transporter protein was 
detectable using a different antibody, BXP-21, however not with BXP-34 (9,10). The reason 
for these controversial findings may be the difference in antibodies used in these studies. 
BXP-34 was obtained after immunization of mice with MCF-7/MR breast cancer cells (10). 
The BXP-21 antibody, however, was obtained after immunization of mice with a fusion 
protein of the Escherichia Coli maltose-binding protein with a 126-amino acid part of 
BCRP/ABCG2 (amino acids 271-396) directed against an internal epitope before the first 
transmembrane segment (9). We used a third antibody, BXP-9 which was generated in rats 
with a fusion protein containing a fragment of mouse bcrp protein corresponding to amino 
acids 221-394 and the Escherichia Coli maltose-binding protein (Kamiya Biomedical 
Company, Seattle). This antibody was also directed against an internal epitope located just 
before the first transmembrane segment. With the use of BXP-9 we could clearly detect and 
localize BCRP/ABCG2 in healthy human kidney tissue. In addition, we used the BXP-21 
antibody to detect BCRP/ABCG2 expression in monolayers of human proximal tubule cells. 
In these primary cultures, we confirmed the apical localization of the transporter protein. 
Using a functional Hoechst 33342 efflux assay, we show for the first time transport activity of 
BCRP/ABCG2 in human primary proximal tubular cells, which can be inhibited by the 
specific BCRP/ABCG2 inhibitor FTC and by the nelfinavir (16). The maximum inhibition of 
dye efflux by nelfinavir was ~2-fold greater than the maximum inhibition of dye efflux 
generated by FTC suggesting that at least part of the nelfinavir inhibition of Hoechst 33342 
dye efflux across the apical membrane of the proximal tubule cells is mediated by P-
gp/ABCB1 (17,18). 
Although its moderate expression levels may suggest a less important role as an efflux 
pump in comparison with other apical transporters, BCRP/ABCG2 can be highly influenced 
and regulated by external factors and may have an important function under pathological 
conditions as well as in the transport of specific substrates. In mice, the absence of bcrp/abcg2 
causes a strong upregulation of abcg5 and abcg8 gene expression in the kidney. This suggests 
a compensatory mechanism further emphasizing the importance of the efflux pump.  
 Chapter 6 123
Epidermal growth factor (EGF), which is also associated to proliferation and 
differentiation of multiple cell types, regulates the expression of BCRP/ABCG2 via a MAPK 
cascade (19). Drugs that target the EGF pathway, like tyrosine kinase inhibitors blocking the 
MAPK cascade, may, therefore, increase the sensitivity to xenobiotics by increasing their 
accumulation as a result of reduced transporter activity (20). Others showed that 
BCRP/ABCG2 expression is regulated by IL-1β and TNF-α (21), and a role for endothelin-1, 
but not for TNF-α, was found in rat brain capillaries (22). In addition, sex hormones influence 
the expression levels of Bcrp (23). These insights illustrate that BCRP/ABCG2 expression is 
highly controlled under varying conditions by signaling pathways that are also effective in 
regulating ABC transporter expression in the kidney (5,24). 
 In conclusion, we identified a new efflux transport protein in the apical membrane of 
human kidney proximal tubules. BCRP/ABCG2 likely contributes to the excretory processes 
of drugs and toxic substances in the urine and has, in this way, an important protective 
function. The relative importance of BCRP/ABCG2 in the human kidney compared to other 
transporters localized at the apical membrane of the proximal tubules, viz. ABCB1/P-
glycoprotein, ABCC2/MRP2 and ABCC4/MRP4, remains to be determined.  
 
Methods 
 
Tissues and primary cultures 
Healthy human material used for quantitative real time PCR and Western Blot analysis was 
obtained from the distant pole of kidneys removed for localized malignancy. For 
immunohistochemistry, material was obtained from donor kidneys not used for 
transplantation. Human tubular epithelial cells were isolated as previously described (25,26) 
and brought into culture as pure cultures of either proximal tubular or distal tubule/cortical 
collecting duct cells or as a mixed population comprising ~80% proximal tubular and ~20% 
distal tubule/cortical collecting duct cells. In each case, cells were seeded directly onto 6.5 
mm 0.4 µm pore size polycarbonate Transwell filter supports (Costar) at a density of 50,000 
cells/filter. Mixed and pure cultures of Proximal Tubular cells (PTC) and Distal Tubule Cells 
(DTC) were grown for 6 to 10 days on polycarbonate transwell filters (Costar) in α-MEM 
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(Life Technologies) modified according to Gibson d’Ambrosio (27), supplemented with 10 % 
fetal calf serum. For efflux studies cells were grown for 6-10 days on solid plastic supports. 
Cell culture medium was replaced by Krebs’ solution (mmol/l): NaCl 140; KCl 5.4; MgSO4 
1.2; KH2PO4 0.3; NaH2PO4 0.3; CaCl2 2; glucose 5; Hepes 10 buffered to pH 7.4 at 37ºC with 
Tris base for transport studies. º 
 
Quantitative real-time PCR 
For quantitative real-time (RQ-RT) PCR, 2 pooled samples obtained from 16 different mice, 3 
pooled samples from 9 different rats and 4 samples from human kidney were used. Primer 
probe sets were designed by Applied Biosystems (Applied Biosystems, Foster City, CA, 
USA). RQ-RT PCR was performed in duplo using the ABI/PRISM 7900 HT Gene Expression 
Micro Fluidic Card, as described (11). The housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an internal standard. Data are expressed as delta Cycle 
Threshold (∆CT) values, indicating the relative ABCG2 expression levels after correcting for 
the household gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase). High CT values 
indicate a low expression of the gene in the sample, a low CT value indicates an early 
detection of the fluorescence signal and represent a high gene expression. To investigate 
expression of BCRP/ABCG2 in human tubule cell monolayers, a quantitative RT-PCR 
approach was employed.  
 
Western blot analysis 
For Western blot analysis, renal total membrane fractions and proximal tubule cells isolated 
from human urines were prepared and isolated as described (11,14,28). Samples were 
solubilized in DL-Dithiothreitol and Laemmli sample buffer. After electrotransfer of the 
proteins onto a nitrocellulose membrane, analysis was performed by the Odyssey infrared 
imaging system (LI-COR, Biosciences, NE, USA). The membrane was blocked in Odyssey 
blocking buffer diluted 1:1 with PBS for 1 hour at room temperature. Subsequently, the 
membrane was incubated overnight with the primary antibodies at 4˚C: BCRP/ABCG2 (BXP-
9, Kamiya Biomedical Company, Seattle USA) diluted 1:200, β-actin (Sigma, Zwijndrecht, 
The Netherlands) diluted 1:100000 in PBS, 0.1% Tween-20 and 0.01% SDS. After three 
washing steps from 10 minutes in PBS, the blot was incubated in the dark at room 
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temperature for 60 minutes with the secondary antibody in PBS 0.1% Tween-20; IRDye 800 
anti-rat and IR-Dye 800 anti-mouse (Rockland Immunohistochemistry Inc., Gilbertsville, 
USA). After repeating the washing steps images were acquired with the Odyssey infrared 
imaging system and analyzed by the software program as specified in the Odyssey software 
manual.  
 
Histological analysis 
Frozen renal sections (1.5 µm) were stained for BCRP/ABCG2 and Na+,K+-ATPase as 
reported previously (11). The primary antibodies for BCRP/ABCG2 and Na+,K+-ATPase 
were diluted 1:50 and 1:1000, respectively. Human proximal tubule cells grown on permeable 
filter supports for 8 days were fixed in 3% paraformaldehyde for 1h before staining with the 
primary BCRP/ABCG2 antibody BXP-9 (Kamiya, Biomedical Company, Seattle, WA, USA) 
at a 1:120 dilution. The secondary antibody was rabbit/mouse FITC at a dilution of 1:50. 
Nuclei were counterstained with propidium iodide (Molecular Probes/Invitrogen, Breda 
Netherlands) at 5 µg/ml for 5 minutes. Sections were examined with a confocal laser-scanning 
microscope (CLSM; Leica lasertechnik GmbH, Heidelberg, Germany).  
 
Functional assay of BCRP activity in Human proximal tubule cell monolayers 
The functional activity of BCRP/ABCG2 expressed at the apical membrane of human 
proximal tubule cell monolayers was assayed using a Hoechst 33342 efflux assay. Cell 
monolayers of human proximal tubule cells were incubated for 90 minutes at 37ºC in 0.5 ml 
Krebs’ solution containing 1 µM Hoechst 33342 or 1 µM Hoechst 33342 plus either 10 µM 
fumitremorgin C (FTC) or 10 µM nelfinavir. At 90 minutes, the uptake buffer was aspirated 
off and the monolayers washed 3x in ice-cold Krebs’ buffer. Cell monolayers were then 
incubated at 37ºC for 30 minutes in 0.5 ml Krebs’ solution in the presence and absence of 
FTC or nelfinavir. This short efflux period increased the sensitivity of the assay. At the end of 
this period cell monolayers were lysed and the Hoechst 3342 content of the lysate assayed on 
a Perkin Elmer fluorimeter with an excitation wavelength of 350 nm and an emission 
wavelength of 480 nm. 
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Data analysis 
Data are given as mean ± SEM. Mean values were considered to be significantly different 
when P<0.05 by use of a Student’s t-test. Software used for statistical analysis was GraphPad 
Prism® (version 4.03 for Windows; Graph Pad Software, San Diego, Ca, USA).  
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Abstract 
 
The kidney has a high capacity to regenerate after ischemic injury via several mechanisms, 
one of which involves bone marrow-derived (stem) cells. The ATP Binding Cassette 
transporters, P-glycoprotein and breast cancer resistance protein, are determinants for the 
enriched stem and progenitor (side population) fraction in bone marrow. Since they are 
upregulated after acute kidney injury, we hypothesized that both efflux pumps may play a role 
in renal repair. Surprisingly, P-glycoprotein- or breast cancer resistance protein-deficiency, 
specifically in bone marrow cells, protected against ischemia-induced renal injury. This was 
at least in part due to an increased infiltration and direct epithelial differentiation of P-
glycoprotein- or breast cancer resistance protein-deficient bone marrow-derived cells in wild 
type kidneys. Furthermore, we demonstrate that bone marrow from P-glycoprotein- or breast 
cancer resistance protein-deficient mice contains significantly more monocytes and 
granulocytes, as well as early outgrowth endothelial progenitor cells potentially fueling the 
regeneration process. 
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Introduction 
 
Acute kidney injury (AKI) is a very frequent clinical problem with a high mortality, affecting 
many patients, particularly in the intensive care unit. Nevertheless, especially the proximal 
tubular epithelium has a high capacity to regenerate after injury. Surviving tubular cells can 
proliferate and spread to the place of injury to repair the damaged epithelium. In addition, 
resident tubular cells may de-differentiate into a more primitive mesenchymal phenotype, 
thought to serve as resident stem cells in the kidney, and repair the renal injury via a process 
called epithelial-to-mesenchymal transition (EMT) (1,2). However, EMT may also lead to 
renal fibrosis (3), eventually compromising renal function. Finally, bone marrow (BM) cells 
may play a role in renal regeneration. Within the BM, several stem cell populations with 
pluripotent characteristics, viz. the multipotent adult progenitor cells (MAPC), the 
hematopoietic stem cell population (HSC), especially the ckit+, Sca-1-, lin-, (KSL) 
subpopulation, and mesenchymal stem cells (MSCs), are present, which may aid in renal 
regeneration (4-9). A key feature of these stem cells, and especially of the side population 
(SP) comprising 73% of the KSL subpopulation in HSC (10), is their expression of P-
glycoprotein (P-gp), the Multidrug Resistance gene 1 (MDR1) product, and Breast Cancer 
Resistance Protein 1, or BCRP. This SP fraction is selected based on the capacity of the two 
efflux pumps to exclude the Rho123 and Hoechst 33342 dyes. 
P-gp/ABCB1 and BCRP/ABCG2 belong to the superfamily of ATP Binding Cassette 
(ABC) transporters. They are expressed mainly in excretory organs, like the liver, intestine 
and the kidney where they protect cells and the body against accumulation of xenobiotics and 
other potentially toxic substances. Moreover, BCRP protects progenitor cells under hypoxic 
conditions by reducing the accumulation of detrimental products like heme and porphyrin 
(11). Both transporters have been implicated in tissue regeneration, as P-gp expression is 
increased in severe human liver disease (12) and expression of BCRP increases following 
stroke (13). In the kidney, differential expression of P-gp and BCRP is detected during 
pathological circumstances. Cadmium and endotoxin mediated renal damage is associated 
with elevated levels of P-gp (14,15), and P-gp and BCRP expression increase after ischemic 
renal injury in mice (16).  
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P-gp and BCRP are expressed in a wide variety of stem cells where they may regulate 
hematopoietic development. When constitutively expressed, BCRP stimulates the growth 
potential of human (hematopoietic) clonogenic progenitor cells (17). On the other hand, 
expression of human BCRP in murine BM cells increased the SP population and blocked 
maturation (18), whereas enforced expression of P-gp in murine HSC resulted in a marked 
expansion of repopulating cells and a myeloproliferative disease (19). Loss of expression of 
P-gp in murine BM resulted in an increased SP fraction, possibly due to compensatory 
upregulation of BCRP. However, loss of the abcg2 gene led to a reduction in the number of 
SP cells (20).  
We hypothesized that if BM-derived cells aid in renal repair following ischemia 
reperfusion, and if P-gp and BCRP play a role in renal repair, deficiency of P-gp or BCRP in 
BM cells will lead to a decreased recovery in renal function following ischemia reperfusion. 
To investigate this, BM from irradiated wild type mice was reconstituted by transplanting BM 
from wild type, P-gp-deficient or BCRP-deficient mice. Four weeks later, kidney injury was 
induced and after seven days its function was assessed and, subsequently, kidneys were 
evaluated for the number and phenotype of BM-derived cells that was present. Surprisingly, 
we found that BM from P-gp- or BCRP-deficient mice had a beneficial effect on renal 
remodeling following an ischemia-reperfusion injury, associated with an increased number of 
BM-derived cells present in the kidney, and an increased number of donor BM-derived cells 
with tubular epithelial phenotype features, which did not appear to be the result of cell fusion.  
 
Results  
 
P-gp- or Bcrp-deficient mice are protected against ischemic renal injury 
As expression of BCRP and P-gp is increased in injured kidneys (16), we hypothesized that 
renal damage would be more severe in BCRP- and P-gp-deficient mice after an ischemic 
insult. Interestingly, we recently showed that P-gp-deficient mice are protected against 
ischemic renal injury (21). Here, we evaluated renal function in 8 BCRP-deficient animals 
following an ischemic insult. In line with P-gp-deficient mice, BCRP-deficient mice had a 
remarkably better recovery of renal function following ischemia compared to wild type mice 
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(n=8; Figure 1A). Creatinine clearance increased in BCRP-deficient mice during the 7 days 
after ischemia, whereas it decreased in wild type animals following a typical pattern of 
reversible renal damage (16), characterized by a decrease in clearance 2 days after the 
induction of ischemia, and restoration to near normal levels by day 7. These findings were 
confirmed by renal histology (Figure 1B) and suggest that the presence of BCRP or P-gp 
inhibits renal repair. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Effects of renal ischemia reperfusion on renal function and histology in wild type (WT) animals () compared to 
BCRP-deficient mice (). WT animals show a normal reaction to an ischemic insult: creatinine clearance decreased after 2 
days and returned to baseline values after 7 days (A). In contrast, bcrp-/- mice showed an increased renal function 7 days after 
ischemia, and no abnormalities were observed in histology (B). Data are expressed as mean ± SEM of 8 mice. *: P<0.05, **: 
P<0.01, ***: P<0.001. Magnifications (x200). 
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It is unlikely that this is caused by physiological abnormalities, as the renal phenotype of 
BCRP-deficient mice shows no similarities with the renal dysfunction of P-gp-deficient mice, 
except for the increased diuresis (Table 1 and Huls et al. (21)). Unlike P-gp-deficient mice, 
the BCRP knockouts show normal proximal tubular function as observed by the fractional 
excretion of sodium and lithium clearance (Table 1). Also, an increased glomerular filtration 
rate is observed whereas P-gp-deficient mice show a decreased glomerular filtration rate (21). 
For P-gp-deficient mice we speculated that the smaller degree of renal damage after ischemia 
was caused by a decreased number of apoptotic cells causing tubular obstruction. In 
agreement, BCRP-deficient BM shows less sensitivity to an apoptosis trigger as compared to 
wild type mice (11% vs. 16% (early apoptosis) and 10% vs. 34% (late apoptosis)). 
 
Table 1. Renal characteristics of BCRP-deficient mice and wild type (WT) mice. 
 
WT (n) BCRP-deficient (n) 
Diuresis (ml/24h)     0.75 ± 0.03 (42)       3.4 ± 1.1*** (41) 
GFR (µl/min)          405 ± 29 (4) 700 ± 200* (4) 
FEsodium (%)  0.093 ± 0.008 (4)                            0.095 ± 0.017 (6) 
Lithium clearance (µl/min)          104 ± 3 (2)                              98.2 ± 15.1 (2) 
GFR: glomerular filtration rate determined by methoxy-[3H]-inulin clearance as described previously (21). Data are presented 
as mean ± SEM. *: P<0.05, ***: P<0.001. 
 
Deficiency of P-gp or BCRP in BM-derived but not in resident cells protects against ischemic 
renal injury 
Multiple mechanisms have been postulated for tubular regeneration following ischemic renal 
injury, both involving resident as well as BM-derived cells (1,2,5-10,22). As P-gp and BCRP 
are expressed on HSC, and overexpression of these pumps affects the proliferation and 
differentiation status of HSC, we tested whether the improved renal repair observed in 
knockout mice is a result of variations in BM-derived cells. Therefore, we transplanted 
enhanced green fluorescent protein (eGFP)-transduced BM cells derived from wild type, 
BCRP-deficient or P-gp-deficient mice in wild type mice (n=8 per genotype). Four weeks 
later, we induced unilateral ischemia in the left kidney by a 30 min clamp and monitored renal 
function and histology. Wild type mice grafted with wild type BM (WT-WT) showed 
decreased creatinine clearance 2 days after the ischemic episode (P<0.001; Figure 2A), which 
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returned to near normal levels on day 7 consistent with non-transplanted wild type animals 
(Figure 1A).  
In contrast, animals transplanted with P-gp-deficient BM (P-gp-WT) had increased creatinine 
clearances 2 days after injury, which were back to baseline after 7 days (Figure 2A). Animals 
transplanted with BCRP-deficient BM (BCRP-WT) showed a comparable increase in 
creatinine clearance, but this remained elevated 7 days after ischemia (Figure 2A), completely 
similar to BCRP-deficient mice (Figure 1A). In addition, fractional sodium excretion (FENa) 
was calculated to determine renal tubular function. Two days after ischemia, wild type BM 
grafted animals had an increased FENa (P<0.001), which, like the calculated creatinine 
clearance, returned to baseline after 7 days. In contrast to WT animals, but in line with the 
creatinine clearances, the FENa did not change in animals transplanted with P-gp-deficient or 
BCRP-deficient BM (Figure 2A).  
Histological analysis (Figure 2B) confirmed the absence of renal damage following 
ischemia-reperfusion injury in animals transplanted with P-gp-deficient or BCRP-deficient 
BM. Animals grafted with wild type BM showed significant damage with a loss of brush 
border membranes (indicated by arrows) and obstruction of the tubular lumen on day 2 
compared to normal histology. By day 7, signs of recovery were observed. Kidneys of BCRP-
deficient or P-gp-deficient BM grafted mice showed intact brush border membranes and no 
tubular obstruction on day 2 and day 7 compared to normal morphology. 
 To further substantiate the role of BCRP on BM-derived cells in renal regeneration, 
we transplanted eGFP-transduced wild type BM in 6 BCRP-deficient mice (WT-BCRP). Four 
weeks later, renal ischemia was established. Creatinine clearance and FEna (Figure 3A) were 
decreased (P<0.05) on day 2 after the injury, but returned to baseline after 7 days, exactly the 
same as observed in wild type mice. This was confirmed by histology (Figure 3B). These 
findings corroborate that absence of BCRP and, most likely also P-gp, in BM-cells, but not in 
resident cells, is beneficial for renal regeneration after injury. 
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Figure 2. Renal function parameters and histopathology after transplantation of eGFP-labeled bone marrow from wild type 
(WT), P-gp- and BCRP-deficient mice in WT mice. (A) WT-WT transplanted animals showed a decrease in creatinine 
clearance 2 days after ischemic injury, which returned to baseline levels 7 days after ischemia. In P-gp-deficient BM (P-gp-
WT) transplanted animals, creatinine clearance increased 2 days after injury and after 7 days levels returned to baseline 
levels. In BCRP-WT transplanted animals, creatinine clearance increased 2 days after injury and was still increasing after 7 
days. These results were confirmed by fractional sodium excretion (FEna) measurements. FEna increased in WT-WT 
transplanted mice 2 days after ischemia and returned to normal levels after 7 days. In BCRP-WT and P-gp-WT transplanted 
animals, fractional sodium excretion did not alter after ischemia. Data are expressed as mean ± SEM of 8 mice. (B) Before 
the induction of ischemia, no abnormalities were seen in the kidneys of the transplanted animals. However, 2 days after 
ischemia, severe damage was seen in the WT-WT transplanted animals, whereas in the P-gp-WT transplanted animals and 
BCRP-WT transplanted animals no signs of ischemic injury were seen. After 7 days tubules had partly recovered in WT-WT 
transplanted animals as can be concluded from the regenerating brush border membranes. In the P-gp-WT and BCRP-WT 
transplanted animals, still no signs of ischemic injury were seen. Arrows indicate brush border membranes. G glomerulus, P 
proximal tubular cells. *: P<0.05, ***: P<0.001. Magnification, (x 200) (x 400). 
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Figure 3. Renal function parameters after transplantation of eGFP-labeled bone marrow from wild type in BCRP-deficient 
mice. As a proof of principle, eGFP labeled bone marrow derived from wild type mice was transplanted in BCRP-deficient 
mice (). (A) After 2 days, creatinine clearance decreased compared to the clearance before the induction of ischemia and 
increased to normal levels after 7 days. In accordance with the creatinine clearance, FEna increased two days after injury and 
decreased to baseline levels after 7 days. (B) This was confirmed by renal histology. #: P<0.05, ##: P<0.01.  
 
Increased engraftment and epithelial differentiation of BM-derived cells from P-gp- and 
BCRP-deficient animals 
We next evaluated the number and fate of BM-derived cells present in the injured kidneys. To 
avoid false positive results, confocal microscopy of eGFP combined with other markers was 
applied. In wild type BM grafted animals, few BM-derived cells were seen 2 days following 
the injury, but on day 7 they could be detected throughout the kidney (Figure 4A). In P-gp-
deficient grafted animals, however, infiltration of eGFP positive cells was already seen 2 days 
after ischemia, and the number of eGFP positive cells was further increased after 7 days. To 
confirm the BM origin of the infiltrating cells, tissues were counterstained with an antibody 
against P-gp demonstrating that eGFP positive cells did not express P-gp. Likewise, in BCRP-
deficient BM grafted animals, infiltration of eGFP positive cells was even more pronounced 
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compared to control situations. It was confirmed that the eGFP positive cells did not express 
BCRP. Furthermore, Western blot analysis of perfused kidney tissue 7 days after ischemia 
also supported the increased infiltration of eGFP positive cells in BCRP-deficient or P-gp-
deficient grafted animals (Figure 4C).  
Counterstaining with an erythrocyte marker clearly showed the localization of peritubular 
capillaries and glomeruli, which were not eGFP positive. Instead, engrafted cells were 
positive for the epithelial-specific marker, E-cadherin (Figure 4D), indicating their 
differentiation towards renal epithelial cells. We next quantified the amount of eGFP-positive 
tubules in WT-WT, P-gp-WT and BCRP-WT 7 days after the injury using confocal 
microscopy, and expressed them as % of total number of tubules (Figure 4B). Significantly 
more eGFP positive proximal tubules were detected in kidneys grafted with P-gp-deficient 
(21.1 + 2.1%; P<0.01) and BCRP-deficient mice (28.6 + 2.8%; P< 0.001) BM cells compared 
with wild type BM grafted mice (9.6 + 2.1%).  
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Figure 4. Infiltration of eGFP-labeled bone marrow-derived cells in wild type (WT) transplanted animals 0, 2 and 7 days 
after ischemia. (A) In WT-WT transplanted mice, no cells from the transplanted bone marrow infiltrated before and 2 days 
after ischemia. After 7 days, eGFP-positive tubules (green) were observed. Counterstaining was performed using antibodies 
against Ter-119, an erythrocyte marker (red). In P-gp-WT transplanted animals infiltration of eGFP-labeled donor bone 
marrow cells was already seen after 2 days and was further increased after 7 days. Counterstaining with an antibody directed 
against P-gp (red) indicated that cells were derived from P-gp-deficient BM. BCRP-WT transplanted animals also showed 
infiltration after 2 days and an increased number of eGFP positive tubules after 7 days. Here, also counterstaining (red) with 
an antibody directed against BCRP confirmed the origin of the donor bone marrow-derived cells. Magnifications (x 400). (B) 
An overview of the kidney after transplantation of WT-WT, P-gp-WT and WT-BCRP transplantations with quantitative 
analysis showing that infiltration of BCRP-deficient bone marrow cells is significantly higher compared to WT-WT 
transplanted mice. PTC’s: proximal tubule cells, magnifications (x 100).  
F 
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(C) Western blot analysis also confirm the increase of BM-derived eGFP labeled cells in BCRP-WT transplanted animals 
after quantitative analysis, 7 days after the induction of ischemia. (D) eGFP positive infiltrated BM cells (green) in a WT-WT 
transplantation are cadherin positive (red), indicating their differentiation towards an epithelial cell type. (E) Female bone 
marrow was transplanted in sublethally irradiated males. Four weeks after transplantation, AKI was induced and after seven 
days, female bone marrow-derived cells were observed in male recipients (indicated with arrows). These cells show 
exclusively two X chromosomes (green), and no Y chromosome (red) was detected. Control image of a female kidney 
showing the specificity of the X chromosomal paint. Control image of a male kidney showing exclusively staining of the Y 
chromosomal paint. Magnification: x630. *: P<0.05 (P-gp-WT), #: P<0.05, ###: P<0.001 (BCRP-WT). (F) An increased 
amount of MAC-1 positive cells (red) was observed in P-gp-WT and BCRP-WT mice, compared to WT-WT mice, indicating 
an enhanced inflammatory response in these mice. Magnifications: x400. 
 
BM-derived cells do not fuse with resident renal tubular cells 
Transdifferentiation of BM-derived cells may be, at least in part, due to fusion between HSC 
derived monocytes and target tissues. We performed gender mismatch transplantations with 
donor wild type BM cells from female mice in 4, sublethally irradiated, wild type male mice. 
After ischemic injury, we found female donor cells engrafted in the tubules of the male 
kidney (Figure 4E). The eGFP positive cells were exclusively XX, and we did not find any 
eGFP positive cells containing a Y chromosome. Figure 4E shows also slices of either female 
or male kidneys as controls for the probes used. It is, therefore, unlikely that fusion between 
donor, eGFP-positive, BM cells and host tubular epithelial cells had occurred. 
 
Increased numbers of mononuclear cells and early outgrowth endothelial progenitor cells in 
BM of P-gp- and BCRP-deficient mice. 
To understand how BM from P-gp-deficient or BCRP-deficient mice may positively affect 
renal repair, we investigated the BM composition of these mice by FACS analysis. A 
significantly increased proportion of monocytes (CD45+, MAC-1+) and granulocytes (CD45+, 
Gr-1) were present in both strains (Table 2), most pronouncedly in P-gp-deficient mice. In 
addition, the frequency of early outgrowth endothelial progenitor cells (EPCs), which were 
shown to be of monocytic origin (23), was significantly higher in P-gp-deficient and BCRP-
deficient mice than in wild type mice, and again was most pronounced in P-gp-deficient mice 
(Table 2). Quantitative RT-PCR analysis of the EPCs demonstrated high expression levels of 
CD45, suggesting their hematopoietic origin, and similar levels of endothelial transcripts, 
indicating a numerical but not qualitative difference (not shown). These findings indicate that 
the increased amount of monocytes and granulocytes and the higher frequency of early 
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outgrowth EPCs in BM of both knockout mice were involved in the increased renal 
regeneration observed in transplantation studies with this BM. This was confirmed by the 
MAC-1 staining of the recipient kidneys transplanted with knockout BM, in which clearly an 
increased amount of MAC-1 positive cells was seen 7 days after renal injury, compared to 
wild type transplanted animals (Figure 4F). The amount of KSL cells in the P-gp- and BCRP-
deficient mice, however, was comparable to wild type mice (Table 2). 
 
Table 2. BM constitution in wild type (WT), P-gp- and BCRP-deficient mice. 
 WT(%) P-gp-deficient (%) BCRP-deficient (%) 
Lin-, ckit+, Sca-1+  0.6 ± 0.1  0.6 ± 0.1  0.60 ± 0.02 
CD45+, Mac+, Gr+         37.6 ± 2.3      52.9 ± 4.5***                            41.2 ± 1.7 
CD45+, Mac+         39.9 ± 0.6      60.0 ± 6.0***                            46.9 ± 0.7* 
CD45+,Gr+         37.2 ± 1.9      52.3 ± 5.4***                            45.6 ± 1.2** 
CD45+, CD4+, CD8+           0.1 ± 0.03            0.20 ± 0.03                            0.30 ± 0.03 
CD45+, CD19+, B220+         15.7 ± 1.2        6.2 ± 0.8***                            11.5 ± 0.5 
CD45-, CD31+         0.10 ± 0.04              0.2 ± 0.1                              0.3 ± 0.1 
CD45-, CD34+ nd nd nd 
Sca-1+, CD45-           0.3 ± 0.1              0.3 ± 0.1                             0.3 ± 0.1 
Sca-1+, CD45+           4.5 ± 0.9              3.6 ± 1.0                             5.2 ± 1.6 
AcLDL+, BS-I lectin+            42 ± 9             237 ± 120##                            110 ± 28* 
After the isolation of BM from wild type (WT; n=6), P-gp-deficient (n=6) and BCRP-deficient (n=6) mice, cells were stained 
and analyzed using FACS. The different cell populations are given as a percentage of the total population of sorted BM cells. 
A significantly increased number of CD45+, Mac+ and CD45+,Gr+ cells was seen in the P-gp- and BCRP-deficient mice, 
compared to WT. Additionally, an increased amount of CD45+, CD19+, B220+ cells was seen in the P-gp-deficient mice. nd: 
not detectable, *: P<0.05, **: P<0.01, ***: P<0.001 compared to WT animals. Frequency of spleen-derived early outgrowth 
endothelial progenitor cells (EPCs) in WT, P-gp- and BCRP-deficient mice was determined after AcLDL uptake and BS-I 
lectin staining. The results show an increased amount of AcLDL+, BS-I lectin+ EPCs in the P-gp- and BCRP-deficient mice 
compared to WT. *: P<0.05, ##: P=0.07. 
 
Discussion 
 
In this study, we show that BM-derived cells have the capacity to migrate to the injured 
kidney and contribute to tubular epithelial regeneration and renal function repair without 
fusing with resident tubular cells. Furthermore, we demonstrate that such repair is 
significantly increased when transplanted BM cells do not express P-gp or BCRP. Absence of 
either of these transporters affects the differentiation state of the BM cells, as more mature 
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monocytes and granulocytes are present in BM of knockout animals, as well as early 
outgrowth EPCs. Together with the enhanced inflammatory reaction observed post-ischemia 
in transporter-deficient BM transplantations, these findings suggest promotion of 
angiogenesis and tissue remodeling in absence of P-gp or BCRP. This is the first report 
describing such crucial role of P-gp and BCRP in renal regeneration by BM-derived cells.  
We found a complete protection against ischemia-reperfusion injury in BCRP-
deficient mice (present study) and P-gp-deficient mice (21). We further demonstrate that 
adoptive transfer of P-gp-and BCRP-deficient BM cells to wild type mice mimics the 
observations in knockout mice, and that adoptive transfer of wild type BM in BCRP-deficient 
mice results in a loss of protection. This remarkable phenomenon is, at least in part, due to 
enhanced BM engraftment in absence of P-gp or BCRP. The role of BM-derived cells in renal 
remodeling is still controversial. Trans-differentiation of BM cells to tubular epithelium has 
been demonstrated (24), while others showed that BM cells may improve renal function, 
without direct involvement in tubular epithelial engraftment (25). In the latter studies, BM 
cells may predominantly contribute to the interstitial myofibroblast pool, whereas we clearly 
show E-cadherin positivity of the engrafted cells, indicating tubular epithelial differentiation. 
This controversy may arise from variable experimental models and various tracking methods 
used to characterize the BM-derived cell phenotype, e.g. transgenic reporter gene labeling of 
the donor BM with GFP or Lac-Z and/or gender mismatch. The use of more than one 
detection method, however, may limit false-positivity. Our gender mismatch study further 
confirmed engraftment of donor BM cells and, moreover, show that the mechanism of BM 
cell conversion into renal cells after AKI does not involve cell fusion between resident tubular 
cells and donor BM cells. This contradicts with processes described for repopulation of other 
tissues, including liver, heart and Purkinje neurons (26-28), but is consistent with a recent 
report showing that fusion with resident renal tubular cells is a rare phenomenon after AKI 
(29). 
Enhanced GFP-tagged wild type BM cells accounted for approximately 10% of post-
ischemic kidney remodeling, which is in close harmony with earlier reports (30,31). After 
measuring the amount of donor BM cells in peripheral blood by FACS analysis, we showed 
that peripheral blood consisted of ~55% eGFP positive donor bone marrow cells, indicating 
that the remaining 45% is still from the recipient animal and that the observed contribution of 
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BM to renal remodeling is slightly underestimated. Still, the majority of epithelial 
repopulation originates from BM-independent processes. It was suggested that the most 
important mechanism of renal regeneration might occur through survival of dedifferentiated 
epithelial cells which proliferate and redifferentiate into mature functional epithelial cells 
(22). This process may, however, also hamper tissue remodeling by fibroblast formation, 
causing renal interstitial fibrosis (3).  
Intriguingly, the limited ability of BM cells to differentiate into renal epithelial cells 
increased to 20% and 30% when BM cells lack P-gp or BCRP, respectively. Renal function 
tests confirmed enhanced tissue recovery, indicating that P-gp and BCRP are potential targets 
for cell-based therapies of AKI. Although BM stem cells may provide a valuable source for 
cell-mediated therapy, a single injection of freshly isolated BM cells did not improve 
restoration of kidney function post ischemia (30). Strategies to enhance BM-derived cell 
conversion into renal epithelial cells are hampered by the lack of insight into the mechanisms 
that control the remodeling processes. As incomplete recovery of the kidney after AKI may 
lead to progressive loss of renal function over time, novel, effective, treatment for AKI 
remains a challenge. A selective knockdown of the functional expression of P-gp or BCRP in 
BM cells by inhibitors or by small interfering RNAs may be a novel pharmacological 
approach. Systemic inhibition of efflux pumps is probably less successful due to the resulting 
accumulation of xenobiotics and metabolic waste products. As a consequence of tissue injury, 
inflammation occurs with involvement of leukocytes, adhesion molecules, and endothelial 
injury. The MAC-1 staining in our transplanted kidneys corroborates the inflammatory 
process, which is increased when BM cells lack P-gp or BCRP. Secondly, monocytes migrate 
to the site of tissue injury and differentiate into mature macrophages. These cells may not 
only propagate renal injury, but may also be important in inflammation resolution. Upon 
activation, macrophages release chemokines and pro-inflammatory cytokines that regulate 
local tissue remodeling by modulating the extracellular matrix components and the immune 
response. Macrophages also remove dying cells and uptake of apoptotic cells inhibits the 
immune response. Indeed, positive effects of macrophages in renal remodeling after injury 
have been documented (32-35). As the BM composition of P-gp- or BCRP-deficient mice 
contains significantly more myeloid cells it is likely that an enhanced macrophage influx 
accelerated the recovery process. Furthermore, we found that P-gp-deficient (21) and BCRP-
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deficient BM cells are less sensitive to apoptosis (this study) and this mechanism might have 
enhanced the differentiation of these cells. This is supported by our in vitro findings with 
cultures of isolated BM cells from wild type, P-gp-deficient and BCRP-deficient mice that 
show a much slower proliferation of wild type cells as compared to knockout BM (data not 
shown).  
In conclusion, we demonstrate that BM cells can directly contribute to tubular 
regeneration in kidneys injured by ischemia, and that this is significantly enhanced when BM 
cells do not express the P-gp or BCRP. The exact mechanism though which P-gp-deficient or 
BCRP-deficient BM prevent renal damage is not fully clear, although we demonstrate that 
such BM contains significantly more monocytes and granulocytes, as well as early outgrowth 
EPCs, suggesting that the altered BM-composition and the eventual resulting altered 
differentiation status of the stem cells in both knockout animals are responsible for this 
phenomenon.  
 
Methods 
 
Animals 
The animal ethics board of the Radboud University Nijmegen Medical Centre approved all 
experimental procedures. Male, wild type (WT), Friend leukaemia virus B strain mice (FVB) 
(6-8 weeks) were obtained from Charles River (Germany), and were housed under routine 
laboratory conditions at the Central Animal Facility Nijmegen. P-gp-deficient (mdr1a/1b-/-) or 
BCRP-deficient (bcrp-/-) mice (6-8 weeks, with an FVB background) were kindly provided by 
the group of Dr. Alfred Schinkel (36,37), and bred and housed in Nijmegen. Embryo transfer 
was performed for both strains to create identical microbiological conditions. For the 
collection of blood and urine, mice were individually housed in metabolic cages (Techniplast, 
Exton, USA). Mice were allowed to adapt to these cages for one day, where after 24-hour 
urine samples were collected. Before their housing in metabolic cages, mice were injected 
intraperitoneally with 0.5 ml of 0.9% NaCl (B. Braun Melsungen AG, Melsungen, Germany) 
in order to maintain a normal fluid balance. Blood and urine were used for standard clinical 
chemistry analyses; serum and urine creatinine levels were measured by HPLC.  
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Renal function assessment 
Determination of the glomerular filtration rate was determined as described previously (21). 
To characterize proximal tubular function, we injected 16 mice subcutaneously with 250 µmol 
of lithium chloride (Merck, Darmstadt, Germany). After collecting blood from all mice before 
injection, mice were divided in groups of 4 and blood was collected 1 hour, 3 hours, 6 hours 
and 8 hours after injection. Lithium concentrations were determined in serum according to the 
method described by (38). Clearances were calculated from the lithium plasma concentration 
versus time curves using WinNonlin Professional (Version 5.2, Pharsight Corporation, 
Mountain View, CA, USA). 
 
Transduction of primary mouse bone marrow cells 
Chemicals and cytokines were obtained from Sigma (Zwijndrecht, the Netherlands) unless 
stated otherwise. BM was harvested from the femurs of 8 week old, male wild type, P-gp- and 
BCRP-deficient mice. Cells were cultured at 37ºC, 5% CO2 for 2 days in IMDM medium 
(Invitrogen, Life Technologies, Breda, the Netherlands) supplemented with 10% FCS 
(Integro, Zaandam, the Netherlands), 1% penicillin (5000 units) and streptomycin (5mg/ml) 
solution (Invitrogen), 7 µl/l β-Mercapto-Ethanol, 1% BSA, 1% nucleoside mix (0.1mg/ml 
cytidine, adenosine, uridine, guanosine, 2’deoxycytidin, 2’deoxyadenosine, thymidine, 
2’deoxyguanosine), 10 µg/mL bovine insulin (Invitrogen), 15 µM cholesterol, 15 µM linolic 
acid, 0.62 mg/mL human transferrin and the following recombinant cytokines: murine SCF 50 
ng/mL, murine IL-12 10 ng/mL, murine IL-3 10 ng/mL, human Flt-3 50 ng/mL, human TPO 
10 ng/mL (ITK Diagnostics, Uithoorn, the Netherlands), anti-TGF-β 1 µg/mL (ITK 
Diagnostics). Cells were plated onto retronectin-coated culture dishes (Takara, Cambrex Bio 
science, Heerhugowaard, the Netherlands) and exposed to the supernatant of packaging, 
ecotropic Phoenix cells, transfected with retroviral vector pLZRS encoding for enhanced 
green fluorescent protein (eGFP) (39,40). 24h after exposure to the retroviral vector, cells 
were collected and GFP positive cells selected using an Epics Altra flow cytometer (Beckman 
Coulter, Miami, FL).  
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Irradiation and transplantation procedure 
Mice were irradiated with a single dose of 3.5 Gy (6 MV) using a Digital Precise SLi Linear 
Accelerator” (Elekta, Crawley, UK) and subsequently, 106 eGFP positive BM cells, diluted in 
100 µl 0.9% NaCl (B. Braun Melsungen AG, Melsungen, Germany) were injected via the tail 
vein. After transplantation, mice were housed under semi sterile conditions to avoid 
infections. The amount of GFP positive cells in the circulation was measured by FACS 
analysis, 24h after induction of ischemia reperfusion injury. After collecting blood from the 
retro orbital sinus in 6 mice, erythrocytes were lysed and the amount of GFP positive cells in 
the peripheral blood was determined.  
 
Induction of Acute Renal Failure 
Four weeks after the transplantation of BM cells, mice underwent unilateral ischemic renal 
injury. Mice were anesthesized using isoflurane, a flank incision was made and ischemia 
induced by clamping the left renal artery and vein for 30 minutes. The flank incision was 
covered with gauze moistened in 0.9% NaCl, and mice maintained at 37ºC using a warming 
path. After 30 minutes, the clamp was removed and reperfusion was visually confirmed. 
Afterwards, animals were evaluated daily. To determine baseline creatinine clearance levels, 
mice were held in metabolic cages (Techniplast, Exton, USA) for 24 hours one week prior to 
the operation. To determine renal function after ischemic injury, mice were held in metabolic 
cages for 24 hours 2 and 7 days after surgery. Before and after they were placed in metabolic 
cages animals were weighed. Creatinine levels were determined by HPLC analysis and 
creatinine clearance was calculated. For the calculation of the fractional sodium excretion, 
sodium levels are determined in blood and urine.  
 
Immunofluorescence and light microcopy 
For immunohistochemistry, kidney fragments were snap frozen in liquid nitrogen, and 2 µm 
cryostat sections were used. Sections were fixed in acetone for 10 minutes and air-dried. 
Subsequently, slices were incubated with the primary antibodies against GFP, diluted 1:200 
(Roche Diagnostics, Basel, Switzerland), Ter-119/Ly-76 diluted 1:200, MAC-1 diluted 1:200 
(Becton Dickinson, Breda, The Netherlands), BCRP (BXP-9) diluted 1:50 (Kamiya 
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Biomedical Systems, Seattle, USA) and P-glycoprotein (C219) diluted 1:100 (Dako 
Diagnostics BV, Herverlee, Belgium) in PBS, 0.5% BSA for 1 hour at room temperature. 
Next, slices were washed 3 times with PBS and incubated with the secondary antibody; goat 
anti-rabbit Alexa Fluo 488 was used for GFP, goat anti-mouse Alexa Fluo 594 for Ter-
199/Ly-76 and P-gp and goat anti-rat Alexa Fluo 594 for BCRP, all diluted 1:200 in 
PBS/0.5% BSA. Sections were examined using a confocal laser-scanning microscope 
(CLSM; Leica lasertechnik GmbH, Heidelberg, Germany).  
For light microscopy, kidney fragments were fixed in Bouin’s solution, dehydrated and 
embedded in paraplast (Amerstad, Amsterdam, the Netherlands). Sections of 3 µm were 
stained with periodic acid-Schiff (PAS). 
 
Fluorescence In Situ hybridization (FISH) 
Fluorescence in situ hybridization was performed using a mouse whole chromosome X paint 
(FITC) and Y (Cy3) (Cambio UK). In brief, slides of perfused frozen mouse kidney, obtained 
from a WT-WT transplantation, were pre-treated with pepsine (Sigma), pre-fixed in 70% 
ethanol -20° C, washed with Nonidet P40 (Fluka) and dehydrated. Of each chromosome paint 
3 µl was used in a total of 10 µl hybridization mix (Cambio) and administered under a 
coverslip of 20x20 mm and denatured simultaneously on a Hybaid Omnislide (Thermo 
Electron). Post-hybridization was performed by a wash step of 0,4SSC/Tween-20 at 68,5°C 
followed by several steps of 2SSC, 4SSC and PBS at room temperature. After dehydration the 
slides were counter-stained with DAPI (Vector) and for GFP, and 100 GFP positive cells 
were analyzed. A Zeiss Axiophot-2 microscope equipped with appropriate fluorescence filters 
was used for analysis of the fluorescence signals. The specimen was scanned for clearly 
recognizable individual cells to facilitate reliable scoring of the chromosome paintings. 
Images were captured by Leica DC 350FX camera using a Leica CW4000 software package. 
 
Western blot analysis 
Total renal fractions of 6 pooled kidneys were obtained using the micro-dismembrator 
(Sartorius BBI Systems GmbH, Melsungen, Germany). To this end, perfused frozen kidneys 
were pulverized (2000 r.p.m., 30s) and transferred to ice-cold TS buffer (10 mM Tris-HCl, 
250 mM sucrose) containing protease inhibitors (1mM phenylmethylsulfonyl fluoride, 1 
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µg/ml aprotinin, 5 µg/ml leupeptin, 1 µg/ml pepstatin and 10 µM E64). These suspensions 
were centrifuged for 12000 g, 30 minutes, 4˚C and the resulting supernatant contains the total 
fraction. From these fractions, 50 µg was solubilized in Laemmli sample buffer, heated at 65 
˚C for 10 minutes, separated on a 10% polyacrylamide gel and transferred to Hybond-C pure 
nitrocellulose membrane. Analysis was performed by the Odyssey infrared imaging system 
(LI-COR, Biosciences, NE, USA). The membrane was blocked in Odyssey blocking buffer 
diluted 1:1 with PBS for 1 hour at room temperature. Subsequently, the membrane was 
incubated overnight with the primary antibodies at 4˚C: GFP (Invitrogen, Breda, The 
Netherlands) diluted 1:200, β-actin (Sigma, Zwijndrecht, The Netherlands) diluted 1:100000 
in PBS, 0.1% Tween-20 and 0.01% SDS. After three washing steps of 10 minutes in PBS, the 
blot was incubated in the dark at room temperature for 60 minutes with the secondary 
antibody in PBS 0.1% Tween-20; IRDye 800 anti-rat and IR-Dye 800 anti-mouse (Rockland 
Immunohistochemistry Inc., Gilbertsville, USA). After repeating the washing steps images 
were acquired with the Odyssey infrared imaging system and analyzed by the software 
program as specified in the Odyssey software manual. For semi-quantification, we measured 
the pixel intensity of the bands using Scion image version beta 4.02 for Windows (Scion 
Corp., Frederick, MD, USA).  
 
Bone marrow cell characterization 
BM cells were isolated as described previously from 6 mice per genotype and erythrocytes 
were lysed. After centrifugation, BM was washed and fractions were stained with the 
following conjugated antibodies: Sca-1, c-kit, Thy1.1, Ter 119, CD45.1, CD45.2, Mac1, Gr-1, 
CD4, CD8, CD19, B220, CD31, CD34 and isotype controls (BD Biosciences, Alphen a/d 
Rijn, The Netherlands). After that, BM cells were analyzed using FACS analysis to determine 
cell surface phenotype.  
 
Isolation and quantification of early endothelial progenitor cells 
Early outgrowth endothelial progenitor cells (EPCs) were isolated from spleens of adult mice 
(6 per genotype) and cultured according to a method adapted from Yoder et al. (23). Briefly, 
spleens were washed in PBS and dissociated by gently rubbing the surface with the back of a 
syringe. Single cell suspensions were obtained by thorough pipetting and passing through a 40 
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µm filter. The mononuclear cell fraction was isolated by density centrifugation using Ficoll 
Paque (Amersham, Diegem, Belgium). To analyze early outgrowth EPCs, cells were plated in 
EGM-2 complete (Lonza, Verviers, Belgium) on fibronectin-coated 6 well plates (3 wells per 
mouse at 5x106 cells/well). Fourty-eight hours later, non-adherent cells were replated in 
fibronectin-coated 24 well plates (5-8 wells per mouse at 1x106 cells/well). Five days later, 
early endothelial outgrowth was scored by incubating the cells with DiI-acetylated low 
density lipoprotein (LDL; Biomedical Technical Inc., Stoughton, USA), staining with 
fluorescein-isothiocyanate (FITC)-Bandeiraea Simplicifolia (BS)-I lectin (Sigma, Belgium) 
and counting the number of double positive cells for each well. Results were expressed as the 
average number of double positive cells per area (in cm2). 
 
Data analysis 
Data are given as mean ± SEM. Mean values were considered to be significant when P<0.05 
by use of a one-way ANOVA followed by Bonferroni's multiple comparison test. Software 
used for statistical analysis was Graphpad Prism® (version 4.03 for Windows; Graphpad 
Software, San Diego, CA, USA).  
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Abstract 
 
The kidney has a high capacity to regenerate after injury. Increasing evidence supports the 
ability of bone marrow-derived stem cells to migrate to the kidney and to help in the 
regenerative process after injury. A relative new discovered stem cell population within the 
bone marrow, the multipotent adult progenitor cells MAPCs, is known for its capacity to 
differentiate into other lineages of cells, like endodermal, ectodermal or mesodermal cells. 
Although MAPCs have a high capacity to differentiate towards many specific cell types, their 
differentiation capacity towards renal cells is unknown. In this study we show the ability of 
MAPCs to differentiate to cells with renal epithelial features, under influence of b-FGF, TGF-
α, LIF and HGF. Morphology of the cells as well as gene and protein expression profiles 
confirm the differentiation towards renal epithelial cells, which is further supported by 
functional assessment. 
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Introduction 
 
In recent years, our knowledge of the pathogenesis of renal failure has increased. Sepsis, 
hypoxia and nephrotoxic agents are the main causes of acute kidney injury (AKI) and the 
mortality rate in the clinic is still between 50 and 80% (1,2). The kidney has, however, the 
capacity to completely recover its function after AKI (3). Differentiated epithelial cells within 
the kidney can acquire mesenchymal characteristics and are able to spread along and migrate 
to the basement membrane (4). In addition to epithelial-to-mesenchymal (EMT) transition, 
stem cells residing within or outside the kidney might play a role in renal repair (5). A number 
of studies have been published wherein the role of putative extra-renal stem cells in renal 
repair has been evaluated, predominantly by donor bone marrow (BM) transplantations in 
recipient mice undergoing AKI. Several studies demonstrated that BM derived cells aid to 
repair renal damage and increase renal function. Candidate cells within BM responsible for 
the regeneration capacity of the kidney are hematopoietic stem cells (HSCs), including side 
population (SP) (6,7) and ckit+, Sca- , lin-, (KSL) cells, (8) and mesenchymal stem cells 
(MSCs) (9,10). Several groups have isolated cells from cultured BM that have greater 
proliferation and extended differentiation potentials (11-16). Among these, multipotent adult 
progenitor cells (MAPCs), present at very low frequency in plastic adherent cultured BM 
cells, can differentiate in vitro in multiple cell types of mesoderm, endoderm and ectoderm 
(11). When grafted into sublethally irradiated nonobese diabetic (NOD)-SCID mice, MAPCs 
contribute to the hematopoietic lineage (17) and at low levels to some endodermal tissues 
(11). It is not known whether MAPCs can also generate renal epithelial cells. In a recent 
study, Kramer et al. (18) described the capacity of mouse embryonic stem cells (ESC) to 
differentiate into cells expressing transcripts and proteins found in renal epithelium. Likewise, 
there is evidence that isolated rat uteric bud cells are able to differentiate in renal epithelium 
(19).  
During embryogenesis, the kidney develops through three differentiation stages. First, 
the pronephric duct arises and tubule formation is induced. Second, the mesonephros is 
introduced and after regression of this structure, the metanephros is made. In this stage, 
mesenchymal tissue aggregates and differentiates into renal nephrons (18). Although most 
epithelial organs originate by the folding or branching of preexisting epithelia, the kidney 
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develops by the process of EMT (18,19). The events of kidney development are controlled by 
several growth factors, including basic fibroblast growth factor (b-FGF), necessary for the 
aggregation of mesenchymal cells in culture (20), and leukemia inhibitory factor (LIF) that 
convert the mesenchymal condensations into epithelial cells (19).  
As we had previously been able to use insights gained from developmental biology 
studies or from differentiation methods to induce mesodermal and endodermal cell lineages 
from MAPCs, we here investigated the ability of MAPCs to differentiate towards renal 
epithelial cells. We demonstrate that MAPCs can be induced to express transcripts and 
proteins consistent with renal epithelial cells, after culturing in medium supplemented with b-
FGF TGF-α, HGF and LIF. Such MAPC progeny has morphological features as well as 
functional characteristics of renal epithelium. 
 
Results 
 
MAPCs treated with b-FGF, LIF, TGF-α and HGF differentiate in cells with epithelial 
morphology 
According to the literature, b-FGF and TGF-α are essential in the first stage of differentiation 
of primitive cells to renal epithelium. Basic-FGF is necessary to induce the aggregation of 
metanephrogenic cells in cultured rat cells (20) and TGF-α is an important metanephric 
growth factor (19). In cultured MAPCs exposed to differentiation medium containing b-FGF 
and TGF-α we observed changes to an epithelial morphology. MAPCs are small cells, 
between 9 and 12 µm in size. Usually, MAPCs are spindle or triangular in shape, but become 
round after dividing (Figure 1A-C). After three days of culture at high density with b-FGF 
and TGF-α, morphology of the round MAPCs changed into elongated shaped cells. Although 
it is difficult to assess from the images, but epithelial cells usually have characteristic coble-
stone-like structures (Figure 1D-F). After day 3, cytokines added were switched to b-FGF, 
LIF and HGF. LIF can convert mesenchymal condensations in kidney tubule epithelium (19). 
HGF, known to support hepatocyte progenitor cells, binds to the cMet receptor, which is also 
present in embryonic kidney (19). By day 7 of differentiation, the morphology of MAPC-
progeny further evolved to an epithelial morphology (Figure 1G-I). To determine whether 
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these cells differentiate towards renal epithelial cells, we performed RQ-RT PCR and Western 
blot analysis for specific renal development markers.  
Figure 1. Multipotent adult progenitor cells differentiate into an epithelial cell line in vitro. After culturing MAPCs in 
differentiation medium for 7 days, cells acquire epithelial characteristics as observed from their long stretched form, 
compared to the round, small and sometimes triangle form of undifferentiated MAPCs. (A-C), morphology of the MAPCs 
before culturing in differentiation media; (D-F), MAPCs acquire a more epithelial phenotype 3 days after culturing in 
differentiation medium. (G-I) a clear shift in phenotype towards epithelial cells is observed 7 days after culturing in 
differentiation medium. Magnification: (A,D,G x10)(B,E,H x20)(C,F,I x 40).  
 
Progressive activation of renal epithelium expressed transcripts during differentiation 
Genes involved in different stages of renal development include Lim-1, Pax-2, Emx-2, Pax-8. 
BMP-7, WT-1, Wnt-4, THP, ksp-cadherin, D3H, RSOR and nephrin which are expressed at 
different stages of renal development (Figure 2). The transcription factors Lim-1, Pax-2 and 
Emx-2 (Figure 2A) are expressed in the early stages of renal development (18,19,21-23). 
Undifferentiated MAPCs did not express significant levels of Pax-2, but express Lim-1 and 
Emx-2. During differentiation, Pax-2 mRNA was detected at day 3 and increased further by 
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day 7. In contrast, levels of Lim-1 and Emx-2 mRNA already present in undifferentiated 
MAPCs, remained unchanged or decreased between day 0 and day 7 of differentiation.  
Figure 2. Different marker genes important in renal development show controlled expression after starting differentiation 
procedure. After culturing cells in medium with different constituents, gene transcription of different markers important in 
renal development is variably expressed. Transcription factors can be divided in early (A), middle (B) and late renal markers 
(C), indicating the phase of renal development. To exclude the possibility that cells differentiate into non-renal epithelial 
cells, gene expression of differentiation markers for other cell types, like intestinal cells, hepatocytes and pancreatic cells, 
were tested (D-F). Data are expressed as mean ± SEM. *: P<0.05, **: P<0.01, ***: P<0.001. 
 
Pax-8, BMP-7, WT-1 and Wnt-4 are genes expressed at somewhat later stages of renal 
development, although some studies suggest that WT-1 has a more important role in the early 
renal developmental phase (18-20,22-24). All genes were expressed at low levels in 
undifferentiated MAPCs. Pax-8, BMP-7 and WT-1 transcript levels did not change after 
starting the differentiation procedure (Figure 2B). In contrast, expression of Wnt-4 increased 
significantly after 7 days. 
 
Genes expressed in more terminally (late) differentiated renal tissue include THP, ksp-
cadherin, D3H, RSOR and nephrin (Figure 2C) (18). THP, ksp-cadherin and nephrin mRNA 
was not detected in undifferentiated MAPCs, while D3H and RSOR transcripts were present. 
THP mRNA was not detected at any stage of the MAPC differentiation culture, and no 
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changes were seen in D3H transcript levels throughout differentiation. Ksp-cadherin 
expression is induced as early as 7 days following differentiation. Levels of RSOR transcripts 
increased significantly by day 3, but decreased again on day 7, remaining at levels also found 
in undifferentiated MAPCs. A progressive increase was seen in transcript levels of nephrin 
throughout the differentiation culture. Oct-4, a transcription factor known to be required for 
the pluripotency of ESCs (25), is also expressed in MAPCs, albeit at lower levels (26). During 
the differentiation process, levels of Oct-4 transcripts remained unchanged (Figure D-F)). 
Abcg2 encodes for a cell membrane pump (breast cancer resistance protein; BCRP) that is 
responsible for eliminating Hoechst from cells, such as in the SP (27,28). BCRP is expressed 
at high levels in ESCs and MAPCs (26) (Figure 3I), but also in the kidney (29). Levels of 
abcg2 (Figure D-F) transcripts remained high throughout differentiation.  
 
To evaluate whether the differentiation scheme employed specifically induced transcripts 
found in renal development, we measured transcript levels for genes known to be expressed 
during mesoderm, endoderm and ectoderm differentiation, during the differentiation of 
MAPCs towards renal epithelium. Genes analyzed included SM-22, α-actin, CDX-2, TITF-1, 
AFP, albumin, VWF, PDX-1 and amylase (Figure 2 D-F). Varying levels of expression were 
found in undifferentiated MAPCs, consistent with what we recently described (26), such as 
high levels of SM-22, VWF and V-cadherin transcripts, and moderate expression levels of 
albumin, CDX-2 and TITF-1. Expression levels of any of the tested transcripts, however, did 
not change during the differentiation culture.  
 
Differentiating MAPCs express WT-1, cadherin, and nephrin proteins 
To further ascertain that MAPCs can differentiate towards cells with renal epithelial 
phenotype, we performed immunohistochemical and Western blot analysis for a number of 
renal-expressed proteins. WT-1 protein could not be detected in undifferentiated MAPCs, but 
could be detected on day 3 and 7 of differentiation by Western blot (Figure 4; protein band at 
52 kDa), which was confirmed for day 7 MAPC progeny by immunohistochemistry 
demonstrating that 69 ± 7% of cells expressed WT-1 (Figure 3 A-B). Nephrin protein could 
not be detected in undifferentiated MAPC by immunohistochemistry (Figure 3, panel C), and 
a very weak signal was seen on Western blot. 63 ± 4% of MAPC progeny on day 7 expressed 
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nephrin (Figure 3, panel D), which was confirmed by Western blot, where both on day 3 and 
day 7 a clear band at 185 kDa could be detected. A comparable protein expression pattern was 
also seen for e-cadherin: minimal (Western blot, Figure 4) to no (11 ± 2% 
immunohistochemical Figure 3E) expression in undifferentiated MAPCs, and expression in 
80 ± 8% percent of lineage committed MAPCs on day 7 (Figure 3F), and a clear band on day 
3 and day 7 at 135 kDa on Western blot (Figure 4).  
 
Oct-4 expression was found in 56 ± 9% of undifferentiated MAPCs, and on day 7 of 
differentiation, 68 ± 7% expressed this protein (Figure 3G-H). Similarly, Western blot 
analysis demonstrated that levels of Oct-4 remained relatively unchanged. Consistent with the 
RQ-RT PCR data, levels of BCRP remained unchanged during differentiation: 64 ± 14% vs. 
76 ± 8% (Figure 3I-J). In contrast, protein expression levels of P-gp increased 7 days after 
differentiation from 22 ± 8% to 44 ± 11% (Figure 3K-L).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Immunohistochemical analysis shows expression of nephrin, cadherin and WT-1 after differentiation in renal cells. 
After 7 days of differentiation, fluorescent signal of WT-1 (B), nephrin (D) and cadherin (F), was increased compared to 
expression before starting differentiation (A, C, E). Oct-4 expression remained equal during the differentiation procedure (G-H), 
which was also seen for BCRP expression (I-J). In contrast, P-gp expression increased after 7 days of differentiation (K-L). (M) 
Percentage of positive cells in which open bars represent day 0 and closed bars day 7. (Original magnification: x200).  
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Functional analysis 
One characteristic of renal epithelial cells is that they express alkaline phosphatase on the 
brush border membrane of the proximal tubule and on podocytes. We demonstrate that 
alkaline phosphatase activity increased significantly 7 days after starting the differentiation 
procedure (Figure 5A), consistent with differentiation towards renal epithelial cells.  
 
Although RQ-RT PCR and protein expression patterns confirmed the differentiation of 
MAPCs into cells with features of renal epithelial cells, further proof of such differentiation 
requires that the cells also have functional characteristics of renal epithelial cells, such as the 
efflux transporter P-gp. The function of the P-gp efflux pump can be evaluated by the calcein-
AM assay (30). Figure 5B shows clearly that P-gp activity increases during the differentiation 
procedure. The fluorescence ratio between calcein and calcein supplemented with the P-gp 
specific inhibitor PSC833 increased significantly from 1.9 ± 0.3 on day 0 till 4.6 ± 0.3 on day 
7. The increased P-gp activity is already seen three days after starting the procedure, 
consistent with differentiation towards an epithelial cell.  
 
 
Figure 4. Western blot 
analysis shows protein 
expression of the renal 
markers nephrin, cadherin 
and WT-1 in MAPC 
differentiation. During the 
differentiation procedure, 
protein expression of the 
markers nephrin, cadherin and 
WT-1 increased, indicating 
the differentiation towards 
renal cells. Protein expression 
levels are comparable with 
gene expression levels. 
Amount of protein transferred 
was tested with β-actin, Oct-4 
levels were similar during the 
differentiation procedure.  
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Figure 5. MAPCs obtain renal functional characteristics after starting the differentiation procedure. Specific renal epithelial 
cells have a high activity from alkaline phosphatase (A). We clearly see that after 7 days, alkaline phosphatase activity is 
increased significantly, confirming the development towards renal epithelial cells. (B) the ratio measured in samples 
incubated with Calcein-AM or Calcein-AM with the P-gp specific inhibitor PSC 833. Three days after starting the 
differentiation, ratio increased and further increased after 7 days, indicating specific P-gp activity. Data are expressed as 
mean ± SEM. *: P<0.05, **: P<0.01, ***: P<0.001. 
 
Discussion 
 
Aside from embryonic stem cells that can generate all 220 cell types of the body, a number of 
recent studies have shown that BM cells in culture have the ability to differentiate into cells of 
mesodermal, endodermal and ectodermal lineage (11-16). One of these cell populations, 
MAPCs, is able to differentiate in vitro in many mesodermal cell types, neuroectodermal cells 
and hepatocyte like cells. In the present study we provide evidence that MAPCs can 
differentiate towards cells with phenotypic and some functional characteristics of renal 
epithelial cells. 
The development of the kidney has been extensively studied, and several studies have been 
performed in which ESCs are stimulated to differentiate into renal cells in vitro (18,31,32). 
We here show for the first time that MAPCs can be induced to cells with morphological and 
phenotypic features of renal epithelial cells, using cytokines, known to act during renal 
epithelium differentiation in vivo, and effective at inducing a renal epithelial fate from ESCs. 
In addition to acquisition of morphology consistent with epithelial cells, we demonstrate that 
gene and protein expression of some, albeit not all genes expressed during renal development 
A B 
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are upregulated, consistent with embryonic development. On the other hand, no significant 
changes were observed in expression of transcripts known to be upregulated during hepatic, 
pancreatic or lung endoderm development, endothelium or smooth muscle development or 
ectodermal differentiation. Moreover, functional activity assays show that the differentiating 
MAPCs express alkaline phosphatase and functional P-gp pumps, consistent mostly proximal 
tubular function but not glomerular cells or interstitial cells. This means that the development 
towards an epithelial cell started almost immediately after starting the differentiation, and the 
development into renal specific cells is first seen after 7 days. Although P-gp is also expressed 
on multiple cell types, including SP cells, its increased activity after 3 and 7 days and the 
absence of activity before starting differentiation, suggest that MAPCs develop in epithelial 
cells.  
 
The differentiation of primitive MAPCs towards renal epithelial cells was carefully examined 
by measurement of several genes involved in renal development. The transcription factors 
Pax-2 and Lim-1 are both involved in the formation of the Wolffian Duct, necessary in the 
first stage of renal development (24). In Lim-1(-/-) mice, the intermediate mesenchyme is 
disorganized and fails to express the transcription factor Pax-2 (21,33). Lim-1 is already 
expressed in undifferentiated MAPCs, and continues to be expressed during the initial 7 days 
of differentiation. Pax-2, not expressed in undifferentiated MAPCs, is strongly upregulated 3 
and 7 days after differentiation, consistent with what is known during renal development. WT-
1 expression is induced in vitro by b-FGF (21), and is necessary for the survival and normal 
behavior of the mesenchyme surrounding the Wolffian Duct (34). Expression of WT-1 is also 
transactivated by the transcription factors Pax-2 and Pax-8 (35). Wnt-4 is expressed in the 
condensed mesenchyme, and is required for the mesenchyme to epithelial conversion (36,37). 
By day 3 and 7 of differentiation, gene expression of both WT-1 and Wnt-4 were higher under 
the differentiation conditions used. For WT-1, we also demonstrated by 
immunohistochemistry that approximately 70% of the cells expressed the protein after 7 days 
of differentiation, suggesting the differentiation towards a renal epithelial phenotype. 
Expression of BMP-7 and Pax-8 was moderate in primitive MAPCs and their downregulation 
suggests a minor role in this second stage of differentiation towards renal cells. Nevertheless, 
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knockout studies show that BMP-7 is not required for the initial induction process. Its exact 
role in in vitro development of renal cells is unknown (23,38).  
THP is an established marker for tubular maturation in vivo (18,39) and, therefore, the low 
gene expression in our differentiation study is not surprising. D3H is a marker molecule for 
proximal tubular cells and the fact that its gene expression remained equal suggests that our 
cells might be in a preliminary stage of renal development. This is in contrast with the 
increased expression levels of RSOR, nephrin and ksp-cadherin, which are also markers for 
late renal development, indicating that MAPCs are in a more advanced differentiated state. 
For cadherin and nephrin, this was also confirmed on the protein level. These observations 
were also done in the differentiation of ES cells towards renal cells (18). The stabile 
expression of genes characteristic for differentiation to other cell types show that MAPCs are 
not differentiating in other cell types using this protocol. Continued presence of Oct-4 mRNA 
and protein suggest that a fraction of the cell culture remains undifferentiated.  
 
In our study we show that MAPCs are able to differentiate towards renal like cells. MAPCs 
do not cause immunological reactions, which is a great advantage in renal diseases where, 
until now, kidney transplantations were required. The differentiation potential of MAPCs will 
have great therapeutic implications in the future in the regeneration of damaged renal tissue, 
and their use in animals with renal developmental defects or renal injury will be a next step to 
investigate their in vivo capacity.  
 
Methods 
 
Cell culture of multipotent adult progenitor cells (MAPCs) 
Mouse MAPCs isolated from C57BL/6 mice carrying the enhanced green fluorescent protein 
(eGFP) described elsewhere (16) were used for differentiation assays. Cells were expanded by 
trypsinization (0.05% trypsin, Cellgro) and replated every two days at a density of 100-200 
cells/cm2 on fibronectin (Sigma, St Louis, MO) coated cell culture dishes. Expansion medium 
consisted of 60% low glucose DMEM (Gibco BRL, Grand Island, NY), 40% MCDB-201 
(Sigma, St Louis, MO) containing 1 ng/mL mEGF (R&D Systems, Minneapolis, MN), 
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hPDGF-BB (R&D Systems, Minneapolis, MN) and 1000 units/ml mLIF (Chemicon 
International, Temecula CA), 2% screened FCS (Hyclone, Logan, UA, Lot ANL19977), 1x 
selenium-insulin-transferrin-ethanolamine (SITE), 0.2 mg/mL linoleic acid-bovine serum 
albumin (LA-BSA), 0.8 mg/mL bovine serum albumin (all from Sigma), 1x chemically 
defined lipid concentrate (Gibco, BRL, city) and 55 µM 2-mercaptoethanol (Gibco), 100 units 
of penicillin, 1,000 units of streptomycin (Cellgro, Herndon, VA) in a humidified, 5% O2 and 
6% CO2, 37oC incubator. 
 
MAPC renal differentiation 
MAPCs were resuspended in expansion medium and seeded at a density of 50,000 cells/cm2 
in 12 or 24 well plates (Corning) coated with 2% Matrigel (BD Biosciences). 24 hours later, 
MAPC medium was removed and differentiation medium added. Differentiation medium 
consisted of 60% low glucose DMEM, 40% MCDB-201, 1X insulin-transferrin-selenium, 1X 
LA-BSA, 0.05x10-6M dexamethasone (Sigma), 10-4M ascorbic acid 3-phosphate, 100 units of 
penicillin, 1,000 units of streptomycin, 55 µM 2-mercaptoethanol, 2% FBS (HyClone; Lot 
ANL19977). The first three days, differentiation medium contained 100 ng/mL basic 
Fibroblast Growth Factor (b-FGF) (R&D Systems) and 10 ng/mL transforming growth factor 
alfa (TGF-α) (R&D Systems). From day 3, cytokines in the differentiation medium were 100 
ng/mL b-FGF, 50 ng/mL LIF and 100 ng/mL Hepatocyte Growth Factor (HGF) (R&D 
systems). Differentiation medium was changed every other day, and morphology of the cells 
was checked every day.  
 
Detection of gene expression by Quantitative Real-Time PCR 
Total RNA (1 x 105–1 x 106 cells) was isolated using an RNeasy Micro Kit (Qiagen, Valencia, 
CA). RNA was treated with Turbo DNA-free (Ambion) according to the manufacturer’s 
protocol and reverse transcribed into cDNA using Superscript III with random hexamers 
(Invitrogen, Carlsbad, CA). For real-time quantitative PCR (RQ-RT PCR), cDNA was 
amplified using SYBR Green PCR Master mix (marker genes listed in table 1) or using primer 
probe sets designed by Applied Biosystems (Applied Biosystems, Zwijndrecht, The 
Netherlands). The thermal cycling conditions were 2 min at 50ºC and 10 min at 90ºC, 
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followed by 40 cycles of 9 s at 95ºC and 1 min at 60ºC. PCR reactions were analyzed using an 
eppendorf realplex detection system.  
 
Immunohistochemistry 
MAPCs were allowed to differentiate on chamber slides seeded at 50x103 cells/cm2, rinsed 
two times with PBS, and fixed for 15 minutes using a 3.7% paraformaldehyde in PBS 
solution. Slides were washed two times with PBS and incubated with the primary antibody 
against abcg2/bcrp BXP-9 (Kamiya Biomedical Company, Seattle, USA), diluted 1:200, Oct-
4 (N-19, Santa Cruz) diluted 1:100, WT-1 (C19, Santa Cruz) diluted 1:100, E-cadherin 
(C3678 Sigma) diluted 1:250 and Nephrin (H-300, Santa Cruz) diluted 1:100 in PBS 0.5% 
BSA, or an isotype control antibody. After incubating 45 min with the primary antibody, 
slides were washed with PBS and incubated with the secondary antibody. After 30 min, slides 
were rinsed and mounted. Analysis was performed with a fluorescence microscope. 
Quantitative analysis was performed on three different differentiation studies, and average 
percentages were calculated. 
 
Western Blot analysis 
For Western blot analysis, MAPCs or differentiated progeny from MAPCs were lysed using 
0.2% triton X-100 made in PBS for 15 min at RT. Mouse kidney protein extracts were 
prepared as described by Huls et al. (40). Samples were solubilized in DL-Dithiothreitol and 
Laemmli sample buffer. After electrotransfer of the proteins onto a nitrocellulose membrane, 
analysis was performed by the Odyssey infrared imaging system (LI-COR, Biosciences, NE, 
USA). The membrane was blocked in Odyssey blocking buffer diluted 1:1 with PBS for 1 
hour at room temperature. Subsequently, the membrane was incubated overnight with the 
primary antibodies at 4ºC: BCRP/ABCG2 (BXP-9, Kamiya Biomedical Company, Seattle 
USA) diluted 1:200, β-actin (AC-15 Sigma, Zwijndrecht, The Netherlands) diluted 1:100000, 
Oct-4 (N-19, Santa Cruz) diluted 1:200, WT-1 (C19, Santa Cruz) diluted 1:200, e-cadherin 
(C3678, Sigma) diluted 1:500 and Nephrin (H-300, Santa Cruz) diluted 1:200 in PBS, 0.1% 
Tween-20 and 0.01% SDS. After three washing steps for 10 minutes in PBS, the blot was 
incubated in the dark at room temperature for 60 minutes with the secondary antibody diluted 
1:10000 in PBS 0.1% Tween-20; IRDye 800 anti-rat, IRDye 680 anti-rabbit or IR-Dye 800 
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anti-mouse (Rockland Immunohistochemistry Inc., Gilbertsville, USA). After repeating the 
washing steps, images were acquired with the Odyssey infrared imaging system and analyzed 
by the software program as specified in the Odyssey software manual.  
 
Functional analysis 
To determine the transport activity of P-gp, a calcein accumulation assay was used. MAPCs 
were cultured and differentiated during 7 days according to the protocol described. At day 0, 
3 and 7 after initiation the differentiation procedure, medium was discarded and cells were 
washed twice with Hanks’ balanced salt solution (Invitrogen, Breda, The Netherlands) 
supplemented with 10 mM Hepes (pH 7.4; HBSS+) at 37ºC. Subsequently, cells were 
incubated for 1 h at 37ºC with 1 µM calcein-acetoxymethylester (calcein-AM) (Invitrogen, 
Breda, The Netherlands) in 500 µl HBSS+ in the absence or presence of 5 µM of the P-gp 
inhibitor PSC833 (Valspodar; kindly provided by Novartis Pharma, Basel, Switzerland). After 
incubation cells were rinsed twice times with HBSS+ and lysed with a 0.1% Triton/HBSS+ 
solution for 15 min. Fluorescence in lysates was measured in the Perkin Elmer Victor3 1420-
015 spectrophotometer (Perkin Elmer, Beaconsfield, Buckinghamshire, UK) using excitation 
and emission wavelengths of 488 nm and 518 nm, respectively. Efflux activity of P-gp was 
calculated as the ratio of the average fluorescence value of cells exposed to transport medium 
supplemented with PSC 833 divided by the average fluorescence value of cells exposed to 
transport medium without the P-gp inhibitor. 
Alkaline phosphatase activity was determined according to a modified protocol of Mircheff 
(41). In our study, cells were lysed with a 0.1% Triton/HBSS solution for 15 minutes and 
alkaline phosphatase was measured as described. 
 
Data analysis 
Data are given as mean ± SEM. Mean values were considered to be significant when P<0.05 
by use of a one way ANOVA. Software used for statistical analysis was Graphpad Prism® 
(version 4.03 for Windows; Graphpad Software, San Diego, CA, USA).  
 
  
Table 1. Oligonucleotide sequences and codes of primers used to study the differentiation of MAPCs to renal cells by RQ-RT PCR.  
Sequences are listed in the order antisense-, sense primer, or by the code number registered by Applied Biosystems (*). Abbreviations: Abc (ATP-binding cassette subfamilies b/g).  
 
Marker gene Sequence/code Reference Marker gene Sequence/code Reference 
Alpha-fetoprotein (AFP) -GCCCTACAGACCATGAAACAAG- 
-GTGAAACAGACTTCCTGGTCCT- 
 Vascular-Endothelial Cadherin (VE-
cadherin) 
-ATTGAGACAGACCCCAAACG- 
-TTCTGGTTTTCTGGCAGCTT- 
 
Albumin -AGACTGCCTTGTGTGGAAGACT- 
-TCAACTGTCAGAGCAGAGAAGC- 
 Von Willebrand Factor (VWF) -GCCAAAGATCTGGAACAGTGT- 
- GATGGAGAGGTTACACATCTC- 
 
Amylase II -GTGGTCAATGGTCAGCCTTT- 
-CCATCACTGCCAACATTCAC- 
(18) Wingless-type MMTV integration site 
family, member 4 (Wnt-4) 
-TGCGGTCCCTGCGACTCCTCGTCTTC- 
-CGGGTCCCTTGTGTCACCACCTTCCC- 
(18) 
Bone Morphogenetic 
Protein-7 (BMP-7) 
-GGACAGCCACTTCCTCACTGACGCCG- 
-TGCTCTGCCCATCCAGGGTCTCCACA- 
(18) Wilm's tumour protein-1 (WT-1) -CAAGGCACCAGGCAAGAATCGTACA- 
-GCAGGAAGGCTCCTCTCCGTCCTAAC- 
(18) 
D3-1a-hydroxylase (D3H) 
 
-GAGCCTCTGCCATTCTTCAC- 
-ATATGGTCTGGCAGCTTTGG- 
(18) Abcg2 mm00496364-m1 * 
Empty spiracles homeobox 2 
(Emx-2) 
-TCGAACCGCCTCCTCGCCGTC- 
-AATTTCGTTCTCCGGTTCTGAAACCA- 
(18) Abcb1a mm00440761-m1 * 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
-CATGGCCTTCCGTGTTCCTA- 
-CTGGTCCTCAGTGTAGCCCAA- 
 Abcb1b mm00440736-m1 * 
kidney-specific (Ksp-
cadherin) 
-GCCGTGGCTACTTTACCTCTCTGTTA- 
-TGATAGGACAATGTGGCCTTCATCTC- 
(18) Paired box gene–2 (PAX-2) mm00477972-m1 * 
Lim-homeobox-1 (Lim-1) -CGTAGGGGACCCCGGACCACGATCA- 
-AGGGGCCGTTGGGGATGAGTTCGCC- 
(18) Glyceraldehyde-3-phosphate (GAPDH) 
dehydrogenase 
mm99999915-g1 * 
Nephrin -CCTGGAAGGAGACAGTGCTAA- 
-CATTCACGCTGGAGGAGACA- 
(18) Octamer-4 (Oct-4) mm00658129-gH * 
Pancreatic and duodenal 
homeobox factor 1 (PDX-1) 
-AACTTAACCTAGGCGTCGCA- 
-CATTCGCTTGGCATCAGAAGC- 
 Caudal-related homeobox 2 (Cdx-2) mm00432449-m1 * 
Paired box gene-8 (PAX-8) -TGTTTGCTTGGGAGATCCGGGAC--
CCACTGCTGCTGCTCTGTGAGTCGAT- 
(18) Thyroid transcription factor 1 (TITF-1) mm00447558-m1 * 
Renal-specific oxido 
reductase (RSOR) 
-GCCACGGATAGAAGGAGTGGAATCG- 
-CTGGTGGACGAATCTGACCCAG- 
(18) Smooth muscle alpha-actin (SM-α-actin) mm00725412-s1 * 
Tamm Horsfall Protein 
(THP) 
-CTAACCCATCCTTGCCTTT- 
-TCACACACCAGCCCATCAC- 
(18) Transgelin (SM-22) mm00724259-m1 * 
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Introduction 
 
This thesis describes the role of ABC proteins in renal regeneration and repair after acute 
kidney injury (AKI). We investigated the expression levels of several ABC transporters 
during renal regeneration and focused specifically on P-gp and BCRP, and the role of bone 
marrow-derived stem cells (BMSCs). For these experiments, we used wild type FVB (WT), 
P-glycoprotein-deficient (mdr1a/1b(-/-)) and BCRP-deficient (bcrp(-/-)) mice. After inducing 
AKI in WT mice, we observed that the expression levels of the ABC transporters abca3, 
bsep/abcb11, mrp2/abcc2 and mrp4/abcc4 changed during the recovery and repair process. 
Moreover, expression levels of P-gp and BCRP were markedly increased, indicating their 
association with the renal regeneration process. To investigate the role of BMSCs in renal 
regeneration we transplanted eGFP-labeled bone marrow from WT mice into sublethally 
irradiated WT mice. After the induction of AKI we showed migration of BMSCs towards the 
recipient kidney, although their contribution to the tubular epithelial repair process was 
approximately 10%. To determine the role of P-gp and BCRP in this process, we transplanted 
bone marrow from P-gp-deficient and BCRP-deficient mice into sublethally irradiated WT 
mice and induced AKI. In both transplantation studies we showed an increased amount 
(~20% and ~30%, respectively) of donor bone marrow cells in the recipient kidney, and an 
increased renal function compared to WT transplantation studies. This indicates that P-gp and 
BCRP have an important role in renal regeneration with BMSCs.  
 AKI affects up to 5% of all hospitalized patients and 10-30% of patients in critical 
care units (1). The most common inducing factor of AKI is ischemia, which is caused by the 
lack of or decrease in oxygen delivery to the kidney. Renal tubules are most vulnerable to 
hypoxia, especially the S3 proximal tubular segments localized in the outer medulla, because 
of their high energy demand and low oxygen tension (2). The burden of AKI is world wide 
and mortality still remains high (over 50% in critically ill patients), which emphasizes the 
need for more efficacious therapies. Despite advances in technologies and new insights in 
renal injury and regeneration mechanisms, therapy is still supportive and primarily focused on 
renal replacement. Until now, hemodialysis is the most often applied treatment after AKI, but 
in cases of chronic injury, ultimately renal transplantation may be necessary. Both therapies 
have many disadvantages. Renal function repair or tissue regeneration is not stimulated 
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during hemodialysis, whereas renal transplantation is hampered by shortage of donor kidneys 
and graft rejection. Therefore, in the last years research has focused on the powerful 
regenerative capacity of the kidney itself. There are three main theories describing the 
regenerative capacity of the kidney. First, tubular cells within the kidney might spread to the 
place of injury and proliferate to repair the damage. As a second repair mechanism, epithelial 
to mesenchymal transition (EMT) may be involved. By dedifferentiation and subsequent 
differentiation, EMT might contribute significantly to renal repair, but it may also contribute 
to the formation of fibrotic tissue, which eventually leads to renal function loss (3). The 
selective blockade of EMT resulted in a decreased formation of fibrotic lesions after injury 
(4). This means that inhibition of EMT could be beneficial to the regeneration process. 
Thirdly, BMSCs are probably involved in renal repair. Although results are still controversial, 
the contribution of these cells seems to be limited compared to the other regeneration 
mechanisms. 
To test our hypothesis that P-gp and BCRP are determinants in renal repair following 
ischemia reperfusion, we used knockout mice. We expected that mdr1a/1b(-/-) and bcrp(-/-) 
mice are more susceptible, however, we found the opposite. Both mice turned out to be 
resistant to ischemic injury. Therefore, further characterization of their renal phenotypes was 
performed.  
 
Phenotypic characterization of P-gp-deficient mice 
 
After investigating some basal characteristics, we found that P-gp-deficient mice suffer from 
proximal tubular dysfunction resembling the human renal Fanconi syndrome. This was 
probably caused by a disturbed energy metabolism, as the ATP levels measured in the P-gp-
deficient mouse kidney cortex homogenates were significantly lower compared to wild type 
animals and abnormal mitochondrial morphology was found. P-gp may be expressed in the 
outer mitochondrial membrane, where it could have an efflux function (5). We speculate that 
absence of P-gp could result in a disrupted mitochondrial integrity eventually leading to 
diminished ATP synthesis. However, in another study, P-gp was localized to the inner 
membrane, suggesting a role for the pump in influx of substances into the mitochondrial 
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matrix (6). In a third report, P-gp was not detected in mitochondria (7). In line with the first 
two publications, an explanation for the renal phenotype of P-gp-deficient mice may be an 
overload of harmful P-gp-substrates within the proximal tubular cells, eventually resulting in 
oxidative stress, decreased intracellular ATP levels and mitochondrial abnormalities.  
Although the generalized proximal tubular dysfunction was obvious in P-gp-deficient mice, 
P-gp polymorphisms or reduced expression have never been linked to patients with renal 
Fanconi syndrome nor has proximal tubular dysfunction been described as a side effect in 
patients using P-gp inhibitors. This may be explained by the fact that in patients using P-gp 
inhibitors P-gp is only inhibited for a restricted period of time, whereas in knockout mice P-
gp is absent throughout development. In an attempt to investigate the possible connection 
between P-gp and so-called ‘unknown’ Fanconi syndrome, i.e. patients in whom the 
mechanism causing the syndrome is unresolved, we performed a PCR analysis on P-gp gene 
sequences of 6 patients. Although several silent mutations were discovered, no changes in 
amino acids associated with altered P-gp function were observed (8). However, this does not 
necessarily mean that a modified P-gp function cannot be associated with Fanconi syndrome. 
In addition, we investigated the P-gp expression in renal cells from two cystinosis patients, 
the most common cause of renal Fanconi syndrome, and we observed a decreased expression 
in P-gp as compared to controls. Although expression may have been reduced secondary to 
the metabolic changes in these cells, it may also indicate that P-gp expression is directly 
involved in the development of renal Fanconi syndrome in these patients. Further research is 
required to elucidate this matter. 
 
The generalized proximal tubular dysfunction observed in P-gp-deficient mice is 
characterized by a highly increased urinary excretion of sodium, amino acids and glucose, 
accompanied by a state of volume depletion. It may be possible that volume depletion causes 
ischemic preconditioning, a situation defined as a rapid, adaptive response to a brief ischemic 
insult, which slows the rate of cell death during a subsequent, prolonged period of ischemia. 
In P-gp-deficient mice this phenomenon might be induced by the decreased blood supply to 
the kidney. Another explanation may be that P-gp-deficient cells are resistant to AKI-induced 
apoptosis. In reaction to AKI, cells may become apoptotic, which may lead to renal fibrosis 
and affect renal function repair. We observed a diminished susceptibility of P-gp-deficient 
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bone marrow to an apoptotic H2O2 stimulus. Whether P-gp-deficient mice show less fibrotic 
tissue after AKI as compared to wild type animals needs to be determined. The formation of 
fibrosis, which also might be caused by EMT, is normally irreversible and the fact that renal 
function returns to normal levels in WT mice after 14 days suggests that the induced injury is 
reversible. The absence of P-gp might reduce the formation of fibrosis either by decreasing 
the rate of apoptosis or by diminishing the contribution of EMT. This means that other 
mechanisms, like an increased contribution of BMSCs might be involved.  
 
Phenotypic characterization of BCRP-deficient mice 
 
Comparable to the male P-gp-deficient mice, male BCRP-deficient animals exhibited an 
increased diuresis accompanied by a loss of salts and proteins. Although our first impression 
was that both knockout mice suffered from a renal disorder, further comparison revealed 
some striking differences (summarized in table 1). First, the filtration rate is much higher in 
BCRP-deficient mice compared to P-gp-deficient mice (700 ± 100 versus 280 ± 30 µl/min, 
P<0.01). Hyperfiltration is probably the cause of the increased renal weight observed in the 
BCRP knockout animals. Although an increased urinary excretion of plasma proteins was 
observed, lithium clearance was not affected in BCRP-deficient mice, which excludes a 
proximal tubular dysfunction.  
The most striking differences, however, were the hormonal abnormalities and the metabolic 
syndrome in the male BCRP knockout mice. This may be caused by a disorder in peripheral 
estradiol transport, regulated by BCRP. In males, negative feedback on the luteinizing 
hormone (LH) production by the pituitary is predominantly regulated by peripheral estrogen 
levels (9). Estradiol is produced by adipocytes, chondrocytes, but also by testicular cells. 
BCRP is expressed in testis, bone, and adipose stem cells and we showed localization in 
mature adipocytes. We hypothesize that absence of BCRP prevents the peripheral excretion of 
estradiol into the circulation and hampers the negative feedback on LH, resulting in increased 
LH levels and an increase in testosterone production. Abnormal high testosterone levels were 
found in BCRP-deficient male mice, and these continuous high levels cause subsequently 
subfertility and metabolic syndrome. In females, the observed phenotype was relatively mild, 
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compared to male mice. Here, the ovaries predominantly produce estradiol, but we could not 
detect BCRP in ovary tissue (data not shown). This may explain the milder phenotype 
observed in BCRP-deficient female mice. But like the male mice, females show severe 
gonadal abnormalities and hypergonadism. In humans, both in men and women, the majority 
of causes of hypergonadism are still unknown. Whether a lack of, or dysfunction in BCRP, 
can (in part) explain genetically determined hypergonadism leading to sub- or infertility needs 
to be defined. Polymorphisms in BCRP have been associated with clinically relevant changes 
in pharmacokinetics and drug response (10-13). 
 
Table 1. Phenotypic differences between P-gp-deficient (mdr1a/1b(-/-)) mice and BCRP-deficient (bcrp(-/-) ) mice. 
 
 
Renal regeneration by bone marrow-derived stem cells 
 
Over the past years, BMSCs have been the subject of extensive research and several studies 
showed that these cells are not lineage restricted and have the ability to cross boundaries and 
form components of other tissues, like the heart, liver or brain (14-17). Three different stem 
cell populations within the bone marrow have been identified that have the potential to 
contribute to tissue repair processes: the HSC population, MSC population and MAPC 
population. Several studies show the involvement of HSCs in renal regeneration in rodents 
 Mdr1a/1b(-/-) mice Bcrp(-/-) mice 
Basal characteristics Increased diuresis (~200%) Increased diuresis (~300%) 
 Normal kidney weight Increased kidney weight 
 Normal gonadal weight Increased gonadal weight 
 Slightly increased blood pressure Normal blood pressure 
Renal function  Decreased GFR Increased GFR 
 Proximal tubular dysfunction Normal proximal tubular function 
 Increased excretion of low-molecular weight plasma 
proteins Increased excretion of plasma proteins 
Basal serum analysis Normal glucose concentration Increased glucose concentration 
 Normal insulin concentration Increased insulin concentration 
Hormone regulation Normal testosterone levels Increased testosterone levels (1000%) 
 Normal LH levels Increased LH levels 
 Normal fertility Subfertility 
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(18-20), although their contribution is limited ((21), this thesis, chapter 7). Interestingly, we 
found that the contribution of BMSCs in renal repair increased to 20-30% when bone marrow 
was isolated from P-gp- or BCRP-deficient mice. MSCs may also directly participate in renal 
regeneration through differentiation towards proximal tubular cells, but also exhibit a 
supportive function for other BMSCs migrating towards the injured tissue (22,23). Finally, 
MAPC are candidate cells in renal repair. Although to date transplantation studies with 
MAPC in renal repair models have not been performed, a role in renal regeneration is likely 
because of their capacity to differentiate towards renal epithelial cells in vitro.  
 
Not much is known about the capacity of BMSCs in renal repair in humans. Most studies 
were performed with rodents and translation to the human situation is difficult. Not only 
because of species differences, but also because of variations in models applied. For example, 
most studies in rodents used transplantations performed before the induction of ischemia, 
while in human studies, transplantation of cells is carried out after the insult. The contribution 
of bone marrow derived donor cells to repaired tubules was less then 1% (24). HSCs did not 
give rise to new tubules, but were found to be involved in vasculogenesis (25). This was 
consistent with findings observed in an animal model of glomerulonephritis, in which bone 
marrow-derived endothelial and mesangial cells integrate in glomerular structures, and, 
eventually, contribute to microvascular repair (26). In another study, the migration towards a 
donor kidney of human mesenchymal progenitor cells was shown, suggesting that donor bone 
marrow cells might play a role in renal tissue remodeling (27). Hence, the amount of BMSCs 
engrafting the kidney seems to be small, indicating that other mechanisms of repair are more 
important. Our findings with transporter-deficient full bone marrow transplantations point to a 
shift towards a more prominent role for BM-derived cells in remodeling. It is unclear if SP 
cells or other BM cells are responsible for this beneficial effect. Migration into the kidney of 
bone marrow cells lacking P-gp or BCRP was faster, but also recovery of renal function was 
better compared to WT mice. Probably, this phenomenon is connected to the resistance 
against renal ischemia observed in both knockout mice. An increased resistance to apoptosis 
in deficient bone marrow cells may have also contributed to the beneficial effect.  
It seems likely that the increased population of macrophages and granulocytes in the 
donor bone marrow of the knockout mice is partly responsible for the increased regenerative 
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process seen in our transplantation study. As a proof of principle, BCRP-deficient mice were 
transplanted with WT bone marrow. These mice showed a decreased renal function after AKI 
compared to BCRP-deficient mice without BM transplantation, although renal function was 
still better as compared to WT bone marrow transplantations in WT mice. This suggests that 
the contribution of bone marrow-derived cells in renal regeneration is high enough to 
influence renal function after AKI.  
The increased percentage of macrophages and granulocytes within the bone marrow of 
P-gp- and BCRP-deficient mice might facilitate angiogenesis in the injured kidney, thus 
supporting renal repair. However, macrophages are also able to influence renal regeneration 
directly (28,29), although controversial findings were reported. A negative contribution of 
macrophages to renal regeneration (30), as well as a positive influence of macrophage 
infiltration in renal regeneration has been reported (28,29). Whether the increased population 
of macrophages in the bone marrow of BCRP- and P-gp-deficient mice is responsible for the 
increased regeneration in our studies remains to be determined. Macrophage phenotype might 
be switched or altered towards a phenotype more involved in tissue regeneration. Mice 
deficient in P-gp and Multidrug Resistance Protein 1 (MRP1; mrp1/mdr1a/1b-double 
knockout mice) expression showed a decreased inflammatory response towards cigarette 
smoking (31). This was likely caused by decreased systemic levels of cytokines and 
chemokines, but also by the altered dendritic cell migration. Subsequently, this might lead to 
a decreased inflammatory reaction observed in these animals which could inhibit tissue repair. 
However, the decreased inflammatory reaction may also have a positive effect in a way that 
repair mechanisms are enhanced. The composition of cytokines released by these cells could 
be altered, resulting in a shift between vasculogenesis and inflammation. In line with the 
results of our study, an increased number of macrophages would indirectly stimulate 
regeneration by tissue remodeling and vasculogenesis. We observed that the amount of early 
endothelial progenitor cells in the bone marrow of both knockout mice was increased. The 
altered balance between inflammation and angiogenesis, controlled by cytokines and 
chemokines, may result in an increased vascularisation in which also endothelial progenitor 
cells are involved. Eventually, it is possible that these mechanisms lead to the stimulation of 
renal regeneration, as we observed in both knockout mice, and even more pronounced in our 
transplantation experiments.  
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Future perspectives and therapeutic potential 
 
The estimated contribution of bone marrow-derived cells to renal regeneration increased from 
10% to 30% in absence of P-gp or BCRP. Renal function tests confirmed tissue repair. The 
contribution of these cells is probably too small to reverse renal injury and to repair renal 
damage and the use of the bone marrow-derived cells in the clinic will be questionable. For 
future clinical applications the focus should be directed towards the in vitro culturing of renal 
cells and the optimization of transplantation studies creating conditions where the 
participation of BMSCs in renal regeneration is enhanced.  
Until recently, it was considered that only embryonic stem cells are able to differentiate in 
multiple cell types. The use of totipotent embryonic stem cells (ESC) is still a major ethical 
and political issue and the discovery of new successful methods creating pluripotent cells 
(Yamanaka, Science 2006, Yamanaka, Cell 2007, Thomson, Science 2007) shows that 
research focus is directed towards the modification of adults cells without involving embryos 
or oocytes. The use of BMSCs also holds great promise. BMSCs have many advantages, 
predominantly by stimulation of renal regeneration and, compared to renal transplantation, by 
the absence of immunologic reactions. Therefore, future research should be directed to 
increase the contribution of BMSCs to renal regeneration, possibly by modifying the 
expression of P-gp or BCRP in the bone marrow. Functional knockdown of P-gp or BCRP in 
the bone marrow cells by specific inhibitors or by small interfering RNA (siRNA) may be a 
novel strategy to treat AKI. The systemic inhibition of P-gp or BCRP is probably less 
successful because of the resulting accumulation of potentially toxic xenobiotics due to 
enhanced absorption and reduced elimination. In addition, long-term P-gp inhibition or BCRP 
downregulation might also provoke renal disorders, as observed in P-gp-deficiency, or 
hormonal disturbances, as was seen in the BCRP knockout animals. A selective 
downregulation of the functional expression of P-gp and BCRP in bone marrow may 
overcome these side effects. Obviously, methods should be developed in vitro and in animal 
models in vivo to test this concept in AKI.  
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The kidney has a remarkable capacity to regenerate and recover after injury. In recent years, 
more insight in the mechanisms of renal repair has been obtained. Specialized tubular cells 
are able to repair the kidney by proliferation, but they may also dedifferentiate in a more 
mesenchymal cell type. In addition to these two repair mechanisms, a lot of attention has been 
focused on the role of bone marrow-derived stem cells. P-glycoprotein (P-gp/ABCB1)/ 
multidrug resistance gene 1 (MDR1) and the Breast Cancer Resistance Protein 1 
(BCRP/ABCG2), two ATP-dependent efflux pumps with a detoxifying function, are 
abundantly expressed on a stem cell population in bone marrow, the side population (SP), 
where they may determine the differentiation status of these cells. A high functional 
expression of P-gp and BCRP keeps the SP cells in a primitive state; downregulation triggers 
their differentiation. 
 
The aim of this thesis was to investigate the role of ABC proteins in renal regeneration and 
repair after acute kidney injury (AKI). For this purpose, we first investigated the renal 
expression levels of several ABC transporters during the regeneration process, after which we 
specifically focused on P-gp and BCRP. Moreover, we investigated the role of stem cells in 
renal repair using an in vivo mouse model, and investigated the role of the ABC transporters 
P-gp and BCRP as regulators in this process. Furthermore, we tested the ability of stem cell 
differentiation towards a renal phenotype in vitro. 
 
In chapter 1, the role of ABC transporters in organ repair and regeneration is reviewed. A 
tight control of their expression levels during and after injury may protect the organs from 
further damage, but may also stimulate the regeneration process. Furthermore, this chapter 
speculates on the potential role of P-gp and BCRP in renal repair after AKI, especially by 
bone marrow-derived cells. 
 
Chapter 2 gives an overview of the methods used to study the contribution of bone marrow-
derived cells to renal regeneration. To investigate the role of these cells, a method was 
developed which consisted of a combination of protocols published in the literature during the 
last four years. The isolation and culture of the donor bone marrow cells, the transplantation 
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of these cells in recipient mice, but also the induction of AKI are described in detail. 
Moreover, the different quantification methods to determine the contribution of donor bone 
marrow cells within the recipient mice and renal function assessments are evaluated. Chapter 
2 also discusses critically the advantages and shortcomings of our method and compared it 
with other methods described. 
 
To study the role of ABC transporters in kidney regeneration, the RNA expression levels of 
45 ABC transporters were investigated using quantitative RT-PCR analysis under basal 
conditions, after induction of ischemia and after regeneration. In chapter 3 we demonstrate 
that gene expression of ABC transporters is differentially regulated after renal injury; P-
gp/abcb1b, abcb11 and abcc4 expression was increased, and expressions of abca3, abcc2 and 
BCRP/abcg2 were decreased. The expression of all transporters returned to baseline after 14 
days, except for abcb11, which was still reduced. Using Western blot analysis, we showed 
that protein expression of P-gp and BCRP was increased after ischemia induction, suggesting 
that these transporters may have an important function in the renal repair process. Moreover, 
for the first time expression and subcellular localization of the transporters abca3 and 
BSEP/abcb11 in mouse kidney were shown. 
 
To investigate the role of P-gp and BCRP in renal regeneration in more detail, knockout mice 
of each transporter were used. First, renal function of the P-gp- (mdr1a/1b(-/-)) and BCRP 
(bcrp(-/-))-deficient mice were thoroughly characterized. In chapter 4, we describe the renal 
phenotype of mice deficient in P-gp expression. After extensive examination of blood and 
urine samples, it appeared that these mice suffer from proximal tubular dysfunction 
resembling the human renal Fanconi syndrome. Typical features were increased diuresis, 
augmented urinary excretion of sodium, amino acids and low molecular weight proteins, and 
increased lithium clearance. Furthermore, reduced inulin and PAH clearances indicated that 
P-gp-deficient mice have diminished glomerular filtration rate and renal plasma flow, 
respectively. Electron microscopy revealed mitochondrial abnormalities in proximal tubular 
cells and decreased renal cortical ATP levels were found, which can explain the observed 
tubular dysfunction. Based on the increased expression of P-gp in the kidney after ischemia 
we expected the P-gp-deficient mice to be more susceptible to acute kidney injury, however, 
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surprisingly, these mice were resistant to ischemia. This may be the result of ischemic 
preconditioning due to the hypovolemic condition of the mice. On the other hand, we also 
found that bone marrow from P-gp-deficient mice show less sensitivity to apoptosis, which 
suggests that the smaller degree of renal damage may be caused by a decreased number of 
apoptotic cells causing tubular obstruction. This, evidently, needs to be investigated further. 
Secondly, BCRP-deficient animals were characterized as well. BCRP transports, like P-gp, a 
wide variety of chemotherapeutic drugs, but it is also involved in the transport of endogenous 
steroid hormones, like dehydroepiandrosterone sulfate (DHEAS) and estradiol. The capacity 
of BCRP to transport estradiol apparently determines the phenotype of the BCRP-deficient 
mice, which is described in chapter 5. The absence of BCRP leads to a disturbed regulation 
of sex hormones; of which elevated levels of serum testosterone (10 fold) and luteinizing 
hormone (LH, 3 fold) seem to be crucial features. The disturbed hormone balance eventually 
results in a metabolic syndrome-like phenotype, characterized by glucose and insulin 
intolerance, but also in morphologic abnormalities of the reproductive organs, leading to 
subfertility. After estradiol administration, serum testosterone, LH and glucose normalized to 
levels of wild type mice. Adipose tissue is one of the most important sources of peripheral 
estradiol, which is essential for the negative feedback on the pituitary gland. We found BCRP 
expression in the adipocyte membrane, suggesting that the transporter may be responsible for 
controlling peripheral estradiol levels. An absence of BCRP may lead to a disturbed negative 
feedback on the pituitary gland. These findings imply a new, key role for BCRP in steroid 
metabolism and glucose homeostasis. 
 
Although expression of BCRP is described in several excretory organs and its mRNA levels 
were detectable in human kidney tissue, its protein expression and localization in the kidney 
was still undefined. In chapter 6, we show for the first time expression, localization and 
transport activity of BCRP in human kidney. In isolated human proximal tubular cells, 
Hoechst 33342 transport could be inhibited by fumitremorgin C nd nelfinavir indicating 
BCRP activity. Finally, immunohistochemistry confirmed the localization of BCRP to the 
proximal tubular apical membrane, the same nephron segment where the ABC transporters, P-
gp, Mrp4 and Mrp2, are localized. Furthermore, a clearly higher expression of BCRP was 
found in rat and mouse kidney as compared to the levels determined in human kidney tissue. 
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Nevertheless, the expression of the efflux pump is highly inducible during stress conditions 
and the transporter may certainly play a role in renal drug excretion. 
 
In chapter 7 we explored the role of P-gp and BCRP in renal regeneration by bone marrow–
derived stem cells. Enhanced green fluorescent protein (eGFP)-labeled bone marrow cells 
isolated from wild type mice, P-gp-deficient mice and BCRP-deficient mice were transplanted 
into wild type recipient mice. The findings indicate that absence of P-gp or BCRP in the 
donor bone marrow stimulates renal regeneration in the recipient mice after ischemic 
reperfusion injury. As a proof of principle that bone marrow cells are important and that the 
transporters play a crucial role in renal repair, bone marrow from wild type animals was 
transplanted in BCRP-deficient mice. Without transplantation, these knockout mice are 
protected against AKI, but interestingly, after transplantation, renal injury and loss of function 
were observed after ischemic injury. The presence of BCRP and most likely also P-gp, seems 
to hamper renal (tubular) remodeling by bone marrow cells and the ischemic resistance 
observed in both knockout mice must originate from (specific populations of) bone marrow 
cells that promote tissue repair. Analysis of the bone marrow composition revealed that the 
number of macrophages and granulocytes was increased in P-gp- and BCRP-deficient mice. 
Moreover, also the amount of endothelial progenitor cells was increased, which possibly fuels 
the remodeling process. 
 
During the last years, a great deal of attention has been focused on the use of bone marrow-
derived stem cells in tissue regeneration, in which the differentiation capacity of bone marrow 
stem cells into diverse non-hematopoietical cells was shown. Within the bone marrow, a rare 
cell population, called the multipotent adult progenitor cells (MAPCs), is localized, which has 
the capacity to differentiate into mesenchymal lineages but also into endothelium, 
neuroectoderm and endoderm. Their capacity to differentiate towards renal cells was, 
however, still unknown. In chapter 8, we determined this capacity under influence of basic-
Fibroblast Growth Factor, Tumor Growth Factor-α, Leukocyte Inhibitory Factor and 
Hepatocyte Growth Factor. After initiating differentiation during culturing, morphology of the 
MAPCs, as well as gene and protein expression of specific renal (tubular) epithelial markers, 
confirm the differentiation of MAPCs towards renal epithelial cells. These findings were 
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supported further by an increased alkaline phosphatase and P-gp activities, indicative for renal 
proximal tubular cells. The ability of MAPCs to differentiate towards renal cells might be a 
new strategy in the treatment of kidney disease, which needs to be explored further. 
 
Chapter 9 contains a general discussion of the results described in this thesis. The 
regenerative capacity of the kidney is discussed, with a focus on renal (stem) cells. Moreover, 
the phenotypes of the P-gp- and BCRP-deficient mice are described in detail, and the use of 
both mice in (experimental) research models is discussed. Although the function of bone 
marrow-derived stem cells in renal regeneration seems less important compared to resident 
renal tubular cells, their role is increased in absence of P-gp or BCRP expression. The 
possible mechanisms responsible for this phenomenon are discussed, including the clinical 
implications and potential therapeutic applications. 
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De nier heeft een groot vermogen om bijna volledig te herstellen na schade. Het 
nefronsegment dat het meest is aangedaan na acute schade is de proximale tubulus. Proximale 
tubuluscellen kunnen door middel van proliferatie en migratie een belangrijke rol spelen in 
het regeneratieproces, maar ook de dedifferentiatie van deze cellen naar een primitiever, 
mesenchymaal celtype is mogelijk van belang. De laatste jaren is er veel onderzoek gedaan 
naar de rol van stamcellen afkomstig uit het beenmerg in het herstelproces van de nier. In het 
beenmerg zijn verschillende stamcelpopulaties gelokaliseerd, waaronder de side population 
(SP) cellen, die een subpopulatie vormen van de hematopoïetische stamcellen. Op deze SP-
cellen komen de ATP-binding-cassette (ABC) transporteiwitten P-glycoproteïne (P-
gp/ABCB1), ofwel het eiwitproduct van het multidrug-resistentie gen 1 (MDR1), en 
borstkankerresistentie-eiwit (Breast Cancer Resistance Protein; BCRP) hoog tot expressie. 
Deze twee efflux-pompen komen voornamelijk voor in organen met een belangrijke 
barrièrefunctie voor lichaamsvreemde stoffen, zoals de lever, darmen, de hersencapillairen en 
de nieren. In deze organen hebben beide transporters een belangrijke ontgiftende functie door 
de uitscheiding te bewerkstelligen van potentiëel schadelijke stoffen. Op SP-cellen hebben 
deze transporters naast hun excretiefunctie waarschijnlijk ook een belangrijke rol in het 
differentiatieproces van deze cellen. Een hoge expressie van P-gp en BCRP houdt de SP-
cellen in een primitieve, niet-gedifferentiëerde staat, terwijl een lage expressie van deze 
transporters hun differentiatie stimuleert. 
 
In dit proefschrift is de rol van ABC-transporters in het proces van nierregeneratie 
onderzocht. Hiervoor hebben wij eerst de globale rol van diverse ABC-transporters in het 
herstelproces van de nier bestudeerd, waarna wij ons specifiek gericht hebben op P-gp en 
BCRP. Vervolgens hebben wij gekeken naar de rol die stamcellen, afkomstig uit het 
beenmerg, vervullen in het herstel van de nier, waarbij de rol van P-gp- en BCRP-expressie 
centraal stond. Dit is onderzocht met behulp van een in vivo-muizenmodel, waarbij P-gp- en 
BCRP-deficiënte muizen werden gebruikt. Daarnaast hebben wij ook een in vitro-model 
gebruikt, waarin geïsoleerde stamcellen vanuit het beenmerg werden gestimuleerd om te 
differentiëren naar nierepitheelcellen. 
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In hoofdstuk 1 beschrijven wij als introductie de rol van ABC-transporters in weefselschade 
en -herstel. Verschillende studies laten zien dat de expressie van bepaalde ABC-transporters 
sterk verandert na weefselschade. Deze regulatie is waarschijnlijk noodzakelijk om de 
beschadigde organen te beschermen tegen additionele schadelijke effecten, maar ook om het 
herstelproces te stimuleren. Bovendien is bekend dat de expressie van ABC-transporters in 
bepaalde ziekteprocessen verhoogd kan zijn, waarschijnlijk om te compenseren voor de 
toename in potentiëel schadelijke cellulaire afvalstoffen die gevormd worden tijdens de 
schadeprikkel. Naast de rol van ABC-transporters in weefselherstel wordt ook gespeculeerd 
over de rol van P-gp en BCRP in nierregeneratie, waarbij de rol van deze stamcellen centraal 
staat. 
 
In hoofdstuk 2 wordt een onderzoeksmethode beschreven waarmee de rol kan worden 
bestudeerd van stamcellen in regeneratie van nierweefsel na acuut nierfalen. Deze methode is 
samengesteld nadat diverse protocollen die de laatste jaren zijn gepubliceerd waren 
bestudeerd. Het transplantatieproces wordt gedetailleerd beschreven waarin de isolatie en het 
kweken van stamcellen, de transplantatie van deze cellen in de ontvangermuis en het 
induceren van acuut nierfalen uitvoerig aan bod komen. Daarnaast worden verschillende 
methoden beschreven die gebruikt worden om het resultaat van de beenmergtransplantatie te 
kunnen beoordelen, zoals het kwantificeren van de hoeveelheid donorbeenmergcellen in de 
ontvangernier, maar ook door het bepalen van de nierfunctie in de ontvangermuis. In dit 
hoofdstuk worden tenslotte de voor- en nadelen van onze methode besproken en vergeleken 
met de verschillende methoden die gebruikt worden op dit gebied. 
 
In hoofdstuk 3 wordt de rol van ABC-transporters in het regeneratieproces van de nier 
beschreven. Hiervoor onderzochten we in de gezonde nier de genexpressies van 45 en de 
eiwitexpressie van 6 ABC-transporters, na het induceren van nierschade en in het 
daaropvolgende herstelproces. In dit hoofdstuk laten wij zien dat de expressie van de ABC-
transporters differentiëel gereguleerd is gedurende de regeneratiefase van de nier. Op 
genniveau nam de expressie van P-gp/abcb1b, abcb11 en abcc4 toe, terwijl de expressie van 
abca3, abcc2 en BCRP/abcg2 afnam. Er was een toename in de eiwitexpressie van zowel P-
gp als BCRP, wat impliceert dat beide transporters waarschijnlijk een belangrijke rol spelen in 
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het herstelproces. Daarnaast hebben wij als eersten laten zien dat abca3 en BSEP/abcb11 in de 
nier van de muis tot expressie komen en hebben we hun subcellulaire lokalisatie vastgesteld. 
 
De rol van P-gp en BCRP in nierregeneratie werd verder onderzocht door gebruik te maken 
van P-gp-deficiënte (mdr1a/1b(-/-)) en BCRP-deficiënte (bcrp1(-/-)) muizen. Allereerst hebben 
wij de nierfunctie van deze muizen in detail onderzocht, en in hoofdstuk 4 beschrijven wij de 
resultaten van de P-gp-deficiënte muis. Na uitvoerig bloed- en urineonderzoek werd duidelijk 
dat deze muizen een gestoorde proximale tubulusfunctie hebben, die sterk overeenkomt met 
het renale Fanconi-syndroom in de mens. De muizen lieten een verhoogde diurese zien en 
verlies van kleine eiwitten, aminozuren en natrium in de urine. Daarnaast was de klaring van 
inuline en PAH verminderd, wat aangaf dat de glomerulaire filtratiesnelheid en 
nierdoorbloeding aanzienlijk slechter was dan normaal. In de proximale tubuluscellen werd 
bovendien een verlaagde ATP-concentratie gemeten, die waarschijnlijk het gevolg is van een 
afwijkende mitochondriële functie. Met electronenmicroscopie werd inderdaad een 
pathologische morfologie van de mitochondriën gevonden. Deze afwijkingen kunnen direct 
verantwoordelijk zijn voor het dysfunctioneren van de proximale tubulus. Door de toename in 
expressie van P-gp na ischemie verwachtten we dat de P-gp-deficiënte muis veel gevoeliger 
zou zijn voor acute nierschade, echter verrassend genoeg bleken deze muizen resistent te zijn. 
Dit zou veroorzaakt kunnen worden door preconditionering als gevolg van een permanente 
ondervullingstoestand waarin de muizen verkeren vanwege, onder meer, de hoge diurese, 
maar ook door een verlaagde gevoeligheid voor apoptose die we vonden in beenmergcellen 
van deze muizen. Deze laatste bevinding suggereert dat de verminderde schade die in de P-
gp-deficiënte muizen wordt waargenomen mogelijk wordt veroorzaakt door een verlaagd 
aantal apoptotische cellen die doorgaans tubulusobstructie, en daarmee gepaard gaande 
nierfunctieverlies, tot gevolg hebben. 
 
In hoofdstuk 5 wordt de fenotypering van de BCRP-deficiënte muizen beschreven. BCRP en 
P-gp hebben een grote overlap in substraatspecificiteit, maar BCRP is ook in staat bepaalde 
steroïdhormonen te transporteren, waaronder dehydroepiandrosteronsulfaat (DHEAS) en 
oestradiol. De rol van BCRP in het transport van oestradiol is mogelijk de reden voor het 
afwijkende fenotype van de BCRP-deficiënte muizen. Een uitgebreide analyse van bloed en 
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urine wees uit dat BCRP-deficiënte muizen een verstoorde geslachtshormoonhuishouding 
hebben, die gepaard gaat met sterk verhoogde concentraties van zowel testosteron (10x) als 
luteïniserendhormoon (LH, 3x) en wat uiteindelijk leidt tot een glucose- en insulinetolerantie. 
Naast dit, voor het metabool syndroom kenmerkende beeld, werden ook ernstige afwijkingen 
in de geslachtsorganen en een verminderde fertiliteit gevonden. De afwijkingen die in de 
BCRP-deficiënte muis werden gezien wijzen op een verstoorde beschikbaarheid in oestradiol. 
Nadat oestradiol werd toegediend, daalden de testosteron-, LH- en glucoseconcentraties in het 
bloed in de BCRP-deficiënte muizen tot waarden die vergelijkbaar waren met de controle 
muizen. Perifeer oestradiol is essentiëel voor een negatieve terugkoppeling op de hypofyse en 
vetweefsel is een belangrijke bron voor dit perifere oestradiol. De expressie en lokalisatie van 
BCRP in dit vetweefsel, suggereert dat BCRP van groot belang is voor de handhaving van 
fysiologische oestradiolspiegels. Uit onze studie blijkt dat BCRP een belangrijke functie heeft 
in de regulatie van steroïdspiegels in het bloed en uiteindelijk in de glucosehuishouding. Een 
verminderde BCRP-functie kan wellicht een nieuw mechanisme zijn bij patiënten die lijden 
aan oestrogeendeficiëntie.  
 
BCRP is in vergelijking met P-gp een relatief ‘nieuwe’ transporter, waar minder over bekend 
is. Deze transporter is, net als P-gp, gelokaliseerd in diverse organen met een excretiefunctie. 
In muizen komt BCRP ook hoog tot expressie in de nier, maar in de mens werd tot nu toe 
alleen expressie op mRNA-niveau beschreven. In hoofdstuk 6 wordt de expressie, lokalisatie 
en transportactiviteit van BCRP in de menselijke nier beschreven. Door middel van 
transportstudies, waarbij gebruik gemaakt is van de selectieve remmers, fumitremorgin C en 
nelfinavir, werd de activiteit van BCRP in humane proximale tubuluscellen bewezen. Met 
immunohistochemie werd voor het eerst aangetoond dat BCRP in de menselijke nier, net als 
in de muis en rat, gelokaliseerd is in de apicale membraan van de proximale tubuluscellen. 
BCRP komt hier echter veel lager tot expressie dan in de nieren van de knaagdieren, maar bij 
cellulaire stress neemt de expressie toe, wat impliceert dat BCRP belangrijk kan zijn bij 
weefschelschade en –herstel. Desondanks kan BCRP ook een belangrijke rol spelen in gezond 
nierweefsel bij de uitscheiding van lichaamsvreemde stoffen, zoals farmaca, in de urine. 
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In hoofdstuk 7 beschrijven wij het gevolg van de aan- en afwezigheid van P-gp en BCRP 
expressie op beenmergstamcellen voor het herstelproces van de beschadigde nier. Om dit te 
onderzoeken werden groen-fluorescerend eiwit-gelabelde beenmergcellen geïsoleerd uit wild 
type, P-gp- en BCRP-deficiënte muizen en vervolgens getransplanteerd in wild type 
(ontvanger)-muizen. Uit deze experimenten is gebleken dat de wild type-muizen 
getransplanteerd met beenmerg afkomstig van P-gp- of BCRP-deficiënte muizen geen verlies 
van nierfunctie laten zien na schade, in tegenstelling tot de transplantaties met het beenmerg 
afkomstig van wild type-muizen. Dit geeft aan dat regeneratie van de nier wordt bevorderd bij 
afwezigheid van één van deze twee transporters. Om dit concept op een andere wijze te 
bewijzen transplanteerden wij beenmerg afkomstig van wild type-muizen in BCRP-deficiënte 
muizen. Normaliter laten deze muizen geen functieverlies van de nier zien na het induceren 
van schade, maar na transplantatie met wild type-beenmerg werd wel degelijk een 
functieverlies geconstateerd en schade in de nieren van de BCRP-deficiënte muizen 
waargenomen. Deze resultaten laten zien dat de (hoge) expressie van P-gp en BCRP in het 
beenmerg kennelijk nadelig is voor het herstelproces van de nier, wat mogelijk veroorzaakt 
wordt door een veranderde samenstelling van de celpopulaties binnen het beenmerg. Een 
toename van het aantal cellen betrokken bij weefselherstel in P-gp-deficiënte en BCRP-
deficiënte muizen kan op deze manier de regeneratie van de nier stimuleren. Na analyse van 
het beenmerg van P-gp- en BCRP-deficiënte muizen werden verhoogde aantallen macrofagen 
en granulocyten aangetoond. Daarnaast lieten wij zien dat de P-gp- en BCRP-deficiënte 
muizen ook beschikken over een groter aantal endotheliale voorlopercellen. Deze gegevens 
duiden erop dat een toename in de angiogenese mogelijk het herstel van de beschadigde nier 
stimuleert, maar het exacte mechanisme moet nog nader worden onderzocht.  
 
In het beenmerg zijn verschillende stamcelpopulaties aanwezig die mogelijk weefselherstel 
stimuleren. Naast hematopoïetische- en mesenchymalestamcellen is er nog niet zo lang 
geleden een nieuwe populatie ontdekt: de multipotent adult progenitor cell (MAPC)-
populatie. Deze cellen zijn in staat te differentiëren naar zowel endotheliale, ectodermale als 
endodermale cellen, maar hun mogelijkheid om te differentiëren naar niercellen was tot nu toe 
nog niet beschreven. In hoofdstuk 8 laten we zien dat onder invloed van basic-Fibroblast 
Growth Factor, Tumor Growth Factor- α, Leukocyte Inhibitory Factor en Hepatocyte Growth 
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Factor deze MAPCs in staat zijn te differentiëren naar nierepitheelcellen. Gedurende dit 
proces veranderde de morfologie van de cellen, maar ook de aanwezigheid van specifieke 
gen- en eiwitmarkers bevestigden een differentiatie in de richting van een nierepitheel-
celtype. Daarnaast zijn functionele studies uitgevoerd, waarbij de activiteit van alkalisch-
fosfatase (een proximale tubulusmarker) en P-gp werd gemeten. De toename in de alkalisch-
fosfatase- en de P-gp-activiteiten bevestigden een differentiatie in een nierepitheel-celtype. 
Hierdoor zijn MAPCs mogelijk een belangrijke bron van cellen voor het behandelen van 
nierziekten. 
 
In hoofdstuk 9 worden de resultaten van dit proefschrift bediscussieerd. Hierin wordt onder 
andere het herstelvermogen van de nier door voornamelijk endogene (stam)cellen besproken. 
Daarnaast worden de fenotypes van de P-gp- en BCRP-deficiënte muizen beschreven en 
vergeleken, en hun mogelijke (toekomstige) rol als onderzoeksmodel voor ziekteprocessen 
wordt besproken. De functie van stamcellen afkomstig uit het beenmerg lijkt beperkt in het 
herstelproces van de nier na acute schade, maar in afwezigheid van P-gp en BCRP op deze 
cellen neemt hun rol sterk toe. De mogelijke mechanismen die hieraan ten grondslag liggen 
worden besproken, evenals het belang van deze resultaten voor de toekomstige behandeling 
van patiënten met acuut nierfalen. 
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Die Niere zeichnet sich durch ein bemerkenswert großes Vermögen aus, sich beinahe 
vollständig nach einem Schaden zu regenerieren. Das Nephronsegment, das am stärksten von 
einer akuten Schädigung betroffen ist, ist der proximale Tubulus. Proximale Tubuluszellen 
können mittels Proliferation und Migration eine belangreiche Rolle spielen im 
Regenerationsprozess, aber auch die Dedifferenzierung dieser Zellen zu einem primitiven, 
mesenchymalen Zelltypus ist möglicherweise von Bedeutung. In den letzten Jahren wurde die 
Rolle von Stammzellen aus dem Knochenmark beim Wiederherstellungsprozess der Niere 
intensiv beforscht. Im Knochenmark sind verschiedene Stammzellpopulationen lokalisiert, 
darunter die Side Population (SP) Zellen, die eine Subpopulation der hämatopoetischen 
Stammzellen darstellen. Auf diesen SP-Zellen kommen die ATP-binding-cassette (ABC) 
Transporteiweisse P-glycoprotein (P-gp/ABCB1), auch multidrug-resistance gen 1 (MDR1) 
genannt, und das für Brustkrebsresistenz mitverantwortliche Eiweiß (Breast Cancer 
Resistance Protein; BCRP) stark zur Expression. Diese zwei Efflux-Pumpen kommen 
hauptsächlich in Organen vor, die eine wichtige Barrierefunktion für körperfremde Stoffe 
besitzen, wie Leber, Darm, Hirnkapillaren und Niere. In diesen Organen nehmen beide 
Transporter eine sehr wichtige Entgiftungsfunktion wahr, indem sie für die Ausscheidung von 
potentiell schädlichen Stoffen sorgen. Auf SP-Zellen besitzen diese Transporter neben der 
Exkretionsaufgabe wahrscheinlich auch eine wichtige Funktion im Rahmen des 
Differenzierungsprozesses dieser Zellen. Eine hohe Expression von P-gp und BCRP hält die 
SP-Zellen in einem primitiven, nicht differenzierten Stadium zurück, wohingegen eine 
niedrige Expression dieser Transporter ihre Differenzierung stimuliert. 
 
Diese Doktorarbeit untersucht die Rolle von ABC-Transportern beim Prozess der 
Nierenregeneration. Hierfür haben wir zuerst die globale Rolle diverser ABC-Transporter im 
Wiederherstellungsprozess der Niere näher betrachtet, danach lag der Fokus spezifisch auf P-
gp und BCRP. Ferner haben wir die Rolle von Stammzellen, die aus dem Knochenmark 
abstammen, bei der Wiederherstellung der Niere untersucht, wobei der Einfluss der P-gp- und 
BCRP-Expression im Mittelpunkt stand. Die Untersuchung wurde mit Hilfe eines in vivo-
Mäusemodells durchgeführt, wobei P-gp- und BCRP-defiziente Mäuse verwendet wurden. 
Zusätzlich verwendeten wir auch ein in vitro-Modell, bei dem aus dem Knochenmark isolierte 
Stammzellen stimuliert wurden, zu Nierenepithelzellen zu differenzieren. 
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In Kapitel 1 wird einleitend die Rolle der ABC-Transporter bei der Reparatur und 
Regeneration von Geweben zusammengefasst. Verschiedene Studien zeigen, dass sich die 
Expression von bestimmten ABC-Transportern stark verändert nach einer 
Gewebeschädigung. Diese Regulation ist wahrscheinlich notwendig, um das beschädigte 
Gewebe vor zusätzlichen schädigenden Einflüssen zu schützen, ferner aber auch, um den 
Regenerationsprozess zu stimulieren. Zusätzlich ist bekannt, dass die Expression von ABC-
Transportern bei bestimmten Krankheitsprozessen erhöht sein kann, wahrscheinlich um der 
Zunahme von potentiell schädlichen zellulären Abfallstoffen, die während der Krankheit 
gebildet werden, entgegenzuwirken. Neben der Rolle von ABC-Transportern bei der 
Wiederherstellung von Geweben wird auch über die Rolle von P-gp und BCRP bei der 
Nierenregeneration spekuliert, wobei die Rolle von Stammzellen aus dem Knochenmark im 
Mittelpunkt steht. 
 
In Kapitel 2 wird eine Untersuchungsmethode beschrieben, mit derer die Rolle von 
Stammzellen bei Regeneration von Nierengewebe nach akutem Nierenversagen näher studiert 
werden kann. Diese Methode basiert auf diversen Protokollen, die in den letzten Jahren 
publiziert wurden. Der Transplantationsprozess wird detailliert beschrieben inklusive der 
Isolation und Kultivierung der Stammzellen, der Transplantation dieser Zellen in die 
Empfängermaus und der künstlichen Induktion von akutem Nierenversagen. Außerdem 
werden verschiedene Methoden beschrieben, die eingesetzt wurden, um das Ergebnis der 
Knochenmarktransplantation beurteilen zu können, wie die Quantifizierung der Anzahl 
Donorknochenmarkzellen im Empfängertier, aber auch die Bestimmung der Nierenfunktion 
in der Empfängermaus. In diesem Abschnitt werden fernerhin die Vor- und Nachteile von 
unserer Methode besprochen und mit verschiedenen auf diesem Gebiet eingesetzten 
Methoden verglichen. 
 
In Kapitel 3 wird die Rolle von ABC-Transportern bei der Nierenregeneration beschrieben. 
Hierfür untersuchten wir die Genexpression von 45 und die Eiweißexpression von 6 ABC-
Transportern sowohl in der gesunden Niere als auch nach der Induktion eines Nierenschadens 
und in der darauffolgenden Wiederherstellungsphase. In diesem Kapitel zeigen wir auf, dass 
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die Expression der ABC-Transporter während der Regenerationsphase der Niere differentiell 
geregelt ist. Auf Genniveau nahm die Expression von P-gp/abcb1b, abcb11 und abcc4 zu, 
wohingegen die Expression von abca3, abcc2 und BCRP/abcg2 abnahm. Es war eine 
Zunahme in der Eiweißexpression von sowohl P-gp als auch BCRP zu verzeichnen, was 
darauf hindeutet, dass beide Transporter wahrscheinlich eine wichtige Rolle im 
Wiederherstellungsprozess spielen. Zusätzlich konnten wir erstmals zeigen, dass abca3 und 
BSEP/abcb11 in der Mäuseniere zur Expression kommen. Ferner waren wir die ersten, die 
deren subzelluläre Vorkommen entdeckten. 
 
Die Rolle von P-gp und BCRP bei der Nierenregeneration wird weiterhin mit Hilfe P-gp-
defizienter (mdr1a/1b(-/-)) und BCRP-defizienter (bcrp1(-/-)) Mäuse untersucht. Als erstes 
haben wir die Nierenfunktion dieser Mäuse im Detail analysiert. Die Ergebnisse der 
Untersuchung sind in Kapitel 4 wiedergegeben. Nach ausführlichen Blut- und 
Urinuntersuchungen wird deutlich, dass diese Mäuse eine gestörte proximale Tubulusfunktion 
haben, die eine starke Übereinstimmung mit dem renalen Fanconi Syndrom des Menschen 
aufweist. Die Mäuse zeigten eine erhöhte Diurese, einen erhöhte urinale Exkretion von 
kleinen Eiweißen, Aminosäuren und Natrium. Außerdem war die Clearance von Inulin und 
PAH vermindert, dies deutete wiederum darauf hin, dass die glomeruläre Filtrationsrate und 
Nierendurchblutung merklich schlechter als normal waren. In den proximalen Tubuluszellen 
wurde obendrein eine erniedrigte ATP Konzentration gemessen, die wahrscheinlich die Folge 
einer abnormen Mitochondrienfunktion ist. Mit elektronenmikroskopischen Aufnahmen 
konnte man tatsächlich eine pathologische Morphologie der Mitochondrien nachweisen. 
Diese Abweichungen können direkt verantwortlich sein für die Dysfunktion des proximalen 
Tubulus. Durch die Zunahme der Expression von P-gp nach Ischämie erwarteten wir, dass die 
P-gp-defizienten Mäuse viel empfindlicher für einen akuten Nierenschaden sein sollten. 
Überraschenderweise schienen die Mäuse aber eher resistent zu sein. Dies könnte einerseits 
durch Präkonditionierung infolge permanenter Hypovolämie der Mäuse verursacht sein, 
andererseits fanden wir aber auch eine niedrigere Empfindlichkeit der Knochenmarkzellen 
dieser Mäuse gegenüber Apoptose. Die letztgenannte Beobachtung legt nahe, dass der 
verminderte Schaden, der in den P-gp-defizienten Mäusen feststellbar ist, möglicherweise 
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durch eine erniedrigte Anzahl apoptotischer Zellen - die potentiell eine Tubulusobstruktion 
und Nierenfunktionsverlust zur Folge haben können - verursacht wird. 
 
In Kapitel 5 wird die Phänotypisierung der BCRP-defizienten Mäuse beschrieben. BCRP und 
P-gp zeigen eine große Überlappung in der Substratspezifität. BCRP ist aber auch im Stande 
bestimmte Steroidhormone zu transportieren, darunter auch Dehydroepiandrosteronsulfat 
(DHEAS) und Östradiol. Die Rolle von BCRP beim Transport von Östradiol ist 
möglicherweise der Grund für den abweichenden Phänotyp der BCRP-defizienten Mäuse. 
Eine ausführliche Analyse des Bluts und Urins ergab, dass BCRP-defiziente Mäuse einen 
gestörten Geschlechtshormonhaushalt haben, der einhergeht mit stark erhöhten 
Konzentrationen von sowohl Testosteron (10x) als auch Luteiniserendem Hormon (LH, 3x). 
Diese abnormen Konzentrationen führen schließlich und endlich zu einer Glukose- und 
Insulinintoleranz. Zusätzlich zu diesem für das metabolische Syndrom typischen Bild kann 
man auch ernsthafte Abweichungen in den Geschlechtsorganen und eine verminderte 
Fertilität beobachten. Diese Abweichungen bei den BCRP-defizienten Mäusen deuten auf 
einen gestörten Östradiolhaushalt hin. Nachdem Östradiol von außen zugeführt wurde, fielen 
die Testosteron-, LH- und Glukosekonzentrationen im Blut der BCRP-defizienten Mäuse auf 
Werte, die vergleichbar waren mit denen von Kontrollmäusen. Peripheres Östradiol ist 
essentiell für eine negative Rückkopplung auf die Hypophyse. Das Fettgewebe stellt eine 
wichtige Quelle für dieses periphere Östradiol dar. Die Expression und Lokalisation von 
BCRP in diesem Fettgewebe lassen vermuten, dass BCRP von großer Bedeutung für die 
Erhaltung physiologischer Östradiolspiegel ist. Unsere Studie zeigt, dass BCRP eine wichtige 
Funktion in der Regulation des Steroidblutspiegels und im Glukosehaushalt hat. Eine 
verminderte BCRP-Funktion stellt eventuell einen neuen Mechanismus bei 
östrogendefizienten Patienten dar. 
 
BCRP ist verglichen mit P-gp ein relativ “neuer” Transporter, über den noch nicht so viel 
bekannt ist. Dieser Transporter ist, genauso wie P-gp, in verschiedenen Organen mit 
Exkretionsfunktion lokalisiert. In Mäusen wird BCRP auch sehr stark in der Niere expremiert. 
Im Menschen hingegen wird bis heute alleine die Expression auf mRNA-Niveau beschrieben. 
In Kapitel 6 wird neu auch die Expression, Lokalisation und Transportaktivität von BCRP in 
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der menschlichen Niere beschrieben. Mit Hilfe von Transportstudien unter Gebrauch der 
selektiven Hemmer Fumitremorgin C und Nelfinavir konnte die Aktivität von BCRP in 
menschlichen proximalen Tubuluszellen bewiesen werden. Mittels Immunohistochemie wird 
hier zum ersten Mal gezeigt, dass BCRP in der menschlichen Niere, genauso wie in der Maus 
und Ratte, auf der apikalen Membran der proximalen Tubuluszellen lokalisiert ist. BCRP 
kommt hier sehr viel niedriger zur Expression als in der Niere der Nagetiere. Bei zellulärem 
Stress jedoch nimmt die Expression zu, was impliziert, dass BCRP von Belang bei 
Gewebeschaden und –reparatur sein kann. Dessen ungeachtet kann BCRP auch eine wichtige 
Rolle im gesunden Nierengewebe bei der Ausscheidung von körperfremden Stoffen, wie 
Pharmaka, in den Urin spielen. 
 
In Kapitel 7 beschreiben wir die Folgen der An- und Abwesenheit von P-gp und BCRP 
Expression auf Knochenmarkstammzellen auf den Wiederherstellungsprozess der 
beschädigten Niere. Um dies zu untersuchen wurden grünfluoreszierend markierte 
Knochenmarkzellen aus dem Wildtyp-, P-gp-, und BCRP-defizienten Mäusen isoliert und 
danach in Wildtyp- (Empfänger-)mäuse transplantiert. Aus diesen Experimenten heraus zeigte 
sich, dass Wildtypmäuse, die mit Knochenmark aus P-gp- oder BCRP-defizienten Mäusen 
transplantiert wurden, keine Einbuße der Nierenfunktion nach einer Schädigung erlitten, im 
Gegensatz zur Transplantation mit Knochenmarkzellen von Wildtypmäusen. Dies weißt 
darauf hin, dass die Regeneration der Niere durch die Abwesenheit von einem der zwei 
Transporter begünstigt wird. Um dieses Konzept auf eine andere Art und Weise zu beweisen, 
transplantierten wir Knochenmark von Wildtypmäusen in BCRP-defiziente Mäuse. 
Normalerweise lassen diese Mäuse keinen Funktionsverlust der Niere nach Induktion eines 
Schadens erkennen. Nach der Transplantation mit Wildtypknochenmark jedoch kann 
tatsächlich ein Funktionsverlust bemerkt und ein Nierenschaden bei den BCRP-defizienten 
Mäusen wahrgenommen werden. Diese Ergebnisse zeigen, dass die (hohe) Expression von P-
gp und BCRP im Knochenmark anscheinend nachteilig für die Wiederherstellung der Niere 
ist. Dies wird möglicherweise durch eine veränderte Zusammensetzung der Zellpopulationen 
im Knochenmark verursacht. Eine Zunahme der Anzahl der Zellen, die an der 
Gewebswiederherstellung in P-gp-defizienten und BCRP-defizienten beteiligt sind, kann auf 
diese Art und Weise die Regeneration der Niere stimulieren. Bei der Analyse des 
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Knochenmarks von P-gp- und BCRP-defizienten Mäusen wurde auch eine erhöhte Anzahl an 
Makrophagen und Granulocyten gefunden. Ferner fanden wir heraus, dass die P-gp- und 
BCRP-defizienten Mäuse auch über eine größere Anzahl endothelialer Vorläuferzellen 
verfügen. Diese Feststellungen deuten darauf hin, dass eine Zunahme in der Angiogenese 
möglicherweise die Wiederherstellung der Niere stimuliert. Der exakte Mechanismus muss 
jedoch noch näher untersucht werden. 
 
Im Knochenmark gibt es verschiedene Stammzellpopulationen, die möglicherweise die 
Gewebswiederherstellung stimulieren. Neben den hämatopoetischen- und mesenchymalen 
Stammzellen wurde vor nicht allzu langer Zeit eine neue Population entdeckt: die Multipotent 
Adult Progenitor Cells (MAPC)-Population. Diese Zellen können in endotheliale, 
ectodermale und auch endodermale Zellen differenzieren, aber ihre Fähigkeit, zu Nierenzellen 
zu differenzieren, wurde bis heute noch nicht beschrieben. In Kapitel 8 zeigen wir, dass unter 
Einfluss von basic-Fibroblast Growth Factor, Tumor Growth Factor- α, Leukocyte Inhibitory 
Factor und Hepatocyte Growth Factor diese MAPCs in der Lage sind, zu Nierenepithelzellen 
zu differenzieren. Während dieses Prozesses veränderte sich die Morphologie der Zellen, aber 
auch die Anwesenheit von spezifischen Gen- und Eiweißmarkern bestätigte eine 
Differenzierung in Richtung Nierenepithelzellen. Danach wurden funktionelle Studien 
ausgeführt, wobei die Aktivität der alkalischen Phosphatase (ein proximaler Tubulusmarker) 
und von P-gp gemessen wurde. Die Aktivitätszunahme der alkalischen Phosphatase und von 
P-gp bestätigte die Differenzierung in einen Nierenepithelzelltyp. Aufgrund dieser Ergebnisse 
könnten MAPCs möglicherweise eine wichtige Quelle für Zellen zur Behandlung von 
Nierenerkrankungen sein. 
 
In Kapitel 9 werden die Resultate dieser Doktorarbeit diskutiert. Hier wird unter anderem das 
Wiederherstellungsvermögen der Niere durch vorwiegend endogene (Stamm)zellen 
besprochen. Danach werden die Phänotypen der P-gp- und BCRP-defizienten Mäuse 
beschrieben und verglichen. Ferner wird ihre mögliche (zukünftige) Rolle als Modell für 
Krankheitsprozesse besprochen. Die Funktion von Knochenmarkstammzellen bei der 
Wiederherstellung der Niere nach akutem Schaden scheint mäßig wichtig. Die Bedeutung 
dieser Zellen nimmt aber in Abwesenheit von P-gp und BCRP auf diesen stark zu. Die 
Chapter 10 203 
möglichen Mechanismen, die zu Grunde liegen, werden besprochen. Außerdem wird der 
Belang dieser Resultate für die zukünftige Behandlung von Patienten mit akutem 
Nierenschaden diskutiert. 
 
In den letzten Jahren ist immer mehr über die verschiedenen Mechanismen, über die die Niere 
mögliche Schäden wieder beheben kann, bekannt geworden. In dieser Dissertation zeigen wir, 
dass die zwei Transporteiweisse P-gp und BCRP eine wichtige Rolle in diesem Prozess 
spielen und dass die Beeinflussung der Expressionsniveaus dieser Transporter in der Zukunft 
einen neuen Angriffspunkt für die Behandlung von Patienten mit Nierenschaden darstellt. 
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Chapter 2 
 
 
 
 
 
 
 
 
 
↑ Figure 1. Infiltration of enhanced green 
fluorescent protein (eGFP) labeled bone 
marrow-derived cells in mouse kidney 
before (A), 2 (B) and 7 days (C) after 
ischemic induction.  
 
 
 
 
 
 
 
 
↑ Figure 2. Ischemic kidney injury recruits bone marrow-derived cells to renal tubules in 
gender mismatched chimeras. 
 
Chapter 3 
 
 
 
 
 
 
 
 
 
 
 
↑ Figure 1. Histopathology of the mouse kidney. 
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↑ Figure 4. Renal distribution of mouse abca3, abcb11, abcc4 and abcg2.  
 
Chapter 4 
 
 
 
 
 
 
 
 
 
↑ Figure 4. Megalin expression in FVB wild type mice and in mdr1a/1b(-/-) mice.  
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↑ Figure 8. Histopathology of the mouse kidney after inducing ischemia.  
 
Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
↑ Figure 2. Breast Cancer Resistance Protein (BCRP) expression in the testes, hypothalamus, pituitary gland 
and abdominal and gonadal fat.  
 
Chapter 6 
  
 
 
 
 
 
 
 
 
↑ Figure 4. Expression of 
BCRP/ABCG2 in human primary 
renal tubule cell cultures. 
 
← Figure 3. Immunofluorescent analysis of BCRP/ABCG2 in 
human, rat and mouse kidney. 
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Chapter 7 
 
 
← Figure 1. Effects of renal ischemia 
reperfusion on renal histology in wild 
type (WT) animals and BCRP-
deficient mice. 
 
 
 
 
 
 
 
 
← Figure 2. Renal function parameters 
and histopathology after transplantation 
of eGFP-labeled bone marrow from wild 
type (WT), P-gp- and BCRP-deficient 
mice in WT mice. 
 
 
 
 
← Figure 3. Renal 
histopathology after 
transplantation of 
eGFP-labeled bone 
marrow from wild type 
in BCRP-deficient mice.  
 
 
← Figure 4A. Infiltration of donor bone 
marrow cells in WT-WT, P-gp-WT and 
BCRP-WT transplanted animals 2 and 7 
days after ischemia induction. 
 ↑ Figure 4F. An increased amount of MAC-1 positive cells (red) was observed in P-
gp-WT and BCRP-WT mice, compared to WT-WT mice, indicating an enhanced 
inflammatory response in these mice. 
← Figure 4D. 
eGFP positive 
infiltrated BM 
cells (green) in 
a WT-WT 
transplantation 
are cadherin 
positive (red), 
indicating 
their 
differentiation 
towards an 
epithelial cell 
type. 
↑ Figure 4E. Female bone marrow was transplanted in sublethally irradiated 
males. Four weeks after transplantation, AKI was induced and after seven days, 
female bone marrow-derived cells were observed in male recipients (indicated with 
arrows). These cells show exclusively two X chromosomes (green), and no Y 
chromosome (red) was detected. Control image of a female kidney showing the 
specificity of the X chromosomal paint. Control image of a male kidney showing 
exclusively staining of the Y chromosomal paint. 
← Figure 4B. An overview 
of the kidney after 
transplantation of WT-WT, 
P-gp-WT and WT-BCRP  
transplantations. 
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Chapter 8 
 
← Figure 1. Multipotent adult 
progenitor cells differentiate into an 
epithelial cell line in vitro.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
↑ Figure 3. Immunohistochemical analysis shows expression of nephrin, cadherin and WT-1 after differentiation in renal 
cells.  
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